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by 
 
Aileen Baecker 
Doctor of Philosophy in Epidemiology 
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Background: Liver cancer is the second most fatal cancer in the world. China is 
disproportionally affected, accounting for approximately 50% of liver cancer cases and deaths 
worldwide. Major risk factors for liver cancer include chronic hepatitis B and C viral infections, 
aflatoxin B1 exposure, alcoholic consumption, and tobacco smoking. Objective and Methods: 
We aimed to update the fraction of liver cancer cases attributable to these known risk factors, as 
well as estimate attributable risk of obesity for liver cancer at country, regional, and global 
levels. At the individual level, a population-based case-control study was conducted in a high 
risk area of China, Jiangsu Province, to evaluate novel associations between dietary intakes of 
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flavonoids as well as glycemic index and load with liver cancer, and to assess original 
relationships of single nucleotide polymorphisms (SNPs) of NF-κB, the stem cell pathway, and 
GWAS SNPs with liver cancer. We constructed a genetic risk score, and evaluated the 
association between these SNPs and liver cancer stratified by flavonoid intake. Results: In the 
global analyses, we found that most liver cancer cases could be attributed to viral hepatitis, 
particularly in low income regions. Alcohol consumption was responsible for more cases than 
any other lifestyle risk factor, and patterns varied geographically. In the case-control study, we 
observed marginal and inverse associations between total flavonoid consumption and liver 
cancer, driven in large part by the protective association between tea drinking and liver cancer. 
Carbohydrate intake was associated with increased odds of liver cancer. No obvious association 
between SNPs of the NF-κB pathway and liver cancer was observed, however, genetic risk 
scores of SNPs of the stem cell pathway and those identified in GWAS studies were associated 
with liver cancer. Furthermore, we found that dietary flavonoid intake modified the associations 
between liver cancer and SNPs associated with the stem cell pathway as well as SNPs identified 
through GWAS studies. Conclusion: This study provides policy-makers updated and regionally 
specific estimates of the burden of cancer. In addition to confirming established risk factors with 
the exception of obesity, the results from the case-control study support a marginally protective 
effect of dietary flavonoid consumption, driven largely by tea drinking, and a marginal increase 
in susceptibility associated with increased glycemic load and liver cancer in a Chinese 
population. Furthermore, there was evidence that dietary intake may modify the associations 
between some SNPs and liver cancer.
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CHAPTER 1. BACKGROUND 
1.1 Liver Cancer 
1.1.1 Worldwide Incidence & Mortality 
In 2012, approximately 50% of all incident liver cancer cases in the world were in China. Liver 
cancer is largely seen in less developed regions of the world, where 83% of the world’s 782,000 
new liver cancer cases in 2012 occurred (Ferlay et al. 2013). 50% of these cases occurred in 
China alone (Ferlay et al. 2013).   
 
Liver cancer disproportionately affects men. It is the fifth most common cancer in men (554,000 
cases) and the ninth most common cancer in women (228,000 cases). Furthermore, it is highly 
fatal, responsible for around 746,000 deaths a year (Ferlay et al. 2013), making liver cancer the 
second most common causes of death from cancer worldwide. Due to the poor prognosis 
associated with liver cancer, the geographical patterns in mortality follow incidence closely. 
 
In the United States, the 5-year survival is 17.5% for all stages, with survival ranging from 
30.9% for localized compared to only a 3.1% 5-year survival rate for patients with distant liver 
cancer (National Cancer Institute 2017). Although lower rates are reported in high income 
countries of the world, mortality rates from liver cancer have already greatly increased in 
countries such as the United States (US) (Bertuccio et al. 2017), and are projected to increase 
even more over the next twenty years (Rahib et al. 2014; Parkin, Boyd, and Walker 2011). 
Published literature suggests that 5-year survival in China is lower than in the United States. A 
global surveillance study from 67 countries found a Chinese 5-year survival rate of 12.5% from 
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2005-2009 (Allemani et al. 2015), with survival rates varying by county. In Dafeng, 5-year net 
survival in adults 15-99 years old was 11.3% (CI: 4.1, 18.5) from 2000-2004 and 16.0% from 
2005-2009. Survival rates in Ganyu were lower, 2.5% (95% CI: 0.9, 4.1) from 2000-2004 and 
5.8% (95% CI: 1.8, 9.7) from 2005-2009 (Allemani et al. 2015). 
1.1.2 HCC Risk Factors 
Accumulated damage over many years can cause liver cancer. This includes chronic 
inflammation, such as inflammation from chronic hepatitis B virus (HBV) infection or non-
alcoholic fatty liver disease. Molecular pathways that have been proposed to affect liver 
carcinogenesis include inflammation, NF-κB, and stem cell pathways. Patients generally present 
with liver cancer after a long period of damage, and liver diseases and conditions that commonly 
precede liver cancer include chronic hepatitis, fibrosis and cirrhosis, alcoholic liver disease, and 
fatty liver disease. 
 
There are two types of liver cancer in adults. The most common form is called hepatocellular 
carcinoma (HCC), and originates in the hepatocytes of the liver. Around four out of five incident 
cases of primary liver cancer are HCC. The other form of liver cancer is cholangiocarcinoma, 
which starts in the ducts carrying bile from the liver to the gallbladder, or from the gallbladder to 
the intestines. Most liver cancers are HCC, with approximately 10-25% of liver cancers 
identified as cholangiocarcinoma. Major risk factors for HCC include chronic infection with 
HBV, HCV, aflatoxin exposure, tobacco smoking, alcohol drinking, and more recently, obesity. 
In contrast, known risk factors for cholangiocarcinoma are parasitic infections, primary 
sclerosing cholangitis, biliary-duct cysts, hepatolithiasis, and toxins (Tyson and El-Serag 2011). 
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Most liver cancers in Jiangsu Province, China are cases of HCC. The etiology of HCC is 
geographically heterogeneous, as the risk factors for HCC vary considerably by region. 
Hepatitis Viruses 
For over forty years (Sherlock 1970), chronic infection with HBV has been a known etiologic 
agent in the development of HCC. Approximately 45% of the world population lives in an area 
where chronic HBV infection is highly endemic, with the highest rates in sub-Saharan Africa, the 
Amazon basin, China, the Republic of Korea, and several countries in southeast Asia (Custer et 
al. 2004). Chronic HBV infection is measured using seropositivity for hepatitis B surface antigen 
(HBsAg). The relative risk associated with seropositivity of HBsAg and liver cancer ranges from 
5.3-148 in cohort studies, and 5 to 30 in case control studies (IARC Working Group 2012a). 
 
HCV has been identified as a carcinogen to humans since the early 1990s (IARC Working Group 
2012b).  The estimated prevalence of HCV worldwide is 2.2%, with region-specific rates as low 
as <1% in northern Europe and ranging to over 3% in northern Africa (IARC Working Group 
2012b). Chronic HCV infection is commonly identified with HCV antibodies (anti-HCV). 
Chronic infection with HCV has been associated with relative risks ranging from ~15 to 25. 
 
Few large-scale population-based studies have reported the number of HBV/HCV coinfection, 
making it difficult to estimate the prevalence worldwide. However, some studies have reported 
that approximately 5-20% of patients with chronic HBV infection are co-infected with HCV 
(Crespo et al. 1994; Fattovich et al. 1991; Gaeta et al. 2003; Chan et al. 1991; Dai et al. 2001; 
Sato et al. 1994; Ohkawa et al. 1994; Xess et al. 2001; Pramoolsinsap et al. 1999). 
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Meta-analyses have reported conflicting results on the joint effects of HBV and HCV, reporting 
both sub-additive and super-additive effects (sub-additive: (Cho et al. 2011); super-additive: 
(Donato, Boffetta, and Puoti 1998) and (Shi et al. 2005)). Cho et al. found an overall sub-
additive effect on risk of hepatocellular carcinoma in more recent studies (2000-2009), cohort 
studies, and studies conducted in areas where HBV and HCV infection were uncommon, an 
additive effect in HBV endemic areas, and a super-additive effect in older studies, case-control 
studies, and in HCV endemic areas (Cho et al. 2011). 
Aflatoxin 
Dietary exposure to aflatoxins is common in areas with unsafe practices of food storage and/or 
contamination of the water supply. Worldwide, millions of people are exposed to these toxic 
metabolites produced by the aspergillus molds. These molds commonly infest staple crops 
including maize, rice, wheat, and peanuts. Aflatoxin poisoning can be acute, however chronic 
low-level exposure to aflatoxins is associated with an increased risk of developing HCC in 
addition to increased risks of impaired immune function and malnutrition. 
 
HBV prevalence is thought to interact with aflatoxin exposure, and together HBV infection and 
aflatoxin exposure greatly increase risk of liver cancer. A review of available studies concluded 
that aflatoxin likely plays a causative role in 4.6-28.2% of all global HCC cases (25,000-
155,000), with the majority of cases occurring in sub-Saharan Africa, Southeast Asia, and China 
(Liu et al. 2012). Exposure to aflatoxin in persons with chronic HBV infection is associated with 
a risk up to 30 times greater than in those exposed to aflatoxin alone (Groopman, Kensler, and 
Wild 2008). Estimates for HBV infected individuals in regions where aflatoxin exposure is 
common, such as parts of Africa and Asia, are likely underestimates. 
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Alcohol 
Since 1988, IARC has classified alcohol as a group 1 carcinogen. Heavy drinking is thought to 
lead to cirrhosis, a major risk factor for liver cancer. The countries with the highest per capita 
alcohol consumption are located in Eastern and Western Europe. The National Institute on 
Alcohol Abuse and Alcoholism defines heavy or “at-risk” alcohol drinking as more than 4 drinks 
on any single day or more than 14 drinks per week for men, and more than 3 drinks on any day 
or more than 7 drinks per week for women (National Institute on Alcohol Abuse and 
Alcoholism). A meta-analysis by Turati et al. found that drinking 37.5g of ethanol (about 3 
drinks) or more per day was associated with a RR of 1.16 (95% CI: 1.01-1.34) for liver cancer 
among heavy drinkers compared to non-drinkers, and that risk increases with drinking (Turati et 
al. 2014). 
Tobacco Smoking 
Studies providing evidence for the carcinogenicity of smoking date back to the 1950s (Doll and 
Hill 1950; Wynder and Graham 1950), including studies showing an association between 
smoking and liver cancer (IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans 2004). There are over 60 known carcinogens in cigarette smoke (US Department of 
Health and Human Services 2010), including polycyclic aromatic hydrocarbons and aromatic 
amines, both which have been associated with risk of HCC (Wang et al. 1998; Chen et al. 2002). 
 
In 2012, Eastern Asia and Eastern Europe had the highest prevalence of daily smokers (Ng et al. 
2014). Recent meta-analyses by Lee et al. (Lee et al. 2009) and Gandini et al. (Gandini et al. 
2008) found that current smokers had about 1.5 times the risk for liver cancer compared to never 
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smokers (Lee et al: 1.51 [1.37,1.67]; Gandini et al: 1.56 [1.29,1.87]). This is consistent with 
IARC’s 2004 findings in their monograph on tobacco smoke and involuntary smoking that an 
association between tobacco smoking and liver cancer has been consistently observed in cohort 
and case control studies (IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans 2004). 
 
Those who smoke tend to drink alcohol as well. A meta-analysis by Lee et al. found that the RR 
for current smokers was slightly lower after adjusting for alcohol (before adjustment: 1.51, 95% 
CI: 1.37, 1.67; after adjustment: 1.43, 95% CI: 1.21, 1.68), while Chuang et al. found that the 
risk ratio for alcohol and liver cancer was 1.29 (95% 95% CI: 1.08, 1.50) before adjusting for 
smoking and 1.33 (95% CI: 1.15, 1.52) after adjusting for smoking (Lee et al. 2009; Chuang et 
al. 2015). 
Obesity 
Obesity has been proposed as a risk factor for liver cancer. The marked increase in the 
worldwide prevalence of obesity, particularly in children, suggests that even a small associated 
increased risk of liver cancer can have wide-reaching future effects. Obesity-induced liver 
inflammation results in elevated production of cytokines and adipokines, and a chronic state of 
inflammation can lead to NAFLD, NASH, fibrosis, and cirrhosis (Sun and Karin 2012). Meta-
analyses looking at obesity (BMI of 30 or more) have found associated RRs ranging from 1.35-
1.89 (Rui et al. 2012; Larsson and Wolk 2007). 
 
Obesity may interact with other lifestyle risk factors. Those who drink alcohol are more likely to 
be obese, and it may be difficult to assess the individual effect of each risk factor as they often 
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co-occur. A meta-analysis of 26 prospective studies by Chen et al. found that the risk of liver 
cancer associated with obesity, adjusted for alcohol was 1.46 (95% CI: 1.25, 1.69) (Chen et al. 
2012). This estimate is similar to the estimate of the association between obesity and liver 
cancer, unadjusted for alcohol intake. 
1.1.3 Previous Descriptive Epidemiology of HCC 
Traditional risk factors that were included in the analysis were chronic infection with hepatitis B 
virus (HBV) and hepatitis C virus (HCV), alcohol drinking, and tobacco smoking. Recently, 
evidence has emerged that obesity may also increase risk of HCC through chronic inflammation 
of the liver (Sun and Karin 2012). The distribution of these risk factors varies geographically, 
creating variability in the disease risk profiles for HCC by geographic region. 
 
Previously published studies on the major attributable risk factors of liver cancer use outdated 
data, and have often looked at a limited number of risk factors. Two studies estimated the 
worldwide risk of liver cancer due to infectious agents only (de Martel et al. 2012; Parkin 2006), 
while another has estimated risk from alcohol intake only (Praud et al. 2016). Studies in France, 
the United Kingdom, the United States (USA), Japan, and China have also looked at the fraction 
of liver cancer cases attributable to both infectious and lifestyle risk factors; nevertheless, these 
studies are country-specific and lack global and regional perspectives (IARC Working Group 
2007; Parkin, Boyd, and Walker 2011; Inoue et al. 2012; Fan et al. 2013; Makarova-Rusher et al. 
2016). The Global Burden of Disease Project has focused on mortality outcomes, estimating the 
years of life lost associated with subtypes of liver cancer (Mortality and Causes of Death 2016). 
There is a pressing need for an updated and comprehensive study of global trends of liver cancer 
risk factors. 
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1.2 Diet and Liver Cancer 
Changes in the disease risk profile of liver cancer have already been observed in some regions of 
the world. Studies reporting the underlying causes of liver cancer and other liver diseases 
increasingly report a large proportion of HCC cases arising from cryptogenic cirrhosis (El-Serag 
and Rudolph 2007), where the cause of disease is unknown and not related to traditional viral 
liver cancer risk factors. Globally, HCC associated with cryptogenic cirrhosis accounts for 
around 15-30% of HCC (Michelotti, Machado, and Diehl 2013). 
 
It is theorized that a large proportion of these cryptogenic cases may be due to a novel risk 
factor: obesity. While viral risk factors for HCC may be projected to decline, obesity has been 
steadily increasing on a global scale, and there is evidence that the increasing rates of non-
alcoholic fatty liver disease (NAFLD) are linked to an increased risk of HCC (Yang et al. 2012; 
Hucke et al. 2011; Ertle et al. 2011; Malik et al. 2009). Lifestyle risk factors will likely play a 
larger role in the etiology of liver cancer in years to come. A better understanding of lifestyle-
related risk factors and how they affect established risk factors is essential to understanding and 
preventing future liver cancer cases. 
1.2.1 Glycemic Index and Glycemic Load 
Diet may affect liver cancer risk through a several pathways, including through glycemic index 
and glycemic load. Diets with low daily glycemic index and glycemic load are linked to 
favorable lipid profiles and lower concentrations of c-reactive protein in overweight and obese 
persons, and may improve glucose intolerance and hyperinsulinemia (Valtuena et al. 2006). High 
carbohydrate intake may contribute to insulin resistance and increased inflammation, and dietary 
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glycemic index has been associated with liver steatosis, a condition which commonly precedes 
liver cancer (Valtuena et al. 2006).  
 
Glycemic index (GI) measures how rapidly a carbohydrate is digested and released as glucose 
into the bloodstream, and foods with a high GI raise blood sugar to a greater extent than foods 
with medium or low GI. On a scale of 0 to 100, pure glucose is given a value of 100. However, 
GI does not take into account the amount of carbohydrate in a food. Foods such as watermelon 
may have a high glycemic index, but one serving of watermelon contains very few carbohydrates 
(about 6g of carbohydrates per 100g of watermelon; versus about 73 g in 100g of rice). Glycemic 
load (GL) is adjusted for the amount of carbohydrate a food contains, giving a better measure of 
not only how much glucose enters the bloodstream, but also how much glucose is delivered. 
 
One meta-analysis of six studies of liver cancer did not find strong evidence of an association 
with GI (RR: 1.11, 95% CI: 0.80, 1.53) or GL (RR: 1.14, 95% CI: 0.78, 1.67). However, five of 
the six studies were conducted in Western populations. It is possible that different dietary 
patterns between Western and Asian populations may modify the association between liver 
cancer and GI or GL. One high GI food commonly eaten in China is white rice, while breads and 
pastas are more common in Western populations. Furthermore, Asian populations tend to 
experience the adverse metabolic effects at lower BMIs, indicating that there could be a 
biological basis for a different association between these two populations as well. One study has 
been conducted in a Chinese population, including 139 female and 208 male cases, and found an 
association between glycemic index and liver cancer among women. No association was 
observed among men or with glycemic load (Vogtmann et al. 2013). 
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1.2.2 Flavonoids 
Plant-based diets, particularly those rich in vegetables and fruits, have consistently been 
associated with a protective effect against cancers of various sites (World Cancer Research 
Fund/American Institute for Cancer Research 1997). This effect is likely due to the low energy 
content of these foods as well as their constituent parts, including vitamins, minerals, and 
bioactive compounds. Flavonoids are one such bioactive compound produced by plants which 
may reduce the risk of cancer. 
 
Flavonoids are present in many dietary plants, are relatively abundant in the diet, and are 
generally heat stable (Ren et al. 2003). They are characterized by their general structure of a 15-
carbon skeleton, consisting of two phenyl rings linked to a heterocyclic ring (Aherne and O'Brien 
2002). Flavonoids can be further subdivided into subclasses of flavones, flavonols, flavanones, 
catechins and epicatechins, anthocyanins, and isoflavones. Human dietary intake from flavonoids 
is estimated to be anywhere from dozens of mg/day (Hertog et al. 1993), to over a hundred 
mg/day (Li et al. 2013). Flavonoid uptake and metabolism is complex, and for this reason plasma 
measurements of flavonoids can be a misleading indication of bioavailability (Batra and Sharma 
2013; Hollman 2004). Dietary measures of flavonoids may give a better estimate of flavonoid 
intake for this reason. 
 
Dietary intake from flavonoids has shown a protective association against cardiovascular disease 
and several cancers (Mulvihill and Huff 2010; Garcia-Lafuente et al. 2009; Hooper et al. 2008). 
Flavonoids have a wide variety of biological effects which are thought to have anti-carcinogenic 
properties. These mechanisms for anti-carcinogenesis include antiproliferative effects and strong 
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antioxidant capacity, in addition to involvement in cell signaling, cell cycle regulation, cell 
differentiation, and angiogenesis (Ren et al. 2003). Another putative mechanism, which has 
mainly been described in breast tissue, is the modulation of estrogen signaling by isoflavones. 
Recently, flavonoids have been investigated in the treatment of ovarian, breast, cervical, 
pancreatic, and prostate cancers, even entering several late phase clinical trials for oncological 
indications (Ferry et al. 1996; Lazarevic, Karlsen, and Saatcioglu 2008; Lin et al. 2009). 
 
Flavonoid-mediated chemoprevention is likely due in part to the anti-inflammatory and 
antioxidant activities of flavonoids. Flavonoids are able to scavenge reactive oxygen species 
(ROS) and growth promoting oxidants that are the major catalysts for tumor promotion (Ren et 
al. 2003; Ravishankar et al. 2013). Furthermore, there is evidence that there exists a close 
association among reactive oxygen species (ROS), chronic inflammation, and cancer (Gupta et 
al. 2012). While acute inflammation is therapeutic, chronic inflammation is a risk factor for 
several diseases, including cancer. ROS regulates several well-known mediators of inflammation 
and tumorigenesis, including COX-2, inflammatory cytokines (TNF-, IL-1, IL-6), chemokines 
(IL-8, CXCR4), and pro-inflammatory transcription factors (NF-κB) (Gupta et al. 2012). 
 
Flavonoids may also affect immune function and directly work to inhibit fungal and viral 
growth. One in vitro study found that the flavonoid apigenin inhibits HCV replication (Shibata et 
al. 2014). Another study tested six different plant flavonoids against a spectrum of bacteria and 
fungi, and found that flavonoids were generally good antimicrobial and antifungal agents (Orhan 
et al. 2010). 
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Several studies have shown a chemoprotective effect of flavonoids in vitro and in animal studies. 
Fang et al. isolated flavonoids from a Chinese herb and applied them to human cancer cells, and 
found that the flavonoids had the strongest inhibitory effect on SK-Hep-1 human hepatocellular 
carcinoma cells (Fang et al. 2010). Other studies observed inhibition of proliferation and 
inducement of apoptosis in hepatocellular carcinoma cells (Hep3B, SMMC-7721, and HepG2) 
after exposure to flavonoids from milkvetch and milk thistle as well as genistein (Yeh et al. 
2007; Hu et al. 2009; Ramakrishnan et al. 2009). Another study by Siess et al. found that rats 
with several flavonoids during two stages of aflatoxin B1 induced hepatocarcinogenesis had 
decreased numbers of preneoplastic foci (Siess et al. 2000), suggesting that flavonoids may act as 
an anti-initiator and anti-promoter in rat hepatocarcinogenesis. 
 
Many epidemiological studies have been conducted on flavonoid intake and cancer; however few 
studies have focused on their association with HCC. One case-control study and one cohort 
study, both in western populations, have looked at total flavonoid intake and HCC. Flavone 
intake was inversely associated with HCC risk in a Greek case-control study described by Lagiou 
et al. (Lagiou et al. 2008). This effect was observed both in participants positive for chronic 
hepatitis virus (highest vs lowest flavonoid quintile, OR=0.50, 95% CI: 0.27-0.94) as well as in 
participants negative for chronic hepatitis (highest vs lowest, OR=0.41, 95% CI: 0.16-1.06) 
(Lagiou et al. 2008). In this population, the main sources of flavonoids were spinach and 
peppers, and were inversely associated in both hepatitis positive and hepatitis negative 
participants. The study included six cholangiocarcinoma cases. A suggestion of an inverse 
association with flavonoids and cholangiocarcinoma was found, however the sample size limits 
the significance of these findings. 
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In addition, a cohort study by Zamora-Ros et al. has also been conducted in the European 
Prospective Investigation Into Cancer and Nutrition study (Zamora-Ros, Fedirko, et al. 2013). 
This study included 191 incident HCC cases over a follow-up of 11years, and found a borderline 
association of HCC with total flavonoid intake when comparing the highest tertile to the lowest 
(HR=0.65, 95% CIL 0.40-1.04). Among the flavonoid subclasses, flavanols were inversely 
associated with HCC (HR=0.62, 95% CI 0.31-0.79). 
Flavonoid Consumption in an Asian Diet 
The sources of flavonoids in Asian diets are different from Western diets. Whereas spinach and 
peppers were the main source of flavonoids in the Greek case-control study by Lagiou et al. 
(Lagiou et al. 2008), soy and tea are commonly consumed sources of flavonoids. In China, Li et 
al. found that the richest sources of total flavonoids in commonly consumed fruits and vegetables 
were apple, plum, pear, peach, lotus root, and taro (Li et al. 2013), while Xu et al. looked at a 
wider variety of foods and beverages and found tea to be the top source of flavonoids (Xu et al. 
2016). Flavonoid studies in China have found that nearly 50% of flavonoids come from tea 
consumption (Xu et al. 2016), while a large cohort study of European countries found that tea 
consumption was responsible for a much smaller portion of total flavonoid intake. In non-
Mediterranean European countries, tea consumption was responsible for 25.7% of total flavonoid 
intake, while 6.8% of total flavonoid intake in Mediterranean countries came from tea (Zamora-
Ros, Knaze, et al. 2013). In two Chinese studies of diet, the daily intake of total flavonoids was 
found to be around 165.6-395 mg/day (Li et al. 2013; Xu et al. 2016) . 
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Although flavonoids are common in dietary plants, the subclasses of flavonoids are not 
uniformly distributed in plants. For example, catechins and epicatechins are more abundant in 
tea, while isoflavones are common in soy. In addition, variation in flavonoids may vary in 
concentration depending on the part of the fruit or vegetable is consumed. For many fruits and 
vegetables, the skins of the fruit or the leaves of the plant contain the most concentrated sources 
of flavonoids. Regional norms and personal preferences in fruit and vegetable preparation may 
affect flavonoid intake. For example, skinning a fruit such as an apple or a pear will reduce 
flavonoid intake.  
 
Furthermore, food preparation and processing also affect flavonoid intake, and conventions vary 
regionally and culturally. For example, the consumption of salads and raw vegetables is more 
common in a Western diet, while most vegetable dishes are cooked in a Chinese diet. Xu et al. 
measured flavonoids in nine kinds of vegetables from a Tianjin market after frying, boiling, 
stewing, and microwaving (Xu et al. 2007). The authors found that the percentage of flavonoids 
reserved after frying ranged from 54.6-115.6%, while boiling resulted in a 33.6-107.8% reserve 
rate, stewing 31.7-100.5%, and microwaving 43.1-109.6%. Additionally, pickling has also been 
thought to affect flavonoid content. A study conducted in China by Chun et al. found that total 
flavonoid content was higher in fresh red cabbage samples (108.1 ± 9.3 mg catechin equivalents 
/100g fresh sample) compared to pickled red cabbage (72.4 ± 4.4 mg catechin equivalents/100g 
fresh sample) (Chun et al. 2004). 
 
Variation in flavonoid intake between a Western and Asian diet may be due to a variety of 
factors. Variation due to common sources of dietary flavonoids likely plays a large role. Other 
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factors are inherent to the biology and growth cycle of the plant, while others can be influenced 
by the processing and preparation of the plant after it has reached the market. While most studies 
of flavonoids have been conducted in Western populations, it is likely that there are large 
differences in flavonoid consumption between Asian and Western populations due to differences 
in flavonoid sources, cultivation methods, and preparation methods. 
 
Current and commonly used databases have been developed by Western countries, including the 
USDA Database for the Flavonoid Content of Selected Foods (US Department of Agriculture 
2013, 2008), Phenol-Explorer (Neveu et al. 2010), and the UK Food Standards Agency database 
(Ward et al. 2010). Food items common in a Chinese diet are not always reflected in these 
databases, necessitating construction of a database that includes Chinese food items and 
reflecting Chinese cultivation and preparation methods. 
1.2.3 Genetic Pathways 
By impacting cell function and the molecular environment, diet may modify the risk between 
these genetic polymorphisms and risk of liver cancer. Of particular interest are diet and diabetes-
related single nucleotide polymorphisms (SNPs). The associations between SNPs located in 
genes associated with nutrient metabolism (such as BCM01) with liver cancer are likely to be 
modified by diet and molecular changes associated with diet. 
 
Another pathway that may be related to diet and liver cancer is the NF-κB pathway. NF-κB is a 
protein that controls transcription of DNA, and is involved in cellular responses to stress, 
cytokines, free radicals, and viral antigens (Gilmore 2006, 1999; Brasier 2006). A variety of 
diseases, including cancer, inflammatory diseases, and viral infection have been linked to 
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dysregulation in NF-κB signaling. One role of NF-κB is to regulate genes controlling cell 
proliferation and cell survival. Thus, many human tumors have activated NF-κB.  
 
The putative chemopreventive effects of flavonoids are not limited to scavenging ROS, they 
have also been shown in several studies of tumor cell lines to inhibit tumor growth and more 
directly inhibit NF-κB signaling (Singh et al. 2005; Shin et al. 2011). Sing et al. observed 
inhibition of NF-κB signaling in the suppression of tumor xenograft growth by the flavonoid 
silibinin (Singh et al. 2005). In addition, several chalcones, which are similar in structure to 
flavonoids, have also been observed to repress NF-κB pathways in endothelial cell lines (Chang 
et al. 2007; Bertl et al. 2004; Zhao et al. 2016) Thus, NF-κB signaling is dysregulated in tumor 
cells, and flavonoids may affect tumor growth through inhibition of NF-κB signaling in addition 
to mechanisms through tumor-related oxidative stress.  
 
Other pathways of interest that may be related to liver carcinogenesis are the stem cell pathway 
and micro RNA (miRNA) pathways. Wnt/β-catenin signaling plays a crucial role in hepatic 
development and regeneration, and dysregulation of this pathway may contribute to liver 
carcinogenesis by affecting cell proliferation, apoptosis, oxidative stress, and differentiation 
(Monga et al. 2003; Monga et al. 2001). Additionally, miRNAs have been linked to enhanced 
hepatitis virus replication, regulation of lipid metabolism, and hepatocellular carcinoma (Otsuka 
et al. 2017). 
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1.3 Gaps in the Literature 
Gaps in the literature that are filled by this study are summarized in Table 1-1. Previous studies 
estimating the number of cases of liver cancer that can be attributed to major risk factors have 
either looked at a limited number of factors or have only looked at a variety of risk factors for a 
single country (de Martel et al. 2012; Parkin 2006; Parkin, Boyd, and Walker 2011; Praud et al. 
2016; IARC Working Group 2007; Inoue et al. 2012; Fan et al. 2013; Makarova-Rusher et al. 
2016). There is a need for updated comprehensive estimates for a variety of risk factors for liver 
cancer on a global, regional, and country level. Very few studies have investigated dietary 
factors and liver cancer, especially in high risk populations. Although dietary intake of 
flavonoids has been associated with a variety of cancers, the association has only been explored 
for liver cancer in two studies with small sample size in Europe. This study is the first to look at 
the association between flavonoid intake and liver cancer in a high-risk population in China, and 
it is the largest study to assess whether flavonoid intake, glycemic index, or glycemic load are 
associated with liver cancer. Additionally, this study assessed interaction between these dietary 
factors and established risk factors of liver cancer. Furthermore, the associations between liver 
cancer and SNPs associated with NF-κB, stem cell pathways, and GWAS studies were assessed. 
This is the first study to evaluate how flavonoid intake modifies the associations between 
established and novel related SNPs on liver cancer susceptibility. SNPs significantly associated 
with liver cancer and included in the genetic risk score were also assessed for interaction with 
established liver cancer risk factors.
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CHAPTER 2. RESEARCH OBJECTIVES 
For Specific Aim 1, we aim to estimate the distribution and determinants of liver cancer at the 
country, regional, global levels. Current literature is either out-of-date or confined to regional 
localities. Many excluded more recently identified risk factors for liver cancer. There have been 
no such estimates at country level worldwide. Understanding how risk factors vary 
geographically is integral to constructing appropriate health policies to address major country-
level and regional risk factors. We studied the global burden of liver cancer and explored 
geographic heterogeneity in terms of attributable risks for established and novel risk factors for 
liver cancer at global, regional and country levels. The methods, results, and conclusions of 
Specific Aim 1 are described in Chapter 3. 
 
Specific Aim2 was conducted in a population-based case-control study in Jiangsu Province, 
China, allowing the study of known and novel risk/protective factors for liver cancer at the 
individual level. Protective dietary factors are less commonly studied for liver cancer. Dietary 
flavonoid intake as well as glycemic index and load, are dietary factors thought to be associated 
liver cancer. Furthermore, these dietary factors vary between Western and Asian populations. 
Animal and in vitro studies have shown promising evidence of an anti-hepatocarcinogenic effect 
of dietary flavonoid intake, and observational studies of total flavonoid and isoflavone intake in 
Western and Japanese populations have generally supported this observation. Similarly, 
observational studies have found a statistically insignificant association between glycemic index 
and glycemic load with liver cancer, however there is evidence that this risk is higher in certain 
subpopulations. Elucidating the association between dietary intake of flavonoids, glycemic 
index, and glycemic load will help improve understanding of the differential effects of an Asian 
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diet on liver cancer risk. The methods, results, and conclusions of Specific Aim 2 are described 
in Chapter 4. 
 
For Specific Aim 3, we aim to assess the potential impact of genetic predisposition on the 
development of liver cancer. Animal models indicate that SNPs involved in inflammation, stem 
cell pathways, as well as candidate SNPs identified through GWAS may be involved in liver 
carcinogenesis. Furthermore, these pathways are affected by diet, and may interact to modify risk 
of liver cancer. No study has yet explored the association of these SNPs with liver cancer, or 
their potential interactions with dietary factors. This study will shed a light on the potential 
interactions between genetics and diet on liver cancer development. The study design of Specific 
Aim 3 is described in Chapter 4, while methods, results, and conclusions are described in 
Chapter 5. 
 
Specific aims are as follows: 1. To describe and update regionally-specific determinants of liver 
cancer throughout the world in 2012 using estimates of incident cancer, regional prevalence, and 
risk estimates of four established risk factors and one novel risk factor from the literature. 2. To 
evaluate the effect of dietary intake of total flavonoids, subclasses of flavonoids, glycemic index, 
and glycemic load on risk of liver cancer, adjusting for potential confounders.  3. To analyze the 
relationship between selected SNPs, both individually and in a genetic risk score, with liver 
cancer, stratifying on diet and adjusting for potential confounders. 
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CHAPTER 3. GLOBAL POPULATION ATTRIBUTABLE FRACTIONS 
METHODS, RESULTS, AND DISCUSSION 
3.1 Methods 
3.1.1 HCC Case Estimation  
The 2012 age-standardized estimated numbers of new cancer cases by country and gender are 
available for 27 of the major cancers in GLOBOCAN 2012 (Ferlay et al. 2013). In 2012 there 
were 782,451 incident cases of liver cancer worldwide, with over two-thirds of cases occurring 
in men. Most cases of liver cancer are HCC, however in some regions where the risk factors for 
cholangiocarcinoma (parasitic infections, particularly) are more common, a larger percentage of 
liver cancer cases are cholangiocarcinoma. Since Globocan only reports liver cancer cases, we 
estimated the percentage of HCC cases by country and by geographic region using IARC's age-
standardized world incidence rates of microscopically verified cases by histological type (IARC 
2014). Cases of HCC were estimated due to the fact that risk factors for HCC are very different 
from cholangiocarcinoma. 
 
The age-standardized incidence rates by histological type are reported by country, and for some 
larger countries rates were reported for multiple regions within the country. Country-wide data 
from large registries were prioritized, and if that wasn't available than country-wide data were 
estimated from regional studies using averages weighted by verified study sample size. While 
most studies reported all histological subtypes, a couple studies did have a high proportion of 
unspecified liver carcinoma or cancer. Studies where more than half of the cases were 
unspecified were not used to calculate the percent of HCC cases. These studies were primarily in 
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Algeria and parts of China, where HCC is predominant. The median percentage of unspecified 
cases in males was 4.1% with an IQR of 0-10%, and for women this was 2.0% (IQR: 0-11.1%). 
 
The HCC rates for the 66 countries that had data were used to calculate the gender-specific rates 
in each Global Burden of Disease region (GBD) for countries that were missing data. Rates were 
weighted by number of cases in each region. No studies were conducted in Central Asia, 
Oceania, Central Sub-Saharan Africa, or West Sub-Saharan Africa. For these regions, percent 
HCC was estimated using the percentages calculated for other regions in the same continental 
division. 
3.1.2 Prevalence Data for HCC Risk Factors 
Prevalence data for major HCC risk factors was extracted from the literature and publicly 
accessible databanks. Prevalence estimates were limited to what was available in the literature 
and from databases. Specific sources used are as follows. HBV prevalence was obtained from a 
study of 161 countries, estimating HBsAg seroprevalence worldwide from 1965-2012 
(Schweitzer et al. 2015). Estimates for both genders from 1990-2013 were used. HCV prevalence 
data came from a study of anti-HCV prevalence in 87 countries for both genders, estimated from 
2000-2010 data (Gower et al. 2014). Alcohol exposure estimates by country were obtained from 
a study of 241 countries and territories, estimating the 2005 distribution of drinking in men and 
women ages 15 and older (Shield et al. 2013). Prevalence estimates were given for never 
drinkers, former drinkers, and in increments of 20 and 40g alcohol consumed per day. 
Prevalence of male and female ever smokers and never smokers in 1996 was obtained a study of 
187 countries (Ng et al. 2014), while prevalence of overweight and obese in men and women in 
1996 was obtained from the WHO data repository (World Health Organization 2017b, 2017a). 
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3.1.3 Geographic Divisions 
The proportion of HCC cases attributable to each risk factor was estimated for each country that 
had available data. In order to look at trends on a regional level, global estimates were grouped 
into the 21 Global Burden of Disease (GBD) Regions. These regional divides partition the world 
into regions based on geography and similar epidemiological profiles (World Health 
Organization 2002). The specific countries included in each grouping in this study are reported 
in Table 3-1. Gender-specific PAFs on the regional level were estimated using the countries for 
which data were available, weighted by the number of HCC cases in each region. 
3.1.4 Relative Risk Estimates 
To assess the RRs associated with individual risk factors and liver cancer, we systematically 
searched publications on PubMed. The search words used with “liver cancer,” “HCC,” and 
“hepatocellular carcinoma” included: HBV, hepatitis B virus, HCV, hepatitis C virus, aflatoxin, 
alcohol, drinking, smoking, tobacco smoking, obesity, adiposity, and meta-analysis. Meta-
analyses were given the highest priority. Separate RRs were abstracted when there was 
indication of variation by gender, geographical location, level of alcohol drinking, and/or 
HBV/HCV status (See Table 3-2). 
 
Risk ratios for HBV and HCV were extracted from a meta-analysis using RRs of measurements 
using second generation measurement techniques (Donato, Boffetta, and Puoti 1998). For HBV, 
the RR used was 22.5 (CI: 19.5-26), and for HCV this was 17.3 (CI: 13.9-21.6). The risk 
associated with a 25g increase in alcohol consumption per day was reported in a meta-analysis of 
27 cohort studies and 63 case control studies (Chuang et al. 2015). A trend line was fitted to the 
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gender-specific reported risk ratios and estimates for the risk associated with a 20g increase in 
daily alcohol intake were estimated in order to correspond to prevalence data. A risk ratio of 1.43 
(CI: 1.21-1.68) was used to estimate the risk associated with ever smoking on liver cancer risk 
(Lee et al. 2009). This estimate was adjusted for alcohol consumption. The gender-specific 
estimates of risk associated with an overweight BMI (>=25) and an obese BMI (>=30) were 
obtained from a meta-analysis of 26 prospective studies (Chen et al. 2012). For risk factors with 
evidence from the literature of possible super- or sub-additive interaction, the potential impact 
this would have on the fraction of attributable cases was hypothesized. 
3.1.5 Calculation of PAF 
The fraction of new liver cancer cases attributable to each infectious risk factor was calculated 
using Levin’s formula, given the prevalence of the risk factor and the associated relative risk:  
𝑃𝐴𝐹𝐿𝑒𝑣𝑖𝑛 =
𝑝(𝑅𝑅 − 1)
1 + 𝑝(𝑅𝑅 − 1)
 
The population attributable fraction, or PAF, represents the proportion of cases of liver cancer 
that could be avoided had exposure to a major risk factor was removed (e.g. through 
vaccination). The population attributable cases (PAC), representing the number of cases that 
could have been avoided had exposure to the risk factor been removed, can be calculated by 
multiplying the number of HCC cases in each region by the PAF. 
 
For alcohol consumption and BMI, data on the prevalence and risk associated at different levels 
of exposure (e.g. for those who consume 0g, 0-20g, 20-40g, 40-60g, and 60+g alcohol daily or 
for those who have a BMI of 18.5-25, 25-30, 30-35, 35+) was widely available. The population 
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attributable fraction was then calculated as a summary measure of these categories to reflect 
varying risk as exposure level increases using the following formula, 
𝑃𝐴𝐹𝑆𝑢𝑚𝑚𝑎𝑟𝑦 =
𝑝1(𝑅𝑅1 − 1) + 𝑝2(𝑅𝑅2 − 1) +⋯+ 𝑝𝑛(𝑅𝑅𝑛 − 1)
1 + 𝑝1(𝑅𝑅1 − 1) + 𝑝2(𝑅𝑅2 − 1) +⋯+ 𝑝𝑛(𝑅𝑅𝑛 − 1)
 
Risk ratio data was extracted from meta-analysis, and the risk associated with each level of 
alcohol drinking or BMI was extracted. For alcohol drinking, risk ratio data was available for 
increments of 25g alcohol/day, while the prevalence data for alcohol consumption was reported 
in 20 gram increments. In order to estimate the risk associated with the available prevalence data, 
a trend line was fitted to risk ratio data and the risk associated with 20 gram increments was 
estimated.  For tobacco smoking, continuous or categorical data that reflected the population 
distribution of tobacco smoking was not available, and Levin’s formula was used as an 
approximation of the fraction of cases attributable to ever smoking. 
3.1.6 Confidence Intervals and Uncertainty 
95% confidence intervals (CIs) were calculated using the 95% CI limits of the reported risk 
ratios and prevalence data. Another factor that contributes to uncertainty in estimation is that 
individuals may have more than one risk factor and these risk factors may interact with one 
another. 
 
3.2 Results 
Worldwide, viral risk factors for liver cancer play a larger role compared to behavioral risk 
factors. Chronic infection with HBV contributes to 43.6% of all HCC cases worldwide, while 
21% of HCC cases can be attributed to HCV (Table 3-3). Alcohol consumption was the strongest 
lifestyle risk factor, contributing to 25.9% of HCC cases, while smoking contributed to 12.6% 
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and obesity to 8.9%. This discrepancy between infectious and lifestyle risk factors is especially 
pronounced in Asian and African regions, as well as Oceania. 
3.2.1 Hepatitis B 
Worldwide, more cases of HCC can be attributed to chronic infection with HBV than any other 
risk factor. 43.6% of the world total of liver cancer cases can be attributed to HBV (Table 3-3). 
The vast majority of cases attributable to chronic infection with HBV occurred in Asia, and in 
particular East Asia (166,977). PAFs were highest (>50%) in Oceania and Sub-Saharan Africa, 
as well as Central, East, and Southeast Asia. 
3.2.2 Hepatitis C 
About 122,132 cases of HCC (21% of all HCC cases) can be attributed to chronic HCV infection 
(Table 3-3). Similar to patterns observed with HBV, Central Asia, Central Sub-Saharan Africa, 
and West Sub-Saharan Africa had a high PAFs due to HCV (>30%), with high proportions of 
attributable cases also in North Africa and the Middle East and Eastern Europe. North Africa and 
the Middle East had the largest PAF due to HCV (56.3%), due to a large PAF (70.6%) for Egypt 
(Table 3-7), where HCV is prevalent and is exacerbated by a possible interaction with 
schistosoma (Bedwani et al. 1996). 
 
Meta-analyses have reported conflicting results on the joint effects of HBV and HCV, reporting 
both sub-additive (Cho et al. 2011) and super-additive effects (Donato, Boffetta, and Puoti 1998; 
Shi et al. 2005). Cho et al. stratified studies and found an overall sub-additive effect on risk of 
HCC in more recent studies (2000-2009), cohort studies, and studies conducted in areas where 
HBV and HCV infection were uncommon. If the effects are in fact sub-additive, then the sum of 
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the PAFs reported here for HBV and HCV are an overestimate. Conversely, if the effects are 
super-additive, then those who are co-infected have a risk of HCC exceeding the sum of their 
risk from HBV and HCV individually, and the sum of these estimates would be an 
underestimate. 
 
Aflatoxin is another risk factor for liver cancer thought to interact with HBV exposure. A review 
of available studies concluded that aflatoxin likely plays a causative role in 4.6-28.2% of all 
global HCC cases (25,000-155,000), with the majority of cases occurring in sub-Saharan Africa, 
Southeast Asia, and China (Liu et al. 2012). Exposure to aflatoxin in persons with chronic HBV 
infection is associated with a risk up to 30 times greater than in those exposed to aflatoxin alone 
(Groopman, Kensler, and Wild 2008). Estimates for HBV infected individuals in regions where 
aflatoxin exposure is common, such as parts of Africa and Asia, are likely underestimates. 
3.2.3 Alcohol 
About 150, 629 cases of HCC can be attributed to alcohol drinking, or 25.9% of the worldwide 
total (Table 3-3). Although infectious diseases had larger PAFs in Asia and Africa, PAFs for 
alcohol drinking were largest (>35%) in Central and Eastern Europe and Tropical Latin America. 
PAFs were larger for men in most regions of the world compared to women due to the higher 
prevalence of drinking among men (Table 3-4). However, in some regions of the world including 
Southern and Andean Latin America, drinking prevalence was similar among men and women 
resulting in higher PAFs due to the increased risk of HCC at lower levels of alcohol 
consumption. 
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3.2.4 Tobacco Smoking 
Overall, around 73,279 cases of liver cancer can be attributed to tobacco smoking, or 12.6% of 
the world total (Table 3-3). Men in all regions had higher attributable fractions compared to 
women due to a higher prevalence of smoking; however, this disparity was more pronounced in 
Asia and Africa. The largest number of cases was in East Asia, due to a large attributable 
fraction among men (18.7%), but not among women (1.7%) (Table 3-4). Central and Western 
Europe, Australasia, North America, and Southern Latin America had high attributable fractions 
among women (>8%). 
 
The meta-analysis by Lee et al. suggests that adjustment for alcohol may slightly lower the RR 
for smoking and liver cancer (Lee et al. 2009). The RR used in this study for smoking was 
adjusted for alcohol consumption, and likely a reasonable estimate of tobacco smoking 
independent of alcohol consumption. The estimates of alcohol are not adjusted for smoking. 
However, if adjustment for smoking were to lower the associated RRs, then the estimates 
presented here would be an overestimate. 
3.2.5 Obesity 
Body fatness, encompassing those overweight and obese, has been proposed as a risk factor for 
liver cancer. The World Cancer Research Fund has found that there is limited but suggestive 
evidence that body fatness is associated with liver cancer, but without more data it is still unclear 
what the associated magnitude of risk might be (World Cancer Research Fund/American 
Institute for Cancer Research 2007). However, even a small increased risk of liver cancer could 
have wide-reaching future effects. 
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Overall, 51,760 HCC cases worldwide in 2012 can be attributed to obesity, or 8.9% of the world 
total (Table 3-3). Australasia, Western Europe, and North America had the highest attributable 
fractions of liver cancer cases due to a high prevalence of overweight and obese (>20%), while 
parts of Asia and Africa had the lowest attributable fractions (<5%) (Table 3-4). Although the 
worldwide prevalence of obesity was generally higher in women, the risk of HCC associated 
with obesity is higher in men, leading to higher PAFs in many geographic regions. If adjustment 
for alcohol lowers the risk ratio by a very slight margin, as might be expected  from the results of 
Chen et al., then these estimates for obesity might be slightly overestimated (Chen et al. 2012). 
 
The five countries with the largest number of HCC cases are: China, Japan, the USA, India, and 
Vietnam. China alone accounts for over half of the cases of HCC worldwide. More cases can be 
attributed to HBV than any other risk factor in China, India, and Vietnam (Table 3-5). Alcohol 
drinking and HCV were major risk factors in Japan and the USA, while obesity was also a main 
risk factor in the USA. Smoking was responsible for a high proportion of cases in men but not 
women in China, Japan, India, and Vietnam. Estimations of percent HCC by country are 
presented in Table 3-6. Table 3-7, Table 3-8, and Table 3-9 include additional country-specific 
estimates of HCC cases attributable to HBV, HCV, alcohol drinking, tobacco smoking, and 
obesity. 
 
High income regions of the world (Asia Pacific, Australasia, Western Europe, and North 
America) had a distinct disease profile compared to other regions of the world (Figure 3-1). 
Lifestyle risk factors were responsible for a larger percentage of HCC cases in high income 
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regions compared to other regions of the world. On average the PAF for alcohol drinking in high 
income regions was 29.5% (vs. 26.5% in other regions), 11.2% for smoking (vs. 9.0%), and 
18.4% for obesity (vs. 12.5%), while the average PAF for HBV (14.0%) and HCV (18.0%) was 
much smaller in these regions compared to other regions of the world (42.3% and 27.0%, 
respectively). When comparing high income regions to other regions of the world, the disparity 
in PAFs was largest for HBV and smallest for tobacco smoking. 
 
3.3 Discussion 
This study provides an estimate of the contribution of known modifiable risk factors of HCC 
cases worldwide. In 2012, liver cancer was the second leading cause of cancer mortality 
worldwide, and many incident cases of liver cancer are due to preventable causes. 
 
The majority of HCC cases can be attributed to viral infections. For both HBV and HCV, regions 
in Asia and Africa had the highest attributable risk fractions. These regions have the highest 
burden of liver cancer disease worldwide, and the effects of vaccination programs in these areas 
will likely have a large impact on liver cancer incidence in years to come. Although the burden 
of disease in areas that do have vaccination programs is still high, this is because of the long lag 
time between chronic hepatitis infection and liver cancer. Compounding the risk associated with 
hepatitis infection, aflatoxin exposure is also seen more commonly in Asia and Africa. Aflatoxin 
exposure can be prevented and monitored in these regions through regulatory measures and 
improved food storage.  
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While infectious disease and contamination are responsible for the majority of cases in Asia and 
Africa, a comparatively higher percentage of cases of liver cancer are due to tobacco smoking, 
alcohol drinking, and obesity in more developed regions of the world such as Europe, America, 
and Australasia. Many HCC cases are due to lifestyle risk factors, and these cases are likely to 
grow in number. The prevalence of lifestyle risk factors are increasing in many developing 
countries, and as infectious diseases and aflatoxin contaminants become more controlled, these 
lifestyle risk factors will likely play a larger role in the global burden of liver cancer in both 
developed and developing countries. 
 
Results from this study were comparable to the results from similar studies conducted in 
individual countries around the world. These studies, conducted in France (IARC Working 
Group, 2007), the United Kingdom (Parkin et al., 2011), Japan (Inoue et al., 2012), and China 
(Fan et al., 2013) found that the population attributable fractions due to infectious diseases (HBV 
and HCV) in Europe were much lower (64.4% and 41.6% for France and the United Kingdom, 
respectively) than the percent of cases due to infectious disease in Asia (92.1% in Japan and over 
70% in China). Similarly, we found that the burden of disease due to infectious agents and 
contaminants were much higher in Asia and Africa than in western populations.  
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CHAPTER 4. DIETARY FACTORS METHODS, RESULTS, AND 
DISCUSSION 
 
4.1 Jiangsu Case-Control Study Design 
4.1.1 Study Population 
A population-based case-control study was designed to evaluate the risk factors for the four most 
common cancers in Jiangsu province, China, from 2003-2010. Jiangsu province is one of the 
highest risk areas for liver cancer in China. In 2007, the incidence from liver cancer in Jiangsu 
province was 32/100,000, while mortality rates were very similar (30/100,000) (Liu 2014). 
Counties from the north of Jiangsu province (Dafeng, Ganyu, Chuzhou, and Tongshan) were 
included in this study. Esophageal, stomach, lung, and liver cancer were all investigated. 
4.1.2 Recruitment and Selection 
Pathologically or clinically confirmed diagnoses of liver cancer from January 2003 to December 
2010 were reported to each county tumor registry. Diagnostic methods included computed 
tomography (CT), ultrasound, alpha-fetoprotein (AFP), cytology, surgery, magnetic resonance 
imaging (MRI), among others. Cases were restricted to newly diagnosed patients, participants 20 
or older, in stable medical condition, without a previous history of cancer, and those who gave 
informed consent to participate in the study. Only participants who had lived in the study area for 
5 or more years were included in the study. Liver cancer cases include both HCC and 
cholangiocarcinoma, with only a very small number of cases of cholangiocarcinoma. A total of 
2,011 patients with primary liver cancer were included and interviewed during the study period. 
The response rate was 44%. 
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Eligibility criteria for controls were the same as for cases. Each control was frequency matched 
to the cases by cancer site for each village or city resident block using sex and age group (± 5 
years) in a 1:1 ratio; however these matches were later pooled to increase statistical power. A 
sensitivity analysis was conducted in order to assess the impact of breaking the matches, and 
estimates were similar. If a control did not fit the criteria or refused to be interviewed, basic 
demographics were recorded and the same selection process was used to choose another control. 
5-8 ml of blood was drawn from each control. A total of 8,720 controls were interviewed, 7,933 
completed questionnaires, and 6,529 had blood samples drawn. The response rates exceeded 
90% at all study sites. A total of 2,011 liver cancer cases and 7,933 controls were recruited into 
the Jiangsu Four Cancer Study.  
4.1.3 In-Person Interview and Questionnaire 
Cases and controls were interviewed using a standard questionnaire by trained interviewers. 
Furthermore, in-person interviews were monitored by professional staff in the Division of 
Chronic Disease Prevention of the county CDC. Interviews took place in either the hospital or at 
home. The collected information included: (1) socio-demographic characteristics, including age, 
gender, residence, place of birth, education, annual income, blood type, and disease diagnostic 
information; (2) residence and drinking water history, including “raw water” intake history as a 
proxy for aflatoxin exposure; (3) detailed dietary history using a pretested Chinese food 
frequency questionnaire, including 90 food items; (4) detailed tobacco smoking history; (5) 
alcohol drinking habits and history; (6) tea drinking habits; (7) detailed information on disease 
history; (8) occupation history and related exposures; (9) family history of liver cancer and other 
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cancers; and (10) physical activities. For female cases and controls, reproductive factors were 
also collected. 
 
The Food Frequency Questionnaire (FFQ) asked participants to recall diet over the past year. 
This was asked in order to capture diet before diagnosis of disease. Frequency consumed was 
reported for each food item, with the option of saying none consumed. The participant could 
state the number of times they ate a standard amount (g) of a food item per day, month, or year. 
Lastly, the questionnaire also asked how many months out of the year the participant consumed 
each food item, in order to reflect seasonal variations in diet. 
 
Five percent of the face-to-face interviews were conducted twice to verify the quality of the data. 
The questionnaire data collected from the first interview was reviewed by a research staff at the 
county level and then by an epidemiologist at the provincial CDC. Data were doubly entered into 
an epidemiology database designed using EpiData (Odense, Denmark) at each county CDC and 
then cleaned and managed at Jiangsu Provincial CDC. 
4.1.4 Collection and Measurement of Biologic Samples 
Five to eight ml of blood was collected for each consenting participant following the in-person 
interview. Blood samples were collected in EDTA or heparin coated tubes, and assigned an 
identification number. The samples were then separated into serum, red blood cells, and white 
blood cells, and then stored under -20 degrees Celsius at local branches of the CDC. Samples 
from all study sites were then sent to the Jiangsu Provincial CDC, which was responsible for 
storing all samples at -70 degrees or colder for future examination. DNA samples were then 
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extracted in a molecular epidemiology lab at the Department of NCD at the Jiangsu Provincial 
CDC. 
 
HBV and HCV markers were measured at the Jiangsu CDC. Presence of serum HBsAg, HBsAb, 
HBeAg, HBeAb, HBcAb and anti-HCV IgG were measured using enzyme-linked 
immunosorbant assay (ELISA) kits from Shanghai Kehua Biological Pharmacy (Shanghai, 
China), according to the manufacturer’s instructions (Liu 2014). Genotyping was performed at 
the UCLA Genotype and Sequencing Core, using a customized Fluidigm Dynamic 96.96 
Array™ Assay (Fluidigm, South San Francisco, CA). Assays were based on allele-specific PCR 
SNP detection and Dynamic Array™ integrated fluidic circuits (IFCs). The SNP assay tagged 
allele-specific PCR primers and a common reverse primer. A universal probe set was used in 
every reaction, producing uniform fluorescence; furthermore, Fluidigm provided locus-specific 
primer sequences that allowed confirmation of target locations. 
4.1.5 Calculation of Daily Caloric Intake 
For each FFQ food item, a corresponding food item or list of food items was found in the China 
Food Composition 2010, released by the China CDC (Institute of Nutrition and Food Safety 
2010). Three graduate students worked to match FFQ items to food items in the China Food 
Composition data, one of them a Chinese national. 
 
In addition to the food name and food code, the edible percentage of food, energy in calories, 
carbohydrates (g), proteins (g), fat (g), fiber (g), and cholesterol (mg) was extracted. Each food 
item was reported in terms of 100g of fresh food. For food categories that were composite 
categories (e.g. apples and pears), constituent food categories were averaged together. Some 
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foods were weighted more heavily to reflect more common consumption in the population, or to 
reflect preparation methods. Two FFQ items could not be found in the China Food Composition 
data, frog and sugar cane. Estimates from the Japanese Food Composition Table were used for 
frog and data from the USDA database for sugar cane (Watanabe 2015; USDA 2017). Caloric 
intake from foods was calculated using grams of food consumption*edible percentage of 
food*kcal/g of food. Calories from alcohol were calculated from grams of reported consumption 
of liquor (both >=38% and <38% alcohol by volume) and beer from one year prior. Calorie 
information for representative liquors and beers were taken from the China Food Composition 
data and converted into kcal/gram. 
4.1.6 Flavonoid Database Construction and Coverage 
A database listing the flavonoid values for common Chinese foods was constructed in order to 
assess the impact of flavonoid intake on liver cancer within the study, and used along with a 
validated FFQ administered to participants of the Jiangsu study to describe consumption of foods 
and flavonoids one year prior to inclusion in the study. 
 
Total flavonoid intake (mg/week) was calculated for each participant, as well as constituent 
flavonoid categories including  flavonols (isorhamnetin, kaempferol, myricetin, quercetin), 
flavones (apigenin, luteolin), flavanones (eriodictyol, hesperetin, naringenin), flavan-3-ols 
(catechin, catechin-3-gallate, epicatechin, epicatechin-3-gallate, epigallocatechin, 
epigallocatechin-3-gallate, gallocatechin, gallocatechin-3-gallate), theaflavins (theaflavin, 
theaflavin-3-gallate, theaflavin-3’-gallate, theaflavin-3,3’-digallate), anthocyanidins (cyanidin, 
delphinidin, malvidin, pelargonidin, peonidin, petunidin) and isoflavones (daidzein, genistein).  
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Figure 4-1 illustrates the process of developing the flavonoid database. In order to reflect foods 
eaten in Jiangsu province, Chinese articles reporting flavonoid values were reviewed for 
inclusion into the database. These articles measured flavonoid intake in fruits and vegetables that 
were not available in the USDA database or the European databases (Guo et al. 2008a, 2008b; 
Li, Ling, et al. 2010; Cao et al. 2002; Huang et al. 2012; Li, Yao, et al. 2010), and covered 
approximately forty different fruits and fifty different vegetables from different areas in China. 
Additionally, articles from countries outside of China that reported values for common Chinese 
food items (e.g. Japan, Fiji, and Hawaii) were also considered (Arai et al. 2000; Lako et al. 2006; 
Sakakibara et al. 2003; San and Yildirim 2010; Franke et al. 2004; Kevers et al. 2007). Pre-
existing databases were also considered due to the large number of studies on a variety of 
flavonoids that these databases represent. Data from the USDA Flavonoid Database and the 
USDA Isoflavone Database were used instead Phenol Explorer or the UK Food Standards 
Agency database because of the diversity of international foods represented, as well as the 
detailed information included on preparation method (e.g. pan-fried, boiled, etc.). 
 
Only articles that used high quality measurement techniques, including high-performance liquid 
chromatography (HPLC), were included. In addition, studies that reported total flavonoids 
instead of totals by flavonoid subclass were excluded. There were only a handful of food items 
where articles for total flavonoids could be found, but not for subclasses of flavonoids (e.g. 
articles on wood ear and sugar cane), and these items were not a major source of flavonoids in 
this population. 
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From each article, flavonoid measurements by subclass were extracted, along with the units of 
measurement, sample size, and standard deviation. The method of sample preparation was noted, 
as well as whether the sample was of fresh food or cooked food. In addition, the location of the 
study (Guangzhou, Shanghai, Beijing, etc.) and type or variety of food (e.g. Fuji apple) was also 
collected. If units were not already reported in mg/100g fresh weight of edible food, then values 
were converted. For beverages, values for brewed teas from the USDA database were used. 
These values were reported as mg flavonoid/1g dry tea, which corresponded to grams of tea 
reported in the questionnaire. Wine was dropped from the analysis as only a handful of 
participants drank grape wines. For values reported as “trace,” values were reported by 
multiplying the Limit of Quantitation, when reported, by 0.71 (US Department of Agriculture 
2013; Mangels et al. 1993). Most foods and flavonoid subclasses did not have a reported value. 
Often this represents a lack of data, rather than a true zero value. 
 
Where multiple data sources were available for the same food item, preparation method and 
sample size were prioritized over location. For example, if cooked values were available from 
the USDA databases for a food that is almost exclusively eaten cooked (e.g. eggplant), this was 
prioritized over raw foods so long as sample size was similar. If a food is commonly eaten raw 
(e.g. bananas), this was not a point of consideration. If a food item was not available, but values 
were available from a similar variety or from a variety of the same botanical family, this was 
used instead (e.g. members of lactuca sativa for asparagus lettuce). 
 
For food categories that encapsulated more than one food item, an average of the constituent 
food categories was calculated. Following an informal consultation with three Chinese nationals, 
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certain foods were weighted more heavily to reflect foods more commonly consumed. If a food 
category did not have any flavonoid value reported in the main data source used, all other data 
sources were searched to fill in missing values. Weekly milligrams of intake from total 
flavonoids and flavonoid subclasses were derived from g weekly consumption of food items. Tea 
was reported in the questionnaire as grams of dry tea consumption per month, and converted into 
individual grams of black, green, flower, or oolong tea consumed per week before multiplying 
by mg flavonoid intake/g of dry tea. 
 
Of the 54 fruit, vegetable, legume, and nut food items, 50 were covered. This is equivalent to a 
93.6% coverage rate. The four items not covered, including pumpkin seeds, wood ear, sugar 
cane, and wheat gluten, are not expected to be a major source of dietary flavonoids in this 
population. The developed flavonoid database covered all fruits on the FFQ, except for sugar 
cane. While one study has been conducted on Chinese sugarcane, this study reported totals for 
the subclass of anthocyanins and total flavonoids, not individual flavonoids (Li, Yao, et al. 
2010). Wheat gluten was the only food item in the vegetable section that was not covered (95.8% 
coverage), and likely only has minimal flavonoid content. 95.8% of vegetable food items were 
covered. No articles on pumpkin seeds could be found, and one study was found on one variety 
of wood ear, auricularia auricular-judae, however this study only reported total flavonoid 
content, not individual flavonoids (Packialakshmi, Sudha, and Charumathy 2015). 100% of the 
tofu and legume category was covered. 
4.1.7 Dietary Glycemic Index, Glycemic Load, and Macronutrients 
Glycemic Index values for major carbohydrate-containing food items were obtained from the 
2002 and 2008 International Table of Glycemic Index and Glycemic Load Values as well as the 
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National Cancer Institute’s Glycemic Load Values (Atkinson, Foster-Powell, and Brand-Miller 
2008; Flood et al. 2006; Foster-Powell, Holt, and Brand-Miller 2002). Of the 65 FFQ items that 
were not meat or fish dishes, GI values could not be found for salty dishes, pickled kohlrabi, 
garlic leaves, wheat gluten, ginger, wood ear fungus, sugar cane, and ginkgo. Of these, salty 
dishes, ginger, and garlic leaves are the most commonly eaten foods (consumed by >30% of 
population), and are not likely to contribute greatly to individual glycemic index due to their 
lower GI values and the smaller portion sizes of these foods. Glycemic index and load were 
calculated for food items only. 
 
Glycemic index (GI) was calculated by multiplying the GI value for each food by the available 
carbohydrates in each food. For each individual, these values were summed together and then 
divided by the total available carbohydrates. Glycemic load (GL) was calculated in the same 
way, except the denominator was 100 instead of total available carbohydrates. GI and GL were 
calculated as daily values, and the grams of available carbohydrates for each food item was 
obtained from the Chinese Food Composition Tables (Institute of Nutrition and Food Safety 
2010). 
 
The percent of kcals from fat, protein, and carbohydrates was calculated by summing the grams 
of each macronutrient and multiplying by the corresponding number of kcals/gram. For fat this 
was 9 kcals/gram, for protein and carbohydrates this was 4 kcals/gram. This was then divided by 
the total number of calories consumed. 
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4.2 Excluded and Missing Data 
Of the 9,944 participants in the study, 2,557 controls and 745 cases were dropped due to 
insufficient or implausible dietary data. Daily caloric intake from food only was used to exclude 
individuals who consumed less than 500 or more than 5,000 calories per day, and those who ate 
only one food item per day were excluded. After reviewing implausible values by county, 
approximately 50% of the dietary data from Tongshan was found to be missing or implausible. 
Much of this data showed individuals who reported eating only 1 food item over the course of 
the year. Of those controls who did eat more than 1 food item per year, the number of food items 
consumed was much less on average (23) compared to the number of food items consumed in 
other counties (40), even though participants from Tongshan were better educated and had 
similar income. Furthermore, the median number of food items consumed in Tongshan County 
was associated to case status. This suggests that these differences were caused by a systematic 
disparity in the collection of data from Tongshan, rather than a real difference in diet between 
Tongshan and the other counties, and that this data could affect the outcome of this study. For 
these reasons, the dietary data collected from Tongshan was considered unreliable and excluded 
from the dietary study. Those with invalid dietary data were less likely to be from Dafeng, and 
more likely to have lower income and to eat fewer food items and fewer calories. Gender, age, 
and education were similar between both groups. 
 
704 cases and 963 controls were missing biological measures of HbsAg. Those missing covariate 
data were more likely to be from Ganyu or Chuzhou counties, to be less than 60, to be better 
educated, and to have reported eating fewer calories. Crude, adjusted, and semi-Bayes adjusted 
logistic models are reported for the restricted dataset. Multiple imputation was used to compare 
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imputed values of HBsAg in the full dataset to the complete case analysis. For those who 
reported smoking or drinking, but were missing any of the variables needed to calculate either 
pack-years or grams of alcohol consumption, imputation using the median in controls was used 
for missing values. 
  
4.3 Statistical Analysis 
Distributions of outcomes within categorical variables were compared using Chi-square tests or 
Fisher’s exact tests. Wilcoxon rank sum tests were used to compare median values. Unless 
otherwise specified, p-values of less than 0.05 were considered significant. Unconditional 
logistic regression was used to obtain odds ratios (OR) with 95% confidence intervals (CI) to 
assess the relationship between the outcome of interest, liver cancer, and dietary factors. Models 
were adjusted for gender (male or female), age, county (Dafeng, Ganyu, Chuzhou), education 
(illiteracy, primary school, middle school, high school and above), HBsAg status (positive or 
negative), past alcohol consumption (non-drinker, <500 g/week, >500 g/week during the 90s), 
pack-years smoking, daily kcal (except SNP) and family history of liver cancer (yes or no). Odds 
ratios for the adjusted logistic models (aOR) were compared to results using multiple imputation 
(miOR) and semi-Bayes adjustment (sbOR). Two-tailed trend tests for tertiles of dietary factors 
were calculated by testing the significance of the regression parameter for tertiles treated as a 
continuous variable in the logistic regression model. Continuous associations were reported 
using odds ratios in the crude (cOR) and adjusted models using the interquartile range of the 
dietary variable of interest. 
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Potential additive and multiplicative interactions were assessed using the relative excess risk due 
to interaction (RERI) and the ratio of odds ratios (ROR), respectively. Preventive factors were 
re-coded as risk factors and the stratum with the lowest risk was set as the reference category for 
examining the joint effect in all analyses for interaction. Continuous dietary and genetic 
measures were recoded as binary variables using the median in controls to assess interaction. All 
statistical analyses were performed using SAS 9.4. 
4.3.1 Multiple Imputation 
Missing values for HBsAg status were imputed using 5 rounds of imputation. The missing data 
were generated from the observed data using proc mi and the Markov chain Monte Carlo 
(MCMC) option. All variables included in the logistic regression models (including gender, 
county, age, education, past alcohol consumption, pack-years smoking, HBsAg status, family 
history of liver cancer, and daily kcal consumption) were included in the imputation model. The 
logistic regression parameters were combined using proc mianalyze for the final adjusted 
models. 
4.3.2 Semi-Bayes Adjustment 
To mitigate the effects of multiple comparisons and sparse-data bias, the data augmentation 
approach of the semi-Bayes shrinkage method was used (Greenland 2007). Shrinkage estimation 
(including semi-Bayes shrinkage estimation) works by pulling or ‘shrinking’ the regression 
coefficient toward prior patterns or values. Parameter estimates are regressed to a degree 
proportional to their estimated variance, therefore pulling unstable coefficients more than stable 
coefficients. When prior values are zero, the coefficients are pulled toward zero (thus, the term 
‘shrinkage’).  
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Practically, this was implemented in our data using a null prior to generate posterior estimates of 
effect measures for risk associated with food categories, macronutrients, flavonoids, and SNPs. 
Few epidemiology studies have been conducted on these associations, justifying the use of the 
more conservative null prior. Information weighting was used to carry out the adjustment, using 
a coefficient prior with median 0 (OR=1) and a prior variance of 0.50 (95% probability of falling 
within 0.25-4.00). This simulated prior was merged with the study data, weighted, and then 
logistic regression models were run in the merged and weighted dataset to calculate semi-Bayes 
adjusted estimates.  
4.3.3 Adjustment for Energy Intake 
Adjusting for energy intake can control for confounding by total energy intake and reduce 
extraneous variation in nutrient intake (Willett, Howe, and Kushi 1997). Additionally, 
adjustment is helpful in mitigating the effects of measurement error in data collected from self-
reported dietary instruments, as individuals tend to under or over report foods to a similar degree 
in the same direction (National Cancer Institute), and is commonly used for analysis of Food 
Frequency Questionnaire data. 
 
Total energy intake (including diet and alcohol) was adjusted for using the residual method. In 
this method, residuals are obtained from a regression model where total energy intake is the 
predictor variable and absolute nutrient intake is the dependent variable, making the residual an 
estimate of nutrient intake uncorrelated with total energy intake. Standard diagnostics for 
regression were conducted, including plotting residuals to assess distribution in the linear models 
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as well as identifying observations with high leverage. Proc robustreg was used with M 
estimation and Huber weights, which down weights observations with larger residuals. 
 
Residuals were calculated for all food items other than macronutrients, which are already 
calculated as a percentage of caloric intake. Tertiles of the residual were used as the predictor of 
interest in the logistic regression model, and other covariates added into the model include 
gender, age, county, education, past alcohol consumption, pack-years of smoking, HBsAg status, 
family history of liver cancer, and daily caloric intake. Residual values were standardized to the 
mean caloric consumption in controls in order to give results better interpretability, and tables 
are reported in both tertiles and the standardized residual equivalents. 
 
4.4 Results 
4.4.1 Socio-Demographic Characteristics 
A total of 1,266 cases and 5,376 controls were included in the dietary analysis. Table 4-1 shows 
the distribution of demographic and socio-demographic characteristics among cases and controls 
in the analysis dataset. Most cases were recruited from Dafeng (48.7%), followed by Ganyu 
(29.2%), and Chuzhou (22.1%). Cases tended to be younger than controls, and a larger 
proportion were male (77.2%) compared to controls (72.8%). In general, cases had slightly 
higher levels of education. Cases were much more likely to have a family history of liver cancer 
(p<0.001). 
45 
 
4.4.2 Established Risk Factors 
Table 4-2 shows major worldwide liver cancer risk factors, chronic hepatitis B infection, 
aflatoxin exposure, alcohol drinking, tobacco smoking, and BMI, and their association with liver 
cancer in this case-control study. The association between HBsAg status and liver cancer was 
very strong in this study (aOR: 20.56, 95% CI 16.41, 25.76), and is comparable to estimates from 
meta-analysis. 60% of cases were HBsAg positive, while 5.5% of controls were HBsAg positive. 
Reports of mildew were associated with a slight increase in liver cancer susceptibility, while 
clean grain storage was associated with a slight decrease. However, neither proxy for aflatoxin 
exposure was significantly associated with liver cancer. Ever drinking alcohol was associated 
with liver cancer in the adjusted models (aOR: 1.39, 95% CI: 1.04, 1.87), however this 
association did not remain significant after semi-Bayes adjustment or multiple imputation. 
Consumption of 500 or more grams of alcohol per week, the equivalent of about 5 drinks per 
day, was significantly associated with liver cancer in both the adjusted and multiple imputation 
models. Ever smoking was marginally associated with liver cancer, and the association for those 
who smoked 0-20 pack-years compared to never smokers (aOR: 1.27, 95% CI: 0.91, 1.77) was 
similar to the association for those who smoked 20 or more pack-years (aOR: 1.28, 95% CI: 
0.84, 1.95). BMI was significantly protective in this study, with a BMI of at least 27.5 (obese 
among Asians) associated with an aOR of 0.23 (95% CI: 0.13, 0.41) compared to those with a 
BMI less than 18.5. 
4.4.3 Food Categories 
Table 4-3 shows food categories and constituent foods, while median food consumption values 
among those with complete dietary data are shown in Table 4-4. Median daily kcal consumption, 
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including dietary and alcohol intake, was not significantly different between cases (2,210 
kcal/day) and controls (2,160 kcal/day). The distribution of macronutrients was similar in cases 
and controls. The most commonly consumed foods were grains and vegetables. Controls 
consumed an average of 3,426 g/week of grains, an equivalent of a little less than 3 cups cooked 
rice/day, and 1,666 g/week of vegetables (equivalent to a little less than 1 1/2 cups of cooked 
vegetable per day). Median values of fruits and vegetables were higher in cases, while median 
values of soy and legumes and fish were lower in cases. Median total flavonoid consumption was 
lower in cases than controls (p=0.025), as well as the subgroups catechins and epicatechins and 
isoflavonoids. Flavone consumption was higher in cases. 
 
Although a number of food items in the crude model were associated with liver cancer, most 
associations disappeared after adjusting for covariates. Table 4-5 presents the association 
between food categories and liver cancer. Fruit consumption did not appear to be associated with 
liver cancer, especially after using multiple imputation. Vegetable consumption was not 
significantly associated with liver cancer when categorized into tertiles, however a 1,261g 
increase in vegetable consumption was marginally associated with increased odds of liver cancer 
(aOR: 1.12, 95% CI: 1.01, 1.24). No statistically significant associations were found after 
looking at the association between liver cancer and vegetable subcategories, including red 
vegetables, green vegetables, starch vegetables, and other vegetables. 
 
The third tertile of meat consumption was marginally protective against liver cancer (aOR: 0.76, 
95% CI: 0.57, 1.02), while a 135g increase in fish consumption was associated with increased 
odds of liver cancer (aOR: 1.05, 95% CI: 1.00, 1.09). The third tertile of grain consumption was 
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associated with an increased odds in liver cancer in the adjusted model (aOR: 1.39, 95% CI: 
1.04, 1.85) as well as the semi-Bayes adjusted model (sbOR: 1.37, 95% CI: 1.03, 1.81). The p for 
trend for grains was also significant (p=0.020), although the second tertile of grain consumption 
was not associated with liver cancer (aOR: 0.98, 95% CI: 0.74, 1.31). A 937g increase in grain 
consumption was significantly associated with liver cancer (aOR: 1.25, 95% CI: 1.09, 1.42). 
4.4.4 Glycemic Index, Glycemic Load, and Macronutrients 
The main source of glycemic load among controls with complete dietary data was rice, 
accounting for 89.9% of the daily glycemic load. After rice, noodles were responsible for the 
second largest percentage of daily glycemic load (6.3%). These two food items were responsible 
for the vast majority of the variation in glycemic load. White rice is a high GI food, while 
noodles are medium GI food. 
 
Table 4-6 shows the associations between GI, GL, and macronutrients with liver cancer. Liver 
cancer did not appear to be associated with percent of calories from protein or fat, however those 
who consumed a higher percentage of carbohydrates appeared to have higher odds of liver 
cancer. Those in the second and third tertile of carbohydrate consumption had an odds ratio of 
1.33 (95% CI 0.99, 1.79) and 1.72 (1.24, 2.39), compared to those in the first tertile. The 
association in the third tertile persisted after semi-Bayes adjustment and after using multiple 
imputation. There appeared to be a monotonic trend, with the association with liver cancer 
increasing with higher consumption of carbohydrates (p=0.001). Furthermore, an 18% increase 
in percent of calories from carbohydrates was associated with an odds ratio of 1.31 (95% CI: 
1.08, 1.59). 
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Although glycemic index was not obviously associated with liver cancer, glycemic load 
appeared to be marginally associated with liver cancer. Those in the third tertile had an adjusted 
odds ratio of 1.36 (95% CI: 0.98, 1.87), and there was a marginally significant trend with 
increasing glycemic load (p=0.055). Furthermore, a 125 unit increase in glycemic load was 
associated with an odds ratio of 1.22 (95% CI: 1.02, 1.46). Along with the results showing 
increased odds of liver cancer associated with percent calories from carbohydrates and the 
highest tertile of grain consumption, this provides compelling evidence that carbohydrates and 
carbohydrate-rich foods may be associated with liver cancer. 
 
Conversely, cholesterol appeared to be marginally and inversely associated with liver cancer. 
Although the p for trend was not significant, the second tertile was associated with decreased 
odds of liver cancer (aOR: 0.73, 95% CI: 0.56, 0.95), although this did not remain statistically 
significant after multiple imputation. As carbohydrate consumption is correlated with 
consumption of fat and cholesterol, it is likely that those who consumed higher amounts of 
cholesterol may have a lower percentage of carbohydrate intake as well. 
4.4.5 Dietary Flavonoids 
Table 4-7 shows the main sources of flavonoids in this population. Among controls, the main 
source of flavonoids was green tea (77.7%), followed by tofu (3.9%) and dried bean curd (2.7%). 
Green tea is rich in flavonoids (135.6 mg/1 gram dried tea leaf), particularly catechins and 
epicatechins as well as theaflavins. Green tea consumption was relatively common in this 
population, and about 30% of controls drank tea daily with the majority (80%) of regular tea 
drinkers preferring green tea. Tea consumption was reported in grams of dried tea leaf, which is 
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an especially potent source of flavonoids. Controls used 10.1 grams of green tea leaves per week 
on average. 
 
Dietary sources of flavonoid subclasses tended to correlate with specific food categories. The 
dietary sources of flavonols were diverse, including onions, grapes, and bananas, while most 
dietary flavonols in the control population came from green tea (43.5%), green vegetables 
(11.1%), and onions (4.6%). Green vegetables were the largest source of dietary flavones 
(45.5%), followed by green pepper (10.2%) and green tea (9.6%). Citrus fruits are rich in 
flavanones, and tangerines (75.7%) provided the majority of dietary flavanones, followed by 
oranges (24.3%). Catechins and epicatechins were found primarily in teas in this population, 
particularly green tea (92.5%), oolong tea (3.0%), and black tea (2.4%). In the dietary items 
measured, green tea was the only source of theaflavins. Anthocyanidins were found primarily in 
radishes (46%), salted vegetables (21%), and beans (12%). Isoflavones are found primarily in 
soy products, although some vegetables, teas, and eggs contain smaller amounts. In the control 
population, tofu was the main source of isoflavones (41.4%), followed by dried bean curd 
(31.1%) and soybeans (19.1%). 
 
Table 4-8 presents the associations between total flavonoids and flavonoid subgroups with liver 
cancer. Increasing consumption of total flavonoids appeared to be inversely and marginally 
associated with liver cancer (p=0.074), with an adjusted odds ratio of 0.77 (95% CI: 0.58, 1.01) 
when comparing the highest tertile of total flavonoid consumption to the lowest. The associations 
between flavonoid subgroups and liver cancer appeared to vary by subgroup. 
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The subgroups of flavonols, flavones, flavanones, and anthocyanidins did not appear to be 
associated with liver cancer. For these subgroups, the p for trend ranged from 0.194 to 0.906, and 
adjusted odds ratios for individual tertiles varied substantially as well. Three subcategories of 
flavonoids appeared to have a significant or marginally significant protective effect against liver 
cancer. The evidence for a protective effect was strongest for catechins and epicatechins, with an 
adjusted odds ratio of 0.70 (95% CI: 0.53, 0.92) and a p for trend of 0.01. This association 
persisted after semi-Bayes adjustment and multiple imputation. Isoflavonoids appeared to have a 
marginally protective effect as well, as those in the third tertile had an adjusted odds ratio of 0.79 
(95% CI: 0.60, 1.02). The p for trend was 0.069. There was some evidence that the highest tertile 
of theaflavins, which exclusively came from green tea in this study, was associated with a 
marginal protective effect (aOR: 0.81, 95% CI: 0.59, 1.10), and the association after semi-Bayes 
adjustment and multiple imputation were similar. None of the continuous measures for 
flavonoids and flavonoid subclasses were statistically significant. 
4.4.6 Tea Consumption 
Table 4-9 shows tea consumption patterns for cases and controls with complete dietary data. 338 
(31%) controls reported ever drinking tea regularly, compared to 26.7% of cases. Regular tea 
drinking was defined as drinking at least one cup of tea once a day. 28.2% of controls were 
current tea drinkers compared to 13.7% of cases. Cases generally started drinking later than 
controls. The most common type of tea consumed among controls was green tea, with over 78% 
of regular tea drinkers preferring green tea. Most tea drinkers had one or two cups per day, and 
re-brewed tea from the same set of tea leaves 3 or more times. Controls generally drank more 
cups of tea every day, and re-brewed more often than cases. Tap water, purified water, and well 
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water were used most commonly to brew tea, and most tea drinkers used between 0 and 50 
grams of tea leaves per month. 
 
Ever drinking tea was inversely associated with liver cancer (aOR: 0.73, 95% CI: 0.56, 0.94). 
This protective effect remained even after semi-Bayes adjustment and after imputing missing 
covariates. Current tea drinking had a strong protective association (aOR: 0.42, 95% CI: 0.31, 
0.56), while former tea drinking was associated with an increased odds (aOR: 4.30, 95% CI: 
2.81, 6.56).  
 
The length of time a person had been drinking did not seem to make a large difference, as those 
who started drinking at age 35 or later and those who had been drinking tea for less than 30 years 
both were inversely associated with  liver cancer (aOR for 35+ years of age: 0.59, 95% CI: 0.41, 
0.84; aOR for <30 years tea drinking: 0.53, 95% CI: 0.39, 0.73), while the associations for those 
who had started drinking tea younger than 35 years old or had been drinking tea for longer than 
30 years were not statistically significant. Green tea drinking was protective against liver cancer 
in the crude (cOR: 0.77, 95% CI: 0.62, 0.97) and adjusted models (aOR: 0.75, 95% CI: 0.57, 
1.00), but this association did not hold after semi-Bayes adjustment and multiple imputation. The 
odds ratios for other types of tea appeared to be protective, but the sample size was not large 
enough for statistical significance. 
 
Drinking as few as one cup per day had a protective effect in crude and adjusted models (aOR: 
0.48, 95% CI: 0.32, 0.72), and this association held even after semi-Bayes adjustment and 
multiple imputation. There was not much evidence that drinking more than one cup per day gave 
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additional protection against liver cancer, however. Although drinking 3 cups of tea had a 
significant protective effect (cOR: 0.60, 95% CI 0.37, 0.98), this effect was only marginally 
significant in the adjusted model, and no association was observed with 2 cups/day or 4 or more 
cups/day. Similarly, re-brewing tea one to two times using the same tea leaves had a protective 
effect in the adjusted and semi-Bayes adjusted models (aOR: 0.50, 95% CI: 0.32, 0.77; sbOR: 
0.54, 95% CI 0.36, 0.81), but this protective effect was only marginally significant for re-
brewing three or more times. Monthly consumption of up to 50 grams of tea leaves had a 
significant protective effect in the adjusted, semi-Bayes adjusted, and multiple imputation 
adjusted models (aOR: 0.72, 95% CI: 0.54, 0.95). The protective effect intensified with 
increasing tea monthly tea leaf consumption, although these associations were not significant as 
only a small number of participants used 50 or more grams of tea leaves each month. The source 
of water used to brew the tea might affect risk, as tea brewed using deep well water was 
inversely associated with liver cancer in the adjusted models, but tea brewed from other sources 
was not. 
4.4.7 Effect Measure Modification 
Interaction on the additive and multiplicative scale was assessed for major liver cancer risk 
factors and dietary factors, including total flavonoid intake, glycemic index, glycemic load, and 
percent calories from carbohydrate. The results are presented in Table 4-10. No statistically 
significant interaction on the additive or multiplicative scale was observed between flavonoid 
intake and GI, GL, or percent calories from carbohydrates. Unclean tools associated with grain 
storage, a surrogate risk factor for aflatoxin exposure, was associated with an increased odds of 
liver cancer in this population. The ROR for the joint associations of unclean grain storage and 
low flavonoid intake on liver cancer was statistically significant (ROR: 0.59, 95% CI: 0.38, 
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0.92), while RERI suggested sub-additive biological interaction (RERI: -0.70, 95% CI: -1.39, 
0.00). Similarly, the ROR for HBsAg+ and low flavonoid intake was statistically significant 
(ROR: 0.62, 95% CI: 0.40, 0.97). There was no strong evidence that chronic hepatitis interacted 
with any other dietary factor. Alcohol consumption (ever/never drinker) and tobacco smoking 
(ever/never smoker) did not appear to modify the association between dietary factors and liver 
cancer. 
 
4.5 Discussion 
Our results confirm associations between chronic hepatitis B infection, alcohol drinking, and 
tobacco smoking with liver cancer. Obesity is not a risk factor, but in fact associated with a 
decreased risk in this study. There are two likely explanations for this association. First, BMI 
was measured after inclusion into the study. One of the first signs of liver cancer is rapid weight 
loss, and reverse causation could explain this association. Furthermore, the metabolic effects of 
obesity may vary with ethnicity. 
 
Evidence is emerging that diet may play a role in the development of chronic liver disease and 
liver cancer. A meta-analysis of 19 studies found that as little as a 100g/day increase in vegetable 
intake was associated with a reduction in liver cancer risk, and that the association with fruit 
intake was in the same direction, but was not statistically significant (Yang, Zhang, et al. 2014). 
We found a non-significant association with tertile of vegetable intake and liver cancer (p for 
trend=0.176), and a marginally significant association when looking at vegetable intake 
continuously (aOR: 1.12, 95% CI: 1.01, 1.24). After assessing the association by vegetable 
54 
 
subgroup, no clear trends were observed. Fruit consumption had a moderately protective 
association, although the p for trend was not significant (p=0.331).  
 
While most studies have been conducted on fruit and vegetable consumption, several studies 
have assessed the association between liver cancer and red meat, saturated fat, and dairy. A 
meta-analysis of 7 cohort and 10 case-control studies as well the multi-center prospective cohort 
study EPIC found no association between red meat consumption or total meat consumption with 
liver cancer (Luo et al. 2014; Fedirko et al. 2013). Our study found a marginally protective effect 
of meat consumption, including both red and white meat consumption, on liver cancer (p for 
trend=0.071), however it is possible that the inclusion of white meat, which was found to be 
protective against liver cancer in the meta-analysis, could bring the estimate down. It is also 
possible that the ability to regularly purchase meat might also be a proxy for higher 
socioeconomic status in this population, although additionally adjusting for income in the model 
resulted in similar estimates. Furthermore, meat consumption in this population was very low 
compared to diets in most Western populations. A 135g increase in fish consumption was 
associated with increased odds of liver cancer. It is possible that this might be linked to pollution 
in this population. Two Italian case-control studies have found a protective effect of milk and 
eggs on hepatocellular carcinoma risk (La Vecchia et al. 1988; Talamini et al. 2006), while a 
Japanese case-control study found an increased risk (Fukuda et al. 1993). Our results were not 
significant, although the direction of the association was protective, suggesting that the 
difference between the Italian and Japanese studies was likely not due to a difference between 
Western and Asian diets. 
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One study of glycemic load, glycemic index, and carbohydrate intake and liver cancer was 
conducted in a cohort study in Shanghai, China. The dietary patterns described in this study are 
similar to ours. Rice was the main contributor, responsible for approximately 81% of the 
glycemic load (90% in our study), followed by noodles and bread. This study did not find strong 
evidence of an association between glycemic index, glycemic load, and carbohydrates with liver 
cancer overall, however this study did find a significant association with glycemic index and 
liver cancer in women. Our study supports the results from two case-control studies conducted in 
the Mediterranean that found evidence of a positive association between glycemic load and liver 
cancer (Rossi et al. 2009; Lagiou et al. 2008), making it unlikely that the different results from 
the Shanghai study were due to a difference between a Western and Asian diet. Estimates 
additionally adjusted for mildew and clean grain storage, proxies for aflatoxin exposure, were 
very similar for GI, GL, carbohydrate intake, and grain consumption, making it unlikely that 
these associations were due to residual confounding by aflatoxin exposure. 
 
To the best of our knowledge, no study has looked at the association between total flavonoid 
intake and liver cancer in a Chinese population. One study of colorectal cancer described 
flavonoid intake in a similar case control study conducted in Guangdong Province in China (Xu 
et al. 2016). In this population, approximately 50% of total flavonoid intake came from tea 
compared to 78% in our study, although the absolute mg of flavonoid consumption per day from 
tea was similar in both studies (Guangdong: 211.90 mg/day Jiangsu: 199.23 mg/day). Fruits and 
vegetables were other main sources of flavonoids in Guangdong and Guangzhou (Li et al. 2013; 
Xu et al. 2016), while tofu products and vegetables contributed substantially to flavonoid intake 
in our study. 
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Results from European countries have found nonsignificant or marginal associations between 
total flavonoid intake and liver cancer, with stronger results for a protective effect of catechins 
and epicatechins against liver cancer (Zamora-Ros, Fedirko, et al. 2013; Lagiou et al. 2008). We 
found similar results in our study showing a marginally significant protective association 
between total flavonoid intake and liver cancer (p for trend=0.074), with the protective 
association most evident in the third tertile of total flavonoid consumption (aOR: 0.77, 95% CI: 
0.58, 1.01). Compared to the study by Lagiou et al., we found limited evidence of sub-
multiplicative effect measure modification of hepatitis infection on the association between total 
flavonoid intake and liver cancer. 
 
Tea is a rich source of catechins and epicatechins. Isoflavonoids, a flavonoid subgroup that is 
strongly influenced by tea intake, also had a marginally protective association with liver cancer 
(isoflavonoids p for trend: 0.069). Tea was protective against liver cancer in our study, and 
results reflect the strong association tea consumption has on the relationship between flavonoid 
intake and liver cancer. There was no evidence that flavonoid-rich vegetables were inversely 
associated with liver cancer; however there did appear to be a marginally protective association 
with fruits. It is possible that, as the association with liver cancer varies by flavonoid source, 
there may be some aspect of tea consumption that confers an additional protective benefit 
beyond the posited benefit of high flavonoid intake. One possibility is a difference in 
bioavailability or dosage between tea and whole foods, as well as other co-factors that exist 
within the beverage or food itself that may affect the association with liver cancer. 
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Although individual food categories were not strongly associated with liver cancer risk, tea 
consumption did have a clear inverse association with of liver cancer in this study. A meta-
analysis of nine prospective cohort studies conducted in Asian populations found that green tea 
consumption was associated with a reduced risk of liver cancer (RR: 0.88, 95% CI: 0.81, 0.97), 
but that this association was only marginally significant for one additional daily cup of tea (RR: 
0.97, 95% CI: 0.95, 1.00). Our results found a similar protective effect associated with regular 
tea consumption (aOR: 0.73, 95% CI: 0.56, 0.94), driven largely by consumption of green tea. 
However, our study results suggested that drinking more than one cup of tea per day, or re-
brewing tea from the same teapot more often did not confer additional health benefits. The 
majority of flavonoids in tea leaves are released during the first time the tea leaves are brewed. 
Consumption of as little as one cup of tea every day had a beneficial association with liver 
cancer (aOR: 0.48, 95% CI: 0.32, 0.72). 
 
58 
 
CHAPTER 5. GENETIC POLYMORPHISMS METHODS, RESULTS, AND 
DISCUSSION 
 
5.1 Methods 
The study of genetic polymorphisms was conducted in the Jiangsu population-based case-control 
study, the details of which can be found in the “study design” section of Chapter 4. 
5.1.1 Selection Criteria 
SNP selection was completed in the following manner. Nonsynonymous SNPs from NF-kB, 
stem cell, and miRNA pathways were identified, as well as SNPs from GWAS studies. Published 
data indicating the functionality of the SNPs was reviewed before selecting SNPs. All SNPs 
included in the analysis had a genotyping call rate greater than 90%, a minor allele frequency 
greater than 5%, and were in Hardy-Weinberg equilibrium among the controls using a 
Bonferonni adjusted p-value cutoff of 0.000521 (0.05/96). One pair of SNPs was in linkage 
disequilibrium (rs1538660 and rs3204145). The results for only rs3204145 are shown here. 
Table 5-1 shows the dbsnp no. of the 43 SNPs included in the study, as well as the gene they are 
associated with. 
5.1.2 Statistical Analysis 
Unconditional logistic regression models were used to estimate genotype-specific ORs and 95% 
CIs for 43 SNPs in a subgroup of the study population. Heterozygous and homozygous carriers 
of the variant were compared to homozygous carriers of the wild type allele, and additional ORs 
were reported assuming a log-additive, dominant, and recessive models. Models were adjusted 
for gender (male or female), age, county (Dafeng, Ganyu, Chuzhou), education (illiteracy, 
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primary school, middle school, high school and above), HbsAg status (positive or negative), past 
alcohol consumption (non-drinker, <500 g/week, >500 g/week during the 90s), pack-years 
smoking, and family history of liver cancer (yes or no). Stratified dietary analyses were 
additionally adjusted for daily kcals. Because there were some cells with sparse data, the semi-
Bayes shrinkage method using data augmentation was used with a null prior of OR=1 and a 
variance of 0.5. Analyses were also stratified by low (less than or equal to the median in 
controls) and high (greater than the median in controls) total flavonoid intake, and we assessed 
additive and multiplicative effect measure modification between SNPs and total flavonoid intake 
using RERI and ROR (Hosmer and Lemeshow 1992). Glycemic index, glycemic load, and 
percent carbohydrates were similarly stratified by low or high intake, and interaction with 
established risk factors, such as grain storage (aflatoxin proxy), hepatitis B status, alcohol 
drinking (ever/never), or smoking (ever/never), was assessed. All variables were re-coded to be 
risk factors when calculating RERI and ROR. 
5.1.3 Genetic Risk Scores 
Genetic risk scores were constructed as a parsimonious way of summarizing the effects across 
several genetic variants in individual subjects. A polygenic risk score (PRS) assesses the number 
of risk alleles an individual has, while the multigenetic index (MGI) includes the number of risk 
genotypes (Mu et al. 2005; Garcia-Closas et al. 2013). The PRS was calculated using the log-
additive models using the weighted sum of all SNPs associated with liver cancer with a p-value 
less than 0.1 in the adjusted model. A weighted variant of the MGI was calculated using the 
weighted sum of all risk genotypes from the dominant models that were associated with liver 
cancer with p value of less than 0.1 in the adjusted model. The genetic risk scores were 
categorized into tertiles based on their distribution in controls, and is estimated only for those 
60 
 
with complete genotype data on all SNPs. Median imputation among controls was used as a 
comparison to the complete case analysis. PRS was stratified into low PRS (less than the median 
in controls) and high PRS (greater than or equal to median in controls), and additive and 
multiplicative interaction with dietary factors (flavonoid intake and glycemic index) as well as 
established risk factors (hepatitis B, mildew exposure, alcohol drinking, and smoking) was 
assessed using RERI and ROR. All continuous factors were re-coded as binary variables, and 
preventive factors were re-coded as risk factors. 
 
5.2 Results 
Table 5-2 shows the adjusted and semi-Bayes adjusted odds ratios for the associations between 
selected SNPs and liver cancer. Positive associations were observed in the full sample for a SNP 
involved in the micro RNA pathway, rs42031 (aOR for A:T vs A:A: 1.78, 95% CI: 1.11, 2.86), 
while protective associations were observed for a SNP involved in the stem cell pathway, 
rs3734637 (aOR for A:C vs A:A: 0.71, 95% CI: 0.50, 1.00). These results remained significant, 
even after semi-Bayes adjustment in the log-additive and dominant models. 
 
In addition, Table 5-2 shows the adjusted and semi-Bayes adjusted odds ratios after stratifying 
for total flavonoid intake. Among those in the upper half of flavonoid intake, the associations 
observed for rs42031 (CDK6) in the overall population persisted in all models and in the 
dominant model for rs3734637 (HEY2). For both SNPs, estimates were slightly further from the 
null compared to the full dataset. Associations were observed among those with low flavonoid 
intake with rs12934922 (BCM01), rs2269700 (stem cell pathway), rs3729629 (stem cell 
pathway), rs738722 (CHEK2), and rs9267673 (ZBTB12-C2), and among those with high 
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flavonoid intake associations were observed with stem cell pathway SNPs rs3130932 (Oct-4) 
and rs3740535 (Ctbp2). There were no associations between NF-kB SNPs and liver cancer in the 
full or stratified dataset. 
 
The association between two SNPs associated with liver cancer and the stem cell pathway, 
rs374053 (Ctbp2) and rs3729629 (WNT2), appeared to vary with total flavonoid intake. Ctbp2, a 
gene associated with liver cancer initiation and progression, was marginally associated with 
increased odds of liver cancer among those with low flavonoid intake, and inversely and 
marginally associated with liver cancer among those with high flavonoid intake. The AG and AA 
genotypes were protective against liver cancer compared to GG, and the log-additive model was 
significantly associated with a decreased susceptibility (aOR: 0.68, 95% CI: 0.47, 0.99), however 
this association did not remain after semi-Bayes adjustment. Among those who consumed a low 
level of flavonoid intake, the AG and AA genotypes were a risk factor for liver cancer. 
Statistically significant interaction (Table 5-3) was observed on the multiplicative scale (ROR: 
0.53, 95% CI: 0.29, 0.98), but did not remain after semi-Bayes adjustment. For rs3729629 
(WNT2), the CG genotype had an adjusted odds ratio of 0.62 (95% CI: 0.40, 0.97) compared to 
the GG genotype. The log-additive and dominant models were significantly protective (log-
additive: 0.64, 95% CI: 0.46, 0.90; dominant: 0.59, 95% CI 0.39, 0.90), and this association 
remained after semi-Bayes adjustment. Furthermore, statistically significant interaction was 
observed on the additive and multiplicative scale (RERI: -1.19, 95% CI: -2.26, -0.11; ROR: 0.43, 
95% CI: 0.23, 0.79), and these associations persisted even after semi-Bayes adjustment. 
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Three other SNPs appeared to vary with flavonoid intake, including rs12934922 (BCM01), 
rs9267673 (ZBTB12-C2), and rs738722 (CHEK2). Among those with low flavonoid intake, 
rs12934922 (BCM01) was inversely associated with liver cancer. Those who had the TT 
genotype had an adjusted odds ratio of 4.84 (95% CI 1.50, 15.58) among those with low 
flavonoid intake, while the TT and AT genotypes were not associated with liver cancer among 
those with high flavonoid intake (aOR TT vs AA: 0.44, 95% CI: 0.07, 2.59). Statistically 
significant interaction was observed (ROR: 0.46, 95% CI: 0.23, 0.93), but did not persist after 
semi-Bayes adjustment. For rs738722, the CT genotype compared to CC was protective against 
liver cancer (aOR: 0.62, 95% CI: 0.38, 0.99), among those with low total flavonoid intake, and 
this association remained after semi-Bayes adjustment. Statistically significant interaction was 
observed on both the additive and multiplicative scale (RERI: -1.12, 95% CI: -2.24, -0.01; ROR: 
0.47, 95% CI: 0.25, 0.89), and these remained significant after semi-Bayes adjustment. One other 
SNP, rs9267673 (ZBTB12-C2) is an HBV-related SNP that was associated with liver cancer for 
those with low flavonoid intake (TT vs CC aOR: 4.53, 95% CI: 1.57, 13.02), but not among 
those with low flavonoid intake (TT vs CC aOR: 0.93, 95% CI: 0.24, 3.60). Although no 
statistically significant interaction was observed, the direction of the association varies clearly 
after stratification. 
5.2.1 Genetic Risk Scores 
Three SNPs were associated with liver cancer with a p-value of less than 0.1 in the log-additive 
model, including: rs3734637 (HEY 2, stem cell pathway), rs42031 (CDK6, micro RNA 
pathway), and rs4730775 (WNT2, stem cell pathway). The association between tertiles of the 
polygenic risk score with liver cancer is presented in Table 5-4. The second and third tertiles of 
the PRS are associated with an increased risk of liver cancer (T3 vs T1, OR: 2.89, 95% CI: 1.68, 
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4.95). After stratifying for total flavonoid intake, the third tertile of the PRS remained significant 
(OR: 3.50, 95% CI: 1.70, 7.24) among those with low flavonoid intake, while median imputation 
of missing genotypes generally increased estimates of the first tertile and lowered estimates of 
the third. Increasing PRS was associated with increasing risk of liver cancer in the full dataset (p 
for trend <0.001, as well as in both the low and high flavonoid subgroups (low flavonoid 
p=0.001; high flavonoid p=0.071).  
 
Four SNPs were associated with liver cancer with a p-value of less than 0.1 in the dominant 
model, including: rs222851 (DVL2, stem cell pathway), rs3734637 (HEY 2, stem cell pathway), 
rs42031 (CDK6, micro RNA pathway), and rs4730775 (WNT2, stem cell pathway), and 
included in the multigenetic index. The associations between the weighted MGI and liver cancer 
were slightly more modest than for the PRS. The third tertile of the weighted MGI was 
significantly associated with liver cancer in the full dataset (aOR: 2.09, 95% CI 1.45, 3.02), as 
well as in the low flavonoid stratified analysis, however, it was not significantly associated with 
liver cancer in the high flavonoid analysis. The trends for the weighted MGI in the full dataset 
and in the low flavonoid dataset were similarly significant (p<0.001), and median imputation 
slightly increased estimates of most associations. 
 
Table 5-5 shows the joint associations between high and low genetic risk scores with proposed 
dietary and established risk factors on liver cancer. Low flavonoid intake and high GI did not 
have any significant interactions, however estimates were in the direction of super-additivity and 
super-multiplicativity. Chronic hepatitis B infection interacted with weighted MGI on the 
additive scale (RERI: 18.27, 95% CI: 1.65, 34.88), however this association did not remain after 
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semi-Bayes adjustment. Furthermore, there was no evidence of multiplicative interaction. 
Mildew exposure, ever drinking, and ever smoking did not significantly interact with either PRS 
or weighted MGI. 
 
5.3 Discussion 
It is thought that flavonoids may affect risk of liver cancer by influencing cell signaling 
pathways and inflammation. We analyzed the association between genetic polymorphisms and 
liver cancer stratified by total flavonoid consumption in order to assess how diet can impact the 
molecular environment for the SNPs associated with the NFKB, microRNA, and stem cell 
pathways, as well as selected SNPs hypothesized to be associated with cancer. Total flavonoid 
intake did not alter associations between rs3734637 (HEY2) and rs42031 (CDK6) and liver 
cancer, however associations were observed among those with low flavonoid intake with 
rs12934922 (BCM01), rs2269700 (stem cell pathway), rs3729629 (stem cell pathway), rs738722 
(CHEK2), and rs9267673 (ZBTB12-C2), and among those with high flavonoid intake 
associations were observed with stem cell pathway SNPs rs3130932 (Oct-4) and rs3740535 
(Ctbp2). Furthermore, statistical interactions were observed between total flavonoid intake and 
rs738722 (CHEK2), rs3729629 (WNT2), and rs3740535 (CTBP2), and rs12934922 (BCM01). 
There was no association between NF-kB SNPs and liver cancer in the full or stratified dataset. 
 
Several SNPs associated with the stem cell pathway were differentially expressed among those 
with low and high flavonoid intake, including DEC1, Oct-4, CTBP2, and WNT2. DEC1 is a 
presumed tumor suppressor for squamous cell carcinomas of the esophagus and head and neck. 
More specifically, the C variant of rs2269700 has been associated with decreased susceptibility 
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to head and neck cancer in non-Hispanic Whites (Huang et al. 2010), although there has been 
evidence that DEC1 is upregulated in hepatocellular carcinoma but regulated by the tumor 
promoter HIF1A (Ma et al. 2013). In our study, the C variant of rs2269700 was associated with a 
decreased susceptibility to liver cancer in the full dataset as well as among those with low 
flavonoid intake; however sample size was very limited. The SNP rs3130932 (Oct-4) has been 
previously associated with cancer initiation (Katafigiotis et al. 2011), in our study the G variant 
was associated with increased susceptibility to liver cancer among those with high flavonoid 
intake. Polymorphisms of rs3740535 (CTBP2) and rs3729629 (WNT2) have been associated 
with liver cancer initiation and progression (Li et al. 2017; Zheng et al. 2015). For rs3729629 
(WNT2), this is through the Wnt/beta catenin pathway which flavonoids and isoflavonoids have 
been shown to suppress in in vitro studies (Park et al. 2005; Li et al. 2008). We observed that low 
flavonoid intake was associated with liver cancer for those with the AG and AA genotypes for 
rs3740535 (Ctbp2), while the CC and CG genotypes were marginally preventively associated 
with liver cancer for rs3729629 (WNT2). Statistically significant sub-additive and sub-
multiplicative associations persisted after semi-Bayes adjustment between total flavonoid intake 
and rs3729629, while a sub-multiplicative association was observed with rs3740535 and total 
flavonoid intake. 
 
The T variant of rs12934922 (BCM01) has been shown to reduce the catalytic activity of beta-
carotene (Leung et al. 2009). In our study the T variant was associated with an increased 
susceptibility to liver cancer among those with low flavonoid intake (T:T vs. A:A aOR: 1.87, 
95% CI: 1.50, 15.58; A:T vs. A:A aOR: 1.69, 95% CI: 1.04, 2.76), but a null association with 
liver cancer among those with a high flavonoid intake (T:T vs. A:A aOR: 0.44, 95% CI: 0.07, 
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2.59; A:T vs. A:A aOR: 0.86, 95% CI: 0.50, 1.49). Increased intake of total flavonoids likely 
corresponds to an increased intake of beta carotene from shared sources, and the harmful 
association between the rs12934922 (BCM01) SNP with liver cancer is possibly mitigated by 
increased vegetable intake. A statistically significant interaction between rs12934922 and total 
flavonoid intake was observed on the multiplicative scale (ROR: 0.46, 95% CI: 0.23, 0.93). 
 
GWAS studies have shown rs9267673 to be associated with hepatitis-related liver cirrhosis and 
cancer (Jiang et al. 2015). We found an association between the T variant and liver cancer in 
those with low flavonoid intake, but not among those who consumed higher amounts of 
flavonoids, suggesting that diet may have some impact on the progression of viral hepatitis to 
liver cancer. Flavonoids and isoflavonoids have been associated with downregulation of CHEK2 
in an in vitro study (Moskot et al. 2015). CHEK2 is a tumor promoter, and the T variant of 
rs738722 has been associated with esophageal squamous cell carcinoma, but not breast cancer 
(Yang, Wu, et al. 2014; Baynes et al. 2007). There was evidence of sub-additive and sub-
multiplicative interaction between flavonoid intake and rs738722 (RERI: -1.12, 95% CI: -2.23, -
0.01; ROR 0.47, 95% CI: 0.25, 0.89). 
 
Construction of genetic risk scores, including the PRS and weighted MGI, was associated with 
increased odds of liver cancer. These scores did not appear to interact with dietary factors total 
flavonoid intake or glycemic index, or with established risk factors mildew exposure, alcohol 
drinking, or tobacco smoking. However, there was some evidence of super-additive interaction 
between hepatitis B infection and the weighted multigenetic index. 
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To our knowledge, the present study is the first to report associations rs12934922 (BCM01) and 
rs738722 (CHEK2) with liver cancer, and furthermore is the first to report effect measure 
modification of total flavonoid intake on the association between any SNPs and liver cancer. 
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CHAPTER 6. CONCLUSION AND PUBLIC HEALTH IMPLICATIONS 
6.1 Limitations and Strengths 
For Specific Aim 1, there are several limitations for estimating global population attributable 
fractions. The risk factors presented often co-occur and it is possible that these factors may 
interact with one another in order to synergistically increase susceptibility of liver cancer (e.g. 
aflatoxin and HBV), or alternatively the co-occurrence of two risk factors may mask in part the 
carcinogenicity of a co-factor (e.g. Cho et al.’s theory of HBV & HCV co-infection). In order to 
take this into account, we hypothesized the effect interactions would have on the population 
attributable fractions reported in this study. 
 
Another limitation of this study is the available data for estimation of continuous variables such 
as alcohol drinking, adiposity, and tobacco smoking. PAFs for alcohol drinking and obesity were 
estimated using categorical prevalence and risk estimates, while these measures were not 
available for tobacco smoking. It is likely that the reported estimates for tobacco do not 
adequately reflect the population distribution of smoking within each GBD region. Furthermore, 
the GBD regions themselves are aggregate measures of country-level data, and thus do not 
reflect the variation that may exist between countries in the same GBD region. However, Table 
3-7, Table 3-8, and Table 3-9 include country-specific estimates of HCC attributable risk to 
HBV, HCV, alcohol drinking, tobacco smoking, and adiposity, reflecting these variations within 
broader regions. 
 
For Specific Aim 2, the study based on the Jiangsu Province case-control study, recall bias may 
have influenced the measurement of dietary factors. Participants were asked to recall their 
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general dietary patterns one year before diagnosis to capture dietary history; however cases may 
have over reported known risk behaviors such as alcohol consumption after experiencing 
symptoms of liver cancer. Cases over-reporting alcohol consumption would lead to differential 
misclassification away from the null, while other dietary risk factors are not likely to vary by 
case status, and therefore non-differential misclassification towards the null is more likely. 
Furthermore, measurement of diet through the FFQ is subject to systematic error which was 
mitigated in this study through residual energy adjustment. In addition, exclusion of participants 
from the analysis due to missing data, either from invalid dietary data or missing measures of 
HbsAg, may have caused selection bias in this study if data were not missing at random. Those 
missing measures of HBsAg were more likely to be from Chuzhou or Ganyu, less than 60, better 
educated, and to have reported eating fewer calories. Those with invalid dietary data were less 
likely to be from Dafeng and more likely to have lower income. Estimates from multiple 
imputation were used in the dietary analysis to compare against the complete case analysis. 
 
For Specific Aim 3, although the study enrolled a large number of cases and controls, the 
subsample that had SNP data was much smaller, and we did not have sufficient statistical power 
for some SNPs to obtain stable estimates after stratifying for flavonoid intake. Additionally, 
multiple comparisons may have also resulted in false positives as we investigated a large number 
of genetic and dietary factors. We applied a semi-Bayesian shrinkage approach to our estimates 
in order to mitigate the effects of sparse data bias and multiple comparisons; however there still 
might be false positive results. Future studies with large sample sizes are warranted to confirm 
the findings in this study, especially as this study is the first to explore several of these 
associations, and their modification by flavonoid status. Furthermore, the genetic risk scores are 
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calculated by summing the individual associations of risk alleles or genotypes from different 
pathways. This may not completely capture individual genetic risk, as individual SNPs may 
interact with one another, and individual SNPs may amplify or mask the effect of another. 
 
Despite these limitations, this study comprehensively updates global estimations of major risk 
factors and is the first study to summarize and report attributable risk of obesity on liver cancer 
on country, regional, and global levels. This is the first study to evaluate the relationship between 
flavonoid intake and liver cancer risk in a Chinese population. Strengths of the Jiangsu study 
include the large number of cases available as well as biological measures of HBV infection and 
SNPs. Furthermore, novel associations between SNPs and liver cancer were the first of their kind 
to be identified, and no other study has looked at the effect modification by flavonoid intake on 
the relationship between these SNPs and liver cancer. 
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6.2 Conclusions and Public Health Implications 
The number of hepatocellular carcinoma cases was estimated that can be attributed to major liver 
cancer risk factors, giving researchers and policymakers an updated estimation of the 
geographical distribution of the number of incident cases of liver cancer worldwide. This is the 
first estimate of liver cancer cases attributable to obesity. Our results may be informative for 
policy-making and program planning for HCC prevention and control in both developing and 
developed countries. Furthermore, this is the first study to assess the association between 
flavonoid intake and liver cancer in a Chinese population, and the largest conducted thus far on 
glycemic index and glycemic load. Tea appeared to be protective against liver cancer in this 
study, however, no clear association was observed between vegetable sources of flavonoids and 
liver cancer. The differences in diet between a Western and Asian diet do not affect the direction 
of the association of flavonoids with liver cancer, but that the association may vary by food 
source. Our study also added to the body of evidence suggesting that higher glycemic index and 
carbohydrate intake may be associated with increased odds of liver cancer. Lastly, this study is 
the first of its kind to assess the potential effect modification of flavonoid intake on the 
associations between genetic polymorphisms and liver cancer. We found that dietary factors may 
modify genetic predisposition by altering the relationship between several SNPs and liver cancer. 
With the increasing interest in precision medicine, more studies are needed that look at the 
interaction between genetics and lifestyle risk factors, and how this affects cancer risk and 
prognosis. 
 
Historically hepatocellular carcinoma is primarily thought of as a result of chronic viral infection 
with hepatitis B and hepatitis C. This has been largely proven, as about 43.6% of global HCC 
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cases can be attributed to infection with HBV, while 21% of the global risk can be attributed to 
HCV infection based on estimates in this study. However as HBV vaccine and HCV treatment 
options become more widely available, the dominant effect of HBV and HCV on the 
development of HCC will likely decline as more of the population becomes vaccinated and 
treated. Lifestyle risk factors will most likely play a larger role in the etiology of liver cancer in 
the future, and may interact with established risk factors, modifying their association with liver 
cancer. 
 
A better understanding of lifestyle-related factors and how they affect established risk and 
preventative factors is paramount to understanding liver cancer etiology to provide effective 
prevention and control measures to reduce liver cancer incidence and mortality
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TABLES AND FIGURES 
Table 1-1. Gaps in the Literature 
 
Aim 1 Aim 2 Aim 3 
Country Regional Global Flavonoid GI/GL NF-κB 
Stem 
cell 
GWAS 
Liver 
Cancer 
? Yes Yes ? ? ??? ? ? 
HBV/HCV ? ? Yes ? ??? --- ? ? 
Alcohol ? Yes Yes ??? ??? --- ? ??? 
Smoking ? ? Yes ??? ??? --- ? ??? 
Aflatoxin 
B1 
--- --- Yes ??? ??? --- ??? ??? 
Obesity ?? ?? ?? --- --- --- --- --- 
Flavonoid --- --- --- --- ??? ??? ??? ??? 
GI/GL --- --- --- ??? --- ??? ??? ??? 
Yes = association established by studies 
--- = not applicable or not examined in this study 
??? = no studies on this interaction (shaded region represents interaction) 
?? =no studies on this association 
? = few studies on this association/interaction 
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Table 3-1. Constituent countries of Global Burden of Disease Regions 
 Region Constituent Countries 
Asia 
Asia Pacific Brunei, Japan, Republic of Korea, Singapore 
Central Asia Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan 
East Asia China, Democratic Republic of Korea 
South Asia Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan 
Southeast Asia 
Cambodia, Indonesia, Lao PDR, Malaysia, Maldives, Mauritius, Myanmar, Philippines, La Reunion (France), Sri 
Lanka, Thailand, Timor-Leste, Viet Nam 
Europe & 
Western Pacific 
Australasia Australia, New Zealand 
Central Europe 
Albania, Bosnia Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, Poland, Romania, Serbia, 
Slovakia, Slovenia, FYR Macedonia 
Eastern Europe Belarus, Estonia, Latvia, Lithuania, Republic of Moldova, Russian Federation, Ukraine 
Western Europe 
Austria, Belgium, Cyprus, Denmark, Finland, France (Metropolitan), Germany, Greece, Iceland, Ireland, Israel, 
Italy, Luxembourg, Malta, Norway, Portugal, Spain, Sweden, Switzerland, The Netherlands, United Kingdom 
Oceania Fiji, French Polynesia, Guam, New Caledonia, Papua New Guinea, Samoa, Solomon Islands, Vanuatu 
Americas 
Caribbean 
Bahamas, Barbados, Belize, Cuba, Dominican Republic, French Guyana (France), Guadeloupe (France), Guyana, 
Haiti, Jamaica, Martinique (France), Puerto Rico, Suriname, Trinidad and Tobago 
Andean Latin America Bolivia, Ecuador, Peru 
Central Latin America Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Venezuela 
Southern Latin America Argentina, Chile, Uruguay 
Tropical Latin America Brazil, Paraguay 
North America Canada, United States of America 
Africa & E. 
Mediterranean 
North Africa & Middle East 
Algeria, Bahrain, Egypt, Islamic Republic of Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, State of Palestine, 
Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, Turkey, United Arab Emirates, Western Sahara, Yemen 
Central Sub-Saharan Africa Angola, Central African Republic, Democratic Republic of Congo, Republic of Congo, Equatorial Guinea, Gabon 
East Sub-Saharan Africa 
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, Sudan, 
Tanzania, Uganda, Zambia, South Sudan 
Southern Sub-Saharan 
Africa 
Botswana, Lesotho, Namibia, South African Republic, Swaziland, Zimbabwe 
West Sub-Saharan Africa 
Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Cote D’Ivoire, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, 
Mauritania, Niger, Nigeria, Senegal, Sierra Leone, The Gambia, Togo 
Regions in italics are high income
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Table 3-2. Summary of risk estimates of major risk factors for hepatocellular carcinoma 
Study Study Design 
Overall RR            
(95% CI) 
Measure of 
Exposure 
Heterogeneity by Region 
Heterogeneity by Gender Heterogeneity by 
Hepatitis 
Other 
Adjustments men women 
HBV 
Donato, 
Boffeta & 
Puoti, 
1998 
32 studies, 21 
case-control 
studies 
20.4 
(18.0, 23.2) 
HBsAg positivity 
vs HBsAg 
negative, in HCV-
negative 
20.8 (17.8, 24.3)  in Africa, 
China, & southeast 
Asia;18.8 (11.8, 30.3) in 
Japan & Mediterranean 
NA 
135 (79.7, 242) in 
anti-HCV/HCV RNA 
positive  
22.5 (19.5, 26) in 
2nd generation 
HBsAg 
measurement 
This Study: 22.5 (19.5, 26) 
HCV 
Donato, 
Boffeta & 
Puoti, 
1998 
32 studies, 21 
case-control 
studies 
23.6 
(20.0, 28.1) 
Anti-HCV/HCV-
RNA positivity vs 
negativity, in 
HBsAg negative 
11.5 (8.8, 15.0) in Africa, 
China, & southeast Asia; 
31.2 (20.9, 47.4) in Japan 
& Mediterranean 
NA 
135 (79.7, 242) in 
HBsAG positive 
17.3 (13.9, 21.6) in 
2nd generation anti-
HCV 
This Study: 17.3 (13.9, 21.6) 
Alcohol 
Chuang et 
al., 2015 
27 cohort 
studies; 63 
case control 
1.2 (1.1, 1.3) 25g/day vs never 1.28 (1.13, 1.44) in Asia, 
1.39 (0.93, 1.85) in 
Europe, 1.20 (0.86, 1.54) 
in North America, ever vs 
never  
1.2 (1.1,1.3) 1.3 (1.1,1.5) 1.12 (0.82,1.52) 
2.06 (1.31, 2.81) in 
former vs never 
drinkers 
1.5 (1.4, 1.7) 50g/day vs never 1.5 (1.3,1.7) 2.1 (1.2,3.6) 1.74 (1.25,2.41) 
2.1 (1.7, 2.6) 75g/day vs never 1.8 (1.5,2.3) 4.7 (1.5,14.5) 3.68 (2.15,6.29) 
3.2 (2.3, 4.4) 100g/day vs never 2.3 (1.7,3.1)   10.6 (3.66,30.7) 
This Study: Chuang et al. gender-specific estimates and former vs never estimate 
Smoking 
Lee et al., 
2009 
13 case-
control; 7 
cohort  
1.51 
(1.37, 1.67) 
Current smokers vs 
never tobacco 
smokers 
1. 56 (1.36, 1.79)  in Asia 
1.61 
(1.38, 1.89) 
1.86 
(1.33, 2.60) 
1.38 (1.01, 1.88) 
adjusted for HBV, 
1.55 (1.00, 2.38) 
adjusted for HCV 
1.43 (1.21, 1.68) 
adjusted for 
alcohol 
This Study: 1.43 (1.21, 1.68) 
Obesity 
Chen et al., 
2012 
26 
prospective 
studies 
1.48 
(1.31, 1.67) 
Overweight vs 
normal weight 1.35 (1.18, 1.54) in Asia, 
1.65 (1.36, 2.02) in non-
Asian countries 
1.42 
(1.22, 1.65) 
1.18 
(1.08, 1.30) 1.74 (1.35, 2.25) 
adjusted for HBV 
and/or HCV 
1.46 (1.25, 1.69) 
adjusted for 
alcohol 1.83 
(1.59, 2.11) 
Obese vs normal 
weight 
1.91 
(1.51, 2.41) 
1.55 
(1.30, 1.85) 
This Study: Chen et al. gender-specific estimates 
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Table 3-3. Fraction of cases of hepatocellular carcinoma attributable to major risk factors by geographic region 
Region  HCC  
(N=)  
HBV PAF  
(CI) 
HCV PAF  
(CI) 
Alcohol PAF  
(CI) 
Smoking PAF  
(CI) 
Obesity PAF  
(CI) 
Asia Pacific 40,303 22.7% 
(20.4%, 25.7%) 
17.4% 
(5.4%, 31.9%) 
27.6% 
(13.9%, 40.5%) 
14.1% 
(7.2%, 21.3%) 
 7.7% 
(4.3%, 11.4%)  
Central Asia 4,687 57.4% 
(48.1%, 67.8%) 
49.7% 
(33.0%, 66.9%) 
27.0% 
(12.1%, 40.9%) 
8.5% 
(4.0%, 13.9%) 
 14.3% 
(7.0%, 23.5%)  
East Asia 310,366 53.8% 
(50.0%, 58.5%) 
17.5% 
(5.3%, 30.2%) 
26.6% 
(12.9%, 39.8%) 
14.3% 
(7.4%, 21.1%) 
 6.5% 
(3.5%, 9.6%)  
South Asia 24,900 26.7% 
(23.6%, 30.8%) 
17.1% 
(6.7%, 25.4%) 
12.6% 
(5.2%, 20.4%) 
8.4% 
(4.0%, 13.3%) 
 3.9% 
(2.1%, 6.0%)  
Southeast Asia 57,264 50.9% 
(46.6%, 56.0%) 
20.3% 
(11.7%, 38.6%) 
19.4% 
(8.9%, 30.3%) 
14.0% 
(7.1%, 21.0%) 
 4.3% 
(2.4%, 6.5%)  
Australasia 1,457 15.5% 
(13.5%, 18.2%) 
22.0% 
(13.7%, 28.6%) 
27.7% 
(13.8%, 40.8%) 
9.7% 
(4.7%, 15.1%) 
 21.3% 
(11.7%, 31.4%)  
Central Europe 5,198 28.5% 
(23.8%, 35.3%) 
19.9% 
(13.3%, 30.3%) 
35.4% 
(17.4%, 51.4%) 
12.3% 
(5.9%, 19.5%) 
 19.0% 
(9.8%, 29.4%)  
Eastern Europe 5,475 39.3% 
(34.5%, 45.4%) 
38.8% 
(14.3%, 52.9%) 
38.5% 
(18.2%, 56.5%) 
13.2% 
(6.5%, 20.4%) 
 17.8% 
(9.4%, 27.2%)  
Western Europe 32,766 12.1% 
(9.8%, 15.3%) 
15.4% 
(8.3%, 32.0%) 
30.4% 
(15.4%, 44.3%) 
12.1% 
(6.0%, 18.7%) 
 20.1% 
(11.0%, 29.9%)  
Oceania 496 78.9% 
(73.5%, 83.8%) 
3.2% 
(2.7%, 16.3%) 
20.8% 
(9.7%, 30.8%) 
13.5% 
(6.3%, 21.8%) 
 16.3% 
(7.7%, 26.9%)  
Caribbean 836 47.9% 
(33.6%, 62.7%) 
NA 27.7% 
(11.7%, 42.2%) 
6.7% 
(2.9%, 11.6%) 
 13.1% 
(6.4%, 21.2%)  
Andean Latin America 1,960 24.3% 
(18.7%, 32.6%) 
16.4% 
(5.3%, 25.7%) 
29.9% 
(12.7%, 44.6%) 
4.9% 
(2.1%, 8.8%) 
 14.6% 
(7.0%, 23.8%)  
Central Latin America 7,231 8.5% 
(6.5%, 11.4%) 
18.7% 
(12.0%, 27.1%) 
26.3% 
(11.1%, 40.9%) 
6.3% 
(2.8%, 10.8%) 
 17.0% 
(8.6%, 26.7%)  
Southern Latin America 1,648 14.2% 
(12.5%, 16.9%) 
19.6% 
(6.5%, 35.1%) 
30.1% 
(13.8%, 43.8%) 
11.3% 
(5.0%, 19.1%) 
 19.6% 
(10.0%, 30.5%)  
Tropical Latin America 7,841 12.1% 
(10.4%, 14.5%) 
20.7% 
(13.3%, 25.7%) 
36.8% 
(16.8%, 54.4%) 
7.3% 
(3.1%, 13.1%) 
 15.3% 
(8.0%, 23.7%)  
North America 25,898 5.8% 
(4.4%, 7.7%) 
17.3% 
(13.9%, 33.4%) 
31.6% 
(15.5%, 46.8%) 
8.9% 
(4.3%, 13.9%) 
 23.6% 
(13.2%, 34.3%)  
North Africa & Middle East 22,147 27.8% 
(24.3%, 32.3%) 
56.3% 
(45.0%, 67.2%) 
20.8% 
(7.7%, 35.0%) 
8.9% 
(4.1%, 14.6%) 
 18.5% 
(9.6%, 28.6%)  
Central Sub-Saharan Africa 3,778 59.5% 41.4% 26.7% 4.1%  4.6% 
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Region  HCC  
(N=)  
HBV PAF  
(CI) 
HCV PAF  
(CI) 
Alcohol PAF  
(CI) 
Smoking PAF  
(CI) 
Obesity PAF  
(CI) 
(54.2%, 65.3%) (30.7%, 74.8%) (11.2%, 40.6%) (1.6%, 7.5%) (2.4%, 7.6%)  
East Sub-Saharan Africa 5,124 57.9% 
(51.5%, 64.8%) 
17.1% 
(9.2%, 46.3%) 
21.4% 
(9.0%, 34.0%) 
5.7% 
(2.4%, 9.9%) 
 4.2% 
(2.2%, 6.9%)  
Southern Sub-Saharan Africa 2,449 62.0% 
(56.0%, 68.6%) 
21.5% 
(12.2%, 41.3%) 
22.5% 
(10.1%, 36.6%) 
9.1% 
(4.3%, 14.7%) 
 12.6% 
(6.3%, 20.3%)  
West Sub-Saharan Africa 19,754 69.2% 
(64.3%, 74.4%) 
53.0% 
(31.1%, 73.4%) 
27.5% 
(12.6%, 42.1%) 
4.4% 
(1.9%, 8.0%) 
 5.8% 
(3.0%, 9.3%)  
WORLD 581,579 43.6% 
(40.0%, 48.1%) 
21.0% 
(9.7%, 34.9%) 
25.9% 
(12.3%, 39.0%) 
12.6% 
(6.4%, 19.0%) 
 8.9%  
(4.8%, 13.3%)  
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Table 3-4. Fraction of cases of hepatocellular carcinoma attributable to major lifestyle risk factors by geographic region and 
gender 
 Men  Women 
GBDR 
HCC 
(N=) 
Alcohol PAF 
(CI) 
Smoking PAF 
(CI) 
Obesity PAF 
(CI) 
 
HCC 
(N=) 
Alcohol PAF 
(CI) 
Smoking PAF 
(CI) 
Obesity PAF 
(CI) 
Asia Pacific 27,417 28.7% 
(16.8%, 40.1%) 
18.7% 
(9.7%, 27.7%) 
9.3% 
(5.4%, 13.2%) 
 12,886 25.4% 
(7.6%, 41.3%) 
4.5% 
(2.1%, 7.6%) 
4.2% 
(1.8%, 7.4%) 
Central Asia 2,688 27.8% 
(15.0%, 40.6%) 
13.1% 
(6.2%, 20.9%) 
17.0% 
(9.0%, 26.3%) 
 1,999 25.8% 
(8.0%, 41.2%) 
2.4% 
(1.0%, 4.4%) 
10.7% 
(4.2%, 19.8%) 
East Asia 230,372 27.8% 
(14.8%, 41.1%) 
18.7% 
(9.7%, 27.4%) 
7.2% 
(4.1%, 10.4%) 
 79,995 23.2% 
(7.4%, 36.2%) 
1.7% 
(0.7%, 2.9%) 
4.2% 
(1.8%, 7.5%) 
South Asia 15,679 15.4% 
(6.8%, 24.5%) 
12.5% 
(6.0%, 19.7%) 
4.3% 
(2.6%, 6.1%) 
 9,220 8.0% 
(2.4%, 13.4%) 
1.3% 
(0.5%, 2.5%) 
3.1% 
(1.2%, 5.7%) 
Southeast Asia 41,782 23.8% 
(11.4%, 36.7%) 
18.3% 
(9.4%, 27.3%) 
4.5% 
(2.7%, 6.3%) 
 15,482 7.2% 
(2.1%, 12.6%) 
2.2% 
(0.9%, 3.9%) 
3.7% 
(1.5%, 7.0%) 
Australasia 1,033 27.5% 
(16.1%, 38.7%) 
9.9% 
(4.9%, 15.4%) 
24.7% 
(14.0%, 35.6%) 
 424 28.4% 
(8.4%, 45.8%) 
9.0% 
(4.3%, 14.3%) 
13.0% 
(6.1%, 21.3%) 
Central Europe 3,293 35.9% 
(21.2%, 50.1%) 
14.5% 
(7.1%, 22.5%) 
22.5% 
(12.2%, 33.4%) 
 1,904 34.5% 
(11.0%, 53.6%) 
8.5% 
(3.8%, 14.3%) 
12.9% 
(5.5%, 22.4%) 
Eastern Europe 3,134 39.0% 
(22.8%, 54.9%) 
18.7% 
(9.5%, 27.9%) 
19.9% 
(11.0%, 29.4%) 
 2,341 37.8% 
(12.0%, 58.6%) 
5.9% 
(2.6%, 10.4%) 
15.0% 
(7.3%, 24.3%) 
Western Europe 23,137 30.2% 
(18.0%, 42.1%) 
13.1% 
(6.5%, 20.0%) 
23.5% 
(13.2%, 33.9%) 
 9,629 30.7% 
(9.1%, 49.8%) 
9.7% 
(4.7%, 15.4%) 
12.1% 
(5.6%, 20.2%) 
Oceania 322 20.4% 
(11.1%, 29.8%) 
16.8% 
(8.1%, 26.1%) 
18.2% 
(9.3%, 28.8%) 
 175 21.5% 
(7.1%, 32.5%) 
7.5% 
(3.1%, 13.8%) 
12.7% 
(4.9%, 23.4%) 
Caribbean 446 28.1% 
(14.3%, 42.4%) 
8.7% 
(3.9%, 14.7%) 
13.6% 
(7.3%, 20.8%) 
 390 27.1% 
(8.9%, 41.9%) 
4.4% 
(1.8%, 8.0%) 
12.4% 
(5.3%, 21.6%) 
Andean Latin America 882 28.4% 
(15.2%, 41.9%) 
7.5% 
(3.3%, 12.8%) 
17.0% 
(9.1%, 25.8%) 
 1,078 31.1% 
(10.7%, 46.8%) 
2.8% 
(1.1%, 5.5%) 
12.6% 
(5.3%, 22.2%) 
Central Latin America 3,523 29.1% 
(15.2%, 43.5%) 
9.5% 
(4.3%, 15.8%) 
19.8% 
(10.8%, 29.5%) 
 3,708 23.6% 
(7.3%, 38.5%) 
3.3% 
(1.4%, 6.1%) 
14.3% 
(6.5%, 24.0%) 
Southern Latin America 912 26.9% 
(15.7%, 37.9%) 
12.3% 
(5.6%, 20.2%) 
23.5% 
(12.7%, 34.9%) 
 736 34.0% 
(11.4%, 51.2%) 
10.2% 
(4.4%, 17.7%) 
14.8% 
(6.6%, 25.0%) 
Tropical Latin America 4,654 36.4% 
(19.1%, 54.3%) 
8.4% 
(3.6%, 14.6%) 
17.7% 
(9.8%, 26.2%) 
 3,187 37.5% 
(13.4%, 54.5%) 
5.8% 
(2.3%, 10.9%) 
11.9% 
(5.4%, 20.1%) 
North America 19,132 31.9% 
(17.5%, 46.4%) 
9.1% 
(4.5%, 14.3%) 
26.5% 
(15.1%, 37.7%) 
 6,767 30.7% 
(9.7%, 48.0%) 
8.1% 
(3.9%, 12.8%) 
15.5% 
(7.6%, 24.6%) 
North Africa & Middle East 15,076 26.7% 
(10.2%, 45.1%) 
12.6% 
(5.8%, 20.4%) 
19.5% 
(10.5%, 29.6%) 
 7,071 8.2% 
(2.5%, 13.4%) 
1.1% 
(0.4%, 2.1%) 
16.4% 
(7.8%, 26.6%) 
Central Sub-Saharan Africa 2,292 26.1% 
(12.3%, 40.5%) 
6.3% 
(2.6%, 11.5%) 
4.5% 
(2.9%, 6.4%) 
 1,486 27.5% 
(9.5%, 40.7%) 
0.6% 
(0.2%, 1.3%) 
4.7% 
(1.7%, 9.4%) 
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 Men  Women 
GBDR 
HCC 
(N=) 
Alcohol PAF 
(CI) 
Smoking PAF 
(CI) 
Obesity PAF 
(CI) 
 
HCC 
(N=) 
Alcohol PAF 
(CI) 
Smoking PAF 
(CI) 
Obesity PAF 
(CI) 
East Sub-Saharan Africa 3,023 23.3% 
(11.3%, 35.8%) 
8.4% 
(3.7%, 14.5%) 
4.3% 
(2.7%, 6.1%) 
 2,101 18.8% 
(5.7%, 31.3%) 
1.6% 
(0.6%, 3.4%) 
4.1% 
(1.5%, 8.0%) 
Southern Sub-Saharan Africa 1,452 27.1% 
(14.3%, 40.4%) 
13.1% 
(6.3%, 20.6%) 
11.0% 
(5.9%, 17.0%) 
 996 15.9% 
(4.0%, 31.0%) 
3.3% 
(1.4%, 6.0%) 
15.0% 
(6.9%, 25.1%) 
West Sub-Saharan Africa 13,229 27.7% 
(14.6%, 41.1%) 
5.8% 
(2.5%, 10.3%) 
5.9% 
(3.4%, 8.7%) 
 6,525 27.2% 
(8.4%, 44.3%) 
1.6% 
(0.6%, 3.1%) 
5.7% 
(2.3%, 10.8%) 
WORLD 413,479 27.5% 
(14.5%, 40.7%) 
16.5% 
(8.5%, 24.7%) 
9.8% 
(5.6%, 14.1%) 
 168,100 22.0% 
(6.9%, 34.9%) 
2.9% 
(1.3%, 5.0%) 
6.5% 
(2.9%, 11.2%) 
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Table 3-5. Hepatocellular carcinoma cases attributable to major risk factors in top five countries worldwide 
Country Risk Factor  PAF Males   PAF Females  PAC Males PAC Females 
1. China      N= 306,508 
  HCC Cases     227,739 78,770 
  HBV 53.8% (50.0%, 58.5%) 164,813 (153,177, 179,421) 
  HCV 17.5% (5.3%, 30.2%) 53,593 (16,144, 92,466) 
  Alcohol 27.8% (14.8%, 41.1%) 23.2% (7.4%, 36.2%) 63,368 (33,659, 93,569) 18,247 (5,837, 28,529) 
  Smoking 18.7% (9.8%, 27.4%) 1.7% (0.8%, 2.9%) 42,593 (22,226, 62,399) 1,332 (591, 2,288) 
  Obesity 7.2% (4.1%, 10.4%) 4.2% (1.8%, 7.4%) 16,461 (9,423, 23,643) 3,334 (1,446, 5,865) 
2. Japan      N=28,591 
  HCC Cases     18,696 9,895 
  HBV 12.4% (10.7%, 14.6%) 3,553 (3,069, 4,188) 
  HCV 19.6% (6.5%, 32.2%) 5,617 (1,858, 9,210) 
  Alcohol 25.6% (14.8%, 36.3%) 23.9% (6.9%, 39.6%) 4,795 (2,767, 6,793) 2,369 (680, 3,914) 
  Smoking 18.2% (9.4%, 27.3%) 5.2% (2.4%, 8.7%) 3,411 (1,764, 5,096) 512 (237, 860) 
  Obesity 9.1% (5.3%, 13.0%) 3.9% (1.7%, 6.8%) 1,703 (985, 2,427) 387 (166, 675) 
3. USA       N=24,223 
  HCC Cases     17,932 6,291 
  HBV 5.3% (4.1%, 7.0%) 1,282 (989, 1,698) 
  HCV 17.5% (14.3%, 34.1%) 4,235 (3,463, 8,270) 
  Alcohol 32.0% (17.5%, 46.5%) 30.7% (9.8%, 48.0%) 5,730 (3,141, 8,342) 1,934 (614, 3,022) 
  Smoking 9.0% (4.5%, 14.1%) 8.0% (3.8%, 12.6%) 1,620 (799, 2,534) 500 (241, 793) 
  Obesity 26.6% (15.2%, 37.8%) 15.6% (7.7%, 24.8%) 4,765 (2,733, 6,775) 981 (485, 1,558) 
4. India       N=19,104 
  HCC Cases     12,011 7,094 
  HBV 23.6% (20.9%, 27.4%) 4,516 (3,997, 5,230) 
  HCV 11.5% (5.3%, 17.8%) 2,204 (1,006, 3,394) 
  Alcohol 18.8% (8.4%, 29.9%) 10.0% (3.0%, 16.9%) 2,259 (1,005, 3,590) 713 (214, 1,200) 
  Smoking 12.1% (5.9%, 18.9%) 1.1% (0.5%, 2.1%) 1,449 (705, 2,266) 81 (34, 146) 
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Country Risk Factor  PAF Males   PAF Females  PAC Males PAC Females 
  Obesity 4.1% (2.5%, 5.7%) 2.9% (1.2%, 5.4%) 495 (295, 684) 207 (85, 380) 
5. Vietnam       N=15,738 
  HCC Cases     12,030 3,708 
  HBV 69.8% (65.5%, 74.6%) 10,988 (10,304, 11,736) 
  HCV NA NA 
  Alcohol 23.9% (11.9%, 36.4%) 4.3% (1.2%, 7.6%) 2,880 (1,432, 4,382) 158 (45, 282) 
  Smoking 20.0% (10.5%, 29.3%) 1.9% (0.8%, 3.4%) 2,408 (1,258, 3,519) 69 (29, 124) 
  Obesity 2.8% (1.8%, 3.5%) 2.2% (0.9%, 4.0%) 341 (222, 421) 81 (32, 149) 
82 
 
 
Figure 3-1. Average PAF in high income countries versus low and middle income countries 
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Figure 3-1. Average PAF in High Income Countries 
Versus Low and Middle Income Countries
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error bars represent range of PAF values
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Table 3-6. Percent and number of hepatocellular carcinoma cases by country 
  
Males 
 
 
 
Females 
 
All 
Country 
Liver 
Cancer 
Cases 
% 
HCC 
HCC 
Cases 
 
Liver 
Cancer 
Cases 
% 
HCC 
HCC 
Cases 
HCC 
Cases 
Afghanistan 477 69.7% 332  283 51.5% 197 530 
Albania 104 58.3% 61  67 45.0% 39 100 
Algeria 214 87.0% 186  213 71.4% 185 372 
Angola 309 81.6% 252  203 66.8% 166 418 
Argentina 1,059 55.4% 587  821 41.2% 455 1,042 
Armenia 260 76.1% 198  204 62.8% 155 353 
Australia 1,180 74.8% 883  478 46.1% 358 1,241 
Austria 644 68.1% 439  311 42.9% 212 651 
Azerbaijan 254 76.1% 193  212 62.8% 161 354 
Bahrain 17 66.7% 11  9 50.0% 6 17 
Bangladesh 1,837 69.7% 1,280  1185 51.5% 826 2,106 
Barbados 4 36.8% 1  7 37.9% 3 4 
Belarus 201 41.7% 84  126 33.3% 53 136 
Belgium 446 74.2% 331  199 54.5% 148 479 
Belize 8 36.8% 3  6 37.9% 2 5 
Benin 471 81.6% 384  249 66.8% 203 587 
Bhutan 18 69.7% 13  7 51.5% 5 17 
Bolivia 128 71.3% 91  148 66.0% 106 197 
Bosnia and 
Herzegovina 
170 58.3% 99  144 45.0% 84 183 
Botswana 50 87.9% 44  25 62.2% 22 66 
Brazil 5,766 79.7% 4,596  3912 56.8% 3,118 7,715 
Brunei 14 74.5% 10  6 64.7% 4 15 
Bulgaria 418 73.9% 309  222 66.7% 164 473 
Burkina Faso 779 81.6% 636  475 66.8% 388 1,023 
Burundi 151 61.4% 93  114 58.8% 70 163 
Cambodia 1,444 71.5% 1,033  820 57.4% 587 1,620 
Cameroon 550 81.6% 449  177 66.8% 144 593 
Canada 1,619 74.1% 1,199  642 50.0% 476 1,675 
Cape Verde 35 81.6% 29  21 66.8% 17 46 
Central African 
Republic 
115 81.6% 94  62 66.8% 51 144 
Chad 307 81.6% 250  140 66.8% 114 365 
Chile 561 48.3% 271  529 26.7% 255 526 
China 293,318 77.6% 227,739  101452 65.1% 78,770 306,508 
Colombia 613 59.0% 362  681 40.7% 402 763 
Comoros 10 61.4% 6  5 58.8% 3 9 
Congo 137 81.6% 112  98 66.8% 80 192 
Costa Rica 123 64.7% 80  83 44.4% 54 133 
Côte d’Ivoire 1,590 81.6% 1,297  647 66.8% 528 1,825 
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Females 
 
All 
Country 
Liver 
Cancer 
Cases 
% 
HCC 
HCC 
Cases 
 
Liver 
Cancer 
Cases 
% 
HCC 
HCC 
Cases 
HCC 
Cases 
Croatia 329 66.7% 219  137 50.0% 91 311 
Cuba 361 23.5% 85  364 28.6% 86 171 
Cyprus 36 50.0% 18  20 42.9% 10 28 
Czech Republic 581 60.5% 351  338 41.2% 204 556 
Democratic Republic 
of the Congo 
2,215 81.6% 1,807  1444 66.8% 1,178 2,985 
Denmark 227 65.7% 149  84 50.0% 55 204 
Djibouti 11 61.4% 7  7 58.8% 4 11 
Dominican Republic 441 36.8% 162  410 37.9% 151 313 
Ecuador 324 71.3% 231  381 66.0% 272 503 
Egypt 12,493 88.5% 11,059  5128 76.9% 4,540 15,599 
El Salvador 181 59.9% 108  266 41.1% 159 268 
Equatorial Guinea 16 81.6% 13  4 66.8% 3 16 
Eritrea 43 61.4% 26  36 58.8% 22 49 
Estonia 34 52.0% 18  30 41.7% 16 33 
Ethiopia 418 61.4% 257  578 58.8% 355 612 
Fiji 45 69.0% 31  25 49.3% 17 48 
Finland 407 65.9% 268  213 46.7% 140 409 
France 6,500 76.6% 4,981  1832 47.8% 1,404 6,385 
Gabon 17 81.6% 14  11 66.8% 9 23 
Georgia 250 76.1% 190  189 62.8% 144 334 
Germany 6,396 72.0% 4,607  2806 44.5% 2,021 6,628 
Ghana 1,502 81.6% 1,225  421 66.8% 343 1,569 
Greece 708 72.7% 515  346 48.9% 252 766 
Guatemala 725 59.9% 434  817 41.1% 490 924 
Guinea 673 81.6% 549  429 66.8% 350 899 
Guinea-Bissau 86 81.6% 70  44 66.8% 36 106 
Guyana 21 36.8% 8  13 37.9% 5 13 
Haiti 256 36.8% 94  204 37.9% 75 169 
Honduras 292 59.9% 175  306 41.1% 183 358 
Hungary 434 58.3% 253  196 45.0% 114 367 
Iceland 6 56.5% 3  4 50.0% 2 6 
India 17,236 69.7% 12,011  10180 51.5% 7,094 19,104 
Indonesia 13,365 71.5% 9,562  4756 57.4% 3,403 12,965 
Iran 889 94.7% 842  678 54.5% 642 1,485 
Iraq 318 87.0% 277  360 71.4% 313 590 
Ireland 152 58.8% 89  87 42.9% 51 141 
Israel 158 85.7% 135  85 71.4% 73 208 
Italy 7,188 76.3% 5,485  3545 58.1% 2,705 8,191 
Jamaica 76 100.0% 76  55 100.0% 55 131 
Japan 23,651 79.0% 18,696  12517 70.4% 9,895 28,591 
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Liver 
Cancer 
Cases 
% 
HCC 
HCC 
Cases 
HCC 
Cases 
Jordan 100 87.0% 87  59 71.4% 51 138 
Kazakhstan 790 76.1% 601  547 62.8% 416 1,017 
Kenya 634 61.4% 389  486 58.8% 298 688 
Kuwait 43 82.8% 36  9 66.7% 7 43 
Kyrgyzstan 186 76.1% 141  138 62.8% 105 246 
Laos 1,486 71.5% 1,063  630 57.4% 451 1,514 
Latvia 96 83.3% 80  58 80.0% 48 128 
Lebanon 69 87.0% 60  47 71.4% 41 101 
Lesotho 65 87.9% 57  18 62.2% 16 73 
Liberia 248 81.6% 202  144 66.8% 117 320 
Libya 123 77.8% 96  94 33.3% 73 169 
Lithuania 111 58.3% 65  64 33.3% 37 102 
Luxembourg 46 72.7% 33  22 48.9% 16 49 
Macedonia 86 58.3% 50  49 45.0% 29 79 
Madagascar 317 61.4% 195  159 58.8% 98 292 
Malawi 111 95.5% 106  95 82.4% 91 197 
Malaysia 1,111 69.1% 768  416 33.3% 287 1,055 
Maldives 6 71.5% 4  0 57.4% 0 4 
Mali 257 81.6% 210  114 66.8% 93 303 
Malta 13 47.8% 6  6 22.2% 3 9 
Mauritania 194 81.6% 158  94 66.8% 77 235 
Mauritius 15 71.5% 11  18 57.4% 13 24 
Mexico 3,068 59.9% 1,839  3319 41.1% 1,989 3,828 
Micronesia, Federated 
States of 
31 69.0% 21  4 49.3% 3 24 
Moldova 277 57.3% 159  171 54.3% 98 257 
Mongolia 888 76.1% 676  630 62.8% 479 1,155 
Montenegro 31 58.3% 18  20 45.0% 12 30 
Morocco 195 87.0% 170  145 71.4% 126 296 
Mozambique 419 61.4% 257  239 58.8% 147 404 
Myanmar 3,421 71.5% 2,448  1491 57.4% 1,067 3,514 
Namibia 19 87.9% 17  8 62.2% 7 24 
Nepal 109 69.7% 76  77 51.5% 54 130 
Netherlands 338 71.4% 241  137 50.0% 98 339 
New Zealand 205 73.1% 150  91 44.4% 67 216 
Nicaragua 225 59.9% 135  208 41.1% 125 260 
Niger 377 81.6% 308  139 66.8% 113 421 
Nigeria 7,875 81.6% 6,425  4172 66.8% 3,404 9,828 
North Korea 3,391 77.6% 2,633  1578 65.1% 1,225 3,858 
Norway 118 81.3% 96  72 50.0% 59 154 
Oman 42 87.0% 37  17 71.4% 15 51 
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Pakistan 2,824 69.7% 1,968  1500 51.5% 1,045 3,013 
Palestine 50 87.0% 44  23 71.4% 20 64 
Panama 98 59.9% 59  77 41.1% 46 105 
Papua New Guinea 334 69.0% 231  209 49.3% 144 375 
Paraguay 73 79.7% 58  86 56.8% 69 127 
Peru 785 71.3% 560  982 66.0% 700 1,260 
Philippines 5,441 80.5% 4,378  2293 74.7% 1,845 6,222 
Poland 1,071 54.1% 579  927 42.8% 502 1,081 
Portugal 772 63.2% 488  232 25.0% 147 634 
Qatar 44 100.0% 44  5 85.3% 5 49 
Romania 1,485 58.3% 866  729 45.0% 425 1,291 
Russia 3,848 61.5% 2,368  2964 60.0% 1,824 4,192 
Rwanda 472 61.4% 290  275 58.8% 169 459 
Samoa 3 69.0% 2  1 49.3% 1 3 
Saudi Arabia 516 84.3% 435  206 76.0% 174 609 
Senegal 451 81.6% 368  282 66.8% 230 598 
Serbia 522 35.5% 185  277 36.8% 98 284 
Sierra Leone 343 81.6% 280  199 66.8% 162 442 
Singapore 588 84.1% 494  175 68.4% 147 641 
Slovakia 258 66.7% 172  140 46.2% 93 265 
Slovenia 157 82.5% 130  59 46.2% 49 178 
Solomon Islands 32 69.0% 22  9 49.3% 6 28 
Somalia 99 61.4% 61  88 58.8% 54 115 
South Africa 1,165 90.0% 1,049  807 50.0% 726 1,775 
South Korea 12,559 65.4% 8,216  4341 48.3% 2,840 11,056 
South Sudan 224 61.4% 138  154 58.8% 95 232 
Spain 4,006 75.1% 3,007  1516 52.7% 1,138 4,145 
Sri Lanka 527 71.5% 377  279 57.4% 200 577 
Sudan 646 61.4% 397  279 58.8% 171 568 
Suriname 20 36.8% 7  15 37.9% 6 13 
Swaziland 60 87.9% 53  15 62.2% 13 66 
Sweden 319 62.5% 199  171 41.2% 107 306 
Switzerland 623 76.0% 473  188 47.9% 143 616 
Syria 321 87.0% 279  244 71.4% 212 492 
Tajikistan 156 76.1% 119  117 62.8% 89 208 
Tanzania 405 61.4% 249  190 58.8% 117 365 
Thailand 14,739 68.4% 10,088  5716 52.2% 3,912 14,000 
The Bahamas 5 36.8% 2  3 37.9% 1 3 
The Gambia 176 81.6% 144  62 66.8% 51 194 
Timor-Leste 29 71.5% 21  15 57.4% 11 31 
Togo 302 81.6% 246  189 66.8% 154 401 
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Trinidad and Tobago 18 36.8% 7  19 37.9% 7 14 
Tunisia 70 80.0% 56  44 50.0% 35 91 
Turkey 1,537 72.4% 1,112  690 52.4% 499 1,611 
Turkmenistan 153 76.1% 116  110 62.8% 84 200 
Uganda 783 60.6% 475  568 58.3% 344 819 
Ukraine 904 40.0% 362  663 33.3% 265 627 
United Arab Emirates 51 87.0% 44  17 71.4% 15 59 
United Kingdom 2,721 57.8% 1,572  1465 36.8% 847 2,419 
United States 22,541 79.6% 17,932  7908 61.1% 6,291 24,223 
Uruguay 70 76.9% 54  33 60.0% 25 79 
Uzbekistan 597 76.1% 454  481 62.8% 366 820 
Vanuatu 21 69.0% 15  5 49.3% 3 18 
Venezuela 554 59.9% 332  434 41.1% 260 592 
Vietnam 16,815 71.5% 12,030  5182 57.4% 3,708 15,738 
Western Sahara 9 87.0% 8  0 71.4% 0 8 
Yemen 222 87.0% 193  127 71.4% 111 304 
Zambia 128 61.4% 79  102 58.8% 63 141 
Zimbabwe 287 81.3% 233  261 85.0% 212 445 
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Table 3-7. Fraction and number of hepatocellular carcinoma cases attributable to chronic 
hepatitis B and hepatitis C infection by country 
Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
Afghanistan 26.00% 137  15.20% 81 
 (19.4%, 34.7%) (103 , 184 )  (7.7%, 29.1%) (41 , 154 ) 
Albania 62.60% 62  . . 
 (58.3%, 67.6%) (58 , 67 )  . . 
Algeria 36.20% 135  18.60% 69 
 (29.1%, 44.9%) (108 , 167 )  (2.7%, 35.1%) (10 , 130 ) 
Angola 73.30% 306  . . 
 (67.8%, 78.8%) (283 , 329 )    
Argentina 14.20% 148  19.60% 205 
 (12.5%, 16.9%) (130 , 176 )  (6.5%, 35.1%) (68 , 365 ) 
Australia 10.10% 125  21.70% 269 
 (8.5%, 12.3%) (105 , 153 )  (14.3%, 28.0%) (177 , 347 ) 
Austria 35.00% 227  7.50% 49 
 (16.5%, 59.8%) (107 , 389 )  (1.4%, 13.1%) (9 , 85 ) 
Azerbaijan . .  33.60% 119 
    (12.2%, 59.1%) (43 , 210 ) 
Bahrain 20.50% 4  . . 
 (14.7%, 28.7%) (3 , 5 )    
Bangladesh 39.90% 841  17.50% 368 
 (35.6%, 45.5%) (750 , 958 )  (2.7%, 32.2%) (57 , 678 ) 
Belarus . .  17.50% 24 
    (11.1%, 38.5%) (15 , 52 ) 
Belgium 13.10% 63  12.80% 61 
 (8.2%, 21.0%) (39 , 100 )  (1.4%, 20.6%) (7 , 99 ) 
Belize 50.40% 3  . . 
 (42.0%, 59.7%) (2 , 3 )    
Benin . .  37.00% 217 
    (33.4%, 73.4%) (196 , 431 ) 
Bhutan 55.60% 10  . . 
 (47.6%, 64.2%) (8 , 11 )    
Bolivia 5.30% 10  . . 
 (1.5%, 17.2%) (3 , 34 )    
Bosnia and Herzegovina 19.30% 35  . . 
 (14.4%, 26.0%) (26 , 48 )    
Brazil 12.10% 933  20.70% 1,596 
 (10.4%, 14.5%) (805 , 1,115 )  (13.3%, 25.7%) (1,023 , 1,981 ) 
Bulgaria 45.60% 216  15.20% 72 
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Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
 (37.0%, 55.5%) (175 , 262 )  (4.0%, 34.1%) (19 , 162 ) 
Burkina Faso 72.20% 738  . . 
 (68.5%, 76.3%) (700 , 781 )    
Burundi 50.30% 82  . . 
 (28.7%, 71.9%) (47 , 117 )    
Cambodia 46.50% 753  27.30% 442 
 (39.8%, 54.4%) (644 , 880 )  (24.2%, 76.0%) (392 , 1,232 ) 
Cameroon 68.30% 405  65.40% 388 
 (63.3%, 73.7%) (375 , 437 )  (37.4%, 86.5%) (222 , 513 ) 
Canada 12.40% 208  15.20% 255 
 (8.9%, 17.6%) (150 , 294 )  (7.7%, 21.9%) (129 , 367 ) 
Central African Republic 75.30% 109  . . 
 (69.6%, 80.9%) (100 , 117 )    
China 53.80% 164,813  17.50% 53,593 
 (50.0%, 58.5%) (153,177 , 179,421 )  (5.3%, 30.2%) (16,144 , 92,466 ) 
Colombia 36.10% 276  . . 
 (28.2%, 45.8%) (215 , 349 )    
Congo 76.30% 146  . . 
 (69.1%, 82.7%) (132 , 159 )    
Côte d’Ivoire 66.70% 1,218  35.00% 638 
 (61.2%, 72.6%) (1,117 , 1,325 )  (10.0%, 73.4%) (183 , 1,340 ) 
Croatia 19.10% 59  . . 
 (14.8%, 25.3%) (46 , 78 )    
Cuba 21.80% 37  . . 
 (10.4%, 40.9%) (18 , 70 )    
Cyprus 38.70% 11  8.90% 2 
 (32.1%, 46.8%) (9 , 13 )  (6.5%, 29.1%) (2 , 8 ) 
Czech Republic 6.80% 38  10.20% 57 
 (3.2%, 14.3%) (18 , 79 )  (2.7%, 13.1%) (15 , 73 ) 
Democratic Republic of the Congo 55.50% 1,658  41.20% 1,230 
 (50.4%, 61.4%) (1,505 , 1,834 )  (30.8%, 74.7%) (919 , 2,231 ) 
Denmark 17.80% 36  10.20% 21 
 (14.9%, 21.6%) (31 , 44 )  (6.5%, 13.1%) (13 , 27 ) 
Djibouti 69.10% 8  . . 
 (64.4%, 74.2%) (7 , 8 )    
Egypt 26.00% 4,048  70.60% 11,006 
 (22.7%, 30.3%) (3,546 , 4,723 )  (58.9%, 79.5%) (9,184 , 12,408 ) 
Equatorial Guinea 65.40% 11  . . 
 (58.6%, 72.4%) (10 , 12 )    
Eritrea 34.90% 17  . . 
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Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
 (30.0%, 41.1%) (15 , 20 )    
Ethiopia 50.00% 306  17.50% 107 
 (44.8%, 56.2%) (274 , 344 )  (8.9%, 55.6%) (54 , 340 ) 
Fiji 41.50% 20  . . 
 (33.5%, 51.0%) (16 , 25 )    
Finland . .  10.20% 42 
    (7.7%, 16.3%) (31 , 67 ) 
France 5.10% 326  8.90% 569 
 (4.3%, 6.3%) (271 , 404 )  (5.3%, 19.2%) (336 , 1,226 ) 
Gabon 72.50% 17  64.60% 15 
 (67.7%, 77.5%) (15 , 18 )  (22.6%, 81.7%) (5 , 19 ) 
Georgia 30.80% 103  52.20% 174 
 (22.1%, 42.2%) (74 , 141 )  (43.8%, 61.2%) (146 , 204 ) 
Germany 10.10% 667  8.90% 590 
 (8.0%, 12.9%) (530 , 855 )  (4.0%, 16.3%) (265 , 1,079 ) 
Ghana 73.60% 1,154  . . 
 (69.8%, 77.8%) (1,095 , 1,220 )    
Greece 12.60% 96  23.60% 181 
 (10.7%, 15.2%) (82 , 117 )  (6.5%, 36.0%) (50 , 276 ) 
Guatemala 4.50% 42  . . 
 (2.7%, 7.7%) (25 , 71 )    
Guinea 76.30% 686  . . 
 (72.0%, 80.6%) (648 , 725 )    
Haiti 76.80% 130  . . 
 (57.3%, 88.6%) (97 , 150 )    
Hungary 7.70% 28  11.50% 42 
 (2.9%, 20.3%) (11 , 75 )  (5.3%, 36.8%) (19 , 135 ) 
India 23.60% 4,516  11.50% 2,204 
 (20.9%, 27.4%) (3,997 , 5,230 )  (5.3%, 17.8%) (1,006 , 3,394 ) 
Indonesia 28.20% 3,661  11.50% 1,496 
 (24.2%, 33.4%) (3,143 , 4,332 )  (5.3%, 30.2%) (683 , 3,911 ) 
Iran 16.70% 247  7.50% 112 
 (14.7%, 19.6%) (218 , 292 )  (2.7%, 17.8%) (40 , 264 ) 
Iraq 12.60% 74  34.30% 202 
 (10.7%, 15.4%) (63 , 91 )  (4.0%, 40.9%) (24 , 241 ) 
Ireland 0.60% 1  15.20% 21 
 (0.2%, 1.8%) (0 , 3 )  (8.9%, 25.7%) (12 , 36 ) 
Israel 15.10% 32  24.60% 51 
 (12.9%, 18.3%) (27 , 38 )  (11.1%, 30.2%) (23 , 63 ) 
Italy 23.80% 1,947  24.60% 2,014 
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Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
 (20.3%, 28.3%) (1,666 , 2,320 )  (18.2%, 61.2%) (1,490 , 5,012 ) 
Jamaica 44.50% 58  . . 
 (32.8%, 57.7%) (43 , 76 )    
Japan 12.40% 3,553  19.60% 5,617 
 (10.7%, 14.6%) (3,069 , 4,188 )  (6.5%, 32.2%) (1,858 , 9,210 ) 
Jordan 28.50% 39  . . 
 (23.6%, 34.8%) (33 , 48 )    
Kazakhstan 45.00% 458  35.00% 356 
 (28.4%, 63.5%) (288 , 645 )  (12.2%, 59.1%) (124 , 601 ) 
Kenya 53.30% 367  . . 
 (47.6%, 59.9%) (327 , 412 )    
Kuwait 14.70% 6  . . 
 (10.7%, 20.1%) (5 , 9 )    
Kyrgyzstan . .  29.00% 71 
    (18.2%, 59.1%) (45 , 146 ) 
Laos 65.30% 988  . . 
 (60.5%, 70.6%) (916 , 1,068 )    
Latvia . .  28.10% 36 
    (19.1%, 41.6%) (25 , 53 ) 
Lebanon 18.70% 19  . . 
 (14.9%, 23.8%) (15 , 24 )    
Liberia 64.60% 207  . . 
 (35.1%, 85.3%) (112 , 273 )    
Libya 31.70% 54  16.40% 28 
 (27.5%, 37.1%) (46 , 63 )  (14.3%, 33.2%) (24 , 56 ) 
Lithuania 26.80% 27  32.10% 33 
 (22.3%, 32.6%) (23 , 33 )  (8.9%, 39.3%) (9 , 40 ) 
Luxembourg . .  12.80% 6 
    (7.7%, 16.3%) (4 , 8 ) 
Madagascar 49.80% 146  16.40% 48 
 (45.0%, 55.5%) (132 , 162 )  (10.0%, 26.9%) (29 , 79 ) 
Malawi 72.30% 142  . . 
 (64.3%, 79.6%) (126 , 157 )    
Malaysia 13.20% 140  19.60% 207 
 (11.0%, 16.1%) (116 , 170 )  (4.0%, 62.5%) (42 , 659 ) 
Mali 72.90% 221  . . 
 (69.2%, 77.0%) (209 , 233 )    
Mauritania 74.00% 174  23.60% 56 
 (68.1%, 79.7%) (160 , 187 )  (13.3%, 69.8%) (31 , 164 ) 
Mexico 3.90% 150  18.60% 711 
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Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
 (3.2%, 4.9%) (123 , 189 )  (13.3%, 25.7%) (508 , 983 ) 
Micronesia, Federated States of 44.00% 11  . . 
 (33.8%, 55.6%) (8 , 13 )    
Moldova 66.90% 172  42.30% 109 
 (60.6%, 73.4%) (156 , 188 )  (24.2%, 49.3%) (62 , 127 ) 
Mongolia 66.10% 763  63.80% 736 
 (60.9%, 71.8%) (703 , 829 )  (54.7%, 77.1%) (632 , 890 ) 
Morocco 18.80% 56  20.70% 61 
 (16.0%, 22.6%) (47 , 67 )  (7.7%, 29.1%) (23 , 86 ) 
Mozambique 58.50% 236  . . 
 (51.7%, 65.9%) (209 , 266 )    
Myanmar 42.20% 1,484  21.70% 763 
 (37.6%, 47.9%) (1,322 , 1,684 )  (12.2%, 36.8%) (429 , 1,295 ) 
Namibia 62.80% 15  . . 
 (57.4%, 68.7%) (14 , 16 )    
Nepal 15.00% 19  . . 
 (12.9%, 17.9%) (17 , 23 )    
Netherlands 7.60% 26  3.20% 11 
 (6.4%, 9.2%) (22 , 31 )  (1.4%, 8.0%) (5 , 27 ) 
New Zealand 46.60% 101  23.60% 51 
 (42.5%, 51.8%) (92 , 112 )  (10.0%, 32.2%) (22 , 70 ) 
Nicaragua 10.10% 26  . . 
 (4.6%, 21.3%) (12 , 55 )    
Niger 76.90% 324  . . 
 (72.7%, 81.2%) (306 , 342 )    
Nigeria 67.80% 6,667  57.80% 5,680 
 (64.0%, 72.2%) (6,295 , 7,096 )  (35.2%, 73.4%) (3,455 , 7,218 ) 
Norway 0.20% 0  10.20% 16 
 (0.0%, 0.5%) (0 , 1 )  (7.7%, 16.3%) (12 , 25 ) 
Oman 54.30% 28  . . 
 (45.3%, 63.9%) (23 , 33 )    
Pakistan 37.20% 1,120  52.20% 1,573 
 (33.5%, 42.0%) (1,009 , 1,264 )  (18.2%, 68.4%) (548 , 2,060 ) 
Palestine 27.90% 18  . . 
 (16.7%, 43.8%) (11 , 28 )    
Papua New Guinea 86.10% 323  . . 
 (81.5%, 90.0%) (305 , 337 )    
Peru 27.20% 343  16.40% 206 
 (21.4%, 35.0%) (269 , 441 )  (5.3%, 25.7%) (66 , 324 ) 
Philippines 47.30% 2,945  12.80% 796 
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Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
 (43.0%, 52.7%) (2,676 , 3,277 )  (4.0%, 30.2%) (249 , 1,877 ) 
Poland 17.80% 193  12.80% 138 
 (12.5%, 25.6%) (135 , 276 )  (7.7%, 19.2%) (83 , 208 ) 
Portugal 16.80% 107  22.70% 144 
 (11.3%, 25.0%) (72 , 158 )  (6.5%, 38.5%) (41 , 244 ) 
Qatar 27.10% 13  12.80% 6 
 (17.5%, 40.4%) (9 , 20 )  (6.5%, 24.5%) (3 , 12 ) 
Romania 54.90% 709  34.30% 443 
 (50.6%, 60.0%) (654 , 775 )  (28.7%, 43.7%) (371 , 565 ) 
Russia 40.20% 1,686  40.10% 1,679 
 (35.8%, 45.8%) (1,499 , 1,920 )  (14.3%, 54.7%) (599 , 2,295 ) 
Samoa . .  3.20% 0 
    (2.7%, 16.3%) (0 , 0 ) 
Saudi Arabia 38.00% 231  19.60% 120 
 (34.0%, 43.1%) (207 , 262 )  (7.7%, 61.2%) (47 , 373 ) 
Senegal 71.70% 429  . . 
 (67.0%, 76.7%) (400 , 459 )    
Serbia 9.40% 27  . . 
 (7.4%, 12.5%) (21 , 35 )    
Sierra Leone 64.20% 284  . . 
 (52.4%, 75.1%) (232 , 332 )    
Singapore 39.00% 250  . . 
 (33.7%, 45.6%) (216 , 292 )    
Slovakia 27.20% 72  18.60% 49 
 (23.3%, 32.5%) (62 , 86 )  (11.1%, 30.2%) (30 , 80 ) 
Slovenia 5.70% 10  . . 
 (4.4%, 7.2%) (8 , 13 )    
Solomon Islands 82.00% 23  . . 
 (78.5%, 85.5%) (22 , 24 )    
Somalia 80.60% 93  . . 
 (76.0%, 85.0%) (87 , 98 )    
South Africa 58.50% 1,038  21.70% 385 
 (52.0%, 65.6%) (922 , 1,165 )  (12.2%, 35.1%) (217 , 622 ) 
South Korea 48.40% 5,349  11.50% 1,275 
 (44.6%, 53.2%) (4,936 , 5,880 )  (2.7%, 31.2%) (299 , 3,450 ) 
Spain 6.10% 251  21.70% 899 
 (4.9%, 7.7%) (204 , 318 )  (5.3%, 36.0%) (218 , 1,491 ) 
Sri Lanka 35.00% 202  . . 
 (25.9%, 46.2%) (149 , 266 )    
Sudan 54.40% 309  . . 
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Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
 (47.5%, 62.1%) (270 , 353 )    
Sweden 14.20% 44  10.20% 31 
 (10.3%, 20.0%) (32 , 61 )  (6.5%, 13.1%) (20 , 40 ) 
Switzerland . .  19.60% 121 
    (8.9%, 28.0%) (55 , 173 ) 
Syria 36.00% 177  . . 
 (28.6%, 45.1%) (141 , 222 )    
Tajikistan . .  33.60% 70 
    (13.3%, 59.1%) (28 , 123 ) 
Tanzania 60.00% 219  . . 
 (54.1%, 66.4%) (198 , 243 )    
Thailand 56.80% 7,954  30.60% 4,278 
 (52.9%, 61.6%) (7,405 , 8,629 )  (20.0%, 44.4%) (2,802 , 6,219 ) 
The Gambia 64.50% 125  25.50% 50 
 (58.2%, 71.2%) (113 , 138 )  (16.3%, 38.5%) (32 , 75 ) 
Togo 70.10% 281  . . 
 (58.2%, 80.3%) (233 , 321 )    
Tunisia 56.50% 52  17.50% 16 
 (51.8%, 62.0%) (47 , 57 )  (4.0%, 35.1%) (4 , 32 ) 
Turkey 46.20% 745  14.00% 226 
 (42.5%, 51.1%) (684 , 823 )  (7.7%, 31.2%) (124 , 503 ) 
Turkmenistan . .  47.70% 95 
    (13.3%, 59.1%) (27 , 118 ) 
Uganda 67.90% 556  . . 
 (63.0%, 73.1%) (516 , 599 )    
Ukraine 23.80% 149  37.00% 232 
 (17.0%, 32.9%) (107 , 207 )  (11.1%, 49.3%) (70 , 309 ) 
United Arab Emirates 12.80% 8  . . 
 (6.9%, 23.3%) (4 , 14 )    
United Kingdom 0.20% 5  8.90% 215 
 (0.0%, 0.3%) (0 , 6 )  (5.3%, 20.6%) (127 , 498 ) 
United States 5.30% 1,282  17.50% 4,235 
 (4.1%, 7.0%) (989 , 1,698 )  (14.3%, 34.1%) (3,463 , 8,270 ) 
Uzbekistan 71.50% 586  64.80% 531 
 (65.0%, 77.9%) (533 , 638 )  (47.1%, 73.9%) (386 , 606 ) 
Vanuatu 69.40% 12  . . 
 (59.4%, 78.4%) (11 , 14 )    
Venezuela 7.90% 47  19.60% 116 
 (6.4%, 10.1%) (38 , 60 )  (4.0%, 36.0%) (24 , 213 ) 
Vietnam 69.80% 10,988  . . 
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Country HBV  HCV 
 
PAF (CI) PAC (CI)  PAF (CI) PAC (CI) 
 (65.5%, 74.6%) (10,304 , 11,736 )    
Yemen 63.80% 194  26.40% 80 
 (58.9%, 69.2%) (179 , 210 )  (13.3%, 43.1%) (40 , 131 ) 
Zambia 56.50% 80  . . 
 (49.6%, 64.1%) (70 , 91 )    
Zimbabwe 76.00% 338  20.70% 92 
  (71.8%, 80.3%) (320 , 358 )  (12.2%, 66.3%) (54 , 295 ) 
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Table 3-8. Fraction and number of hepatocellular carcinoma cases attributable to lifestyle risk factors in men by country 
Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
Afghanistan 8.60% 28 . . 4.20% 14 
 (3.7%, 15.0%) (12 , 50 )   (2.6%, 5.9%) (9 , 19 ) 
Albania 14.60% 9 . . 17.90% 11 
 (6.9%, 23.2%) (4 , 14 )   (9.5%, 27.2%) (6 , 17 ) 
Algeria 13.20% 25 12.70% 24 17.10% 32 
 (6.1%, 21.4%) (11 , 40 ) (4.6%, 21.3%) (9 , 40 ) (9.0%, 26.1%) (17 , 49 ) 
Angola 7.00% 18 . . 4.90% 12 
 (2.9%, 12.7%) (7 , 32 )   (2.9%, 7.2%) (7 , 18 ) 
Argentina 11.10% 65 26.80% 157 24.10% 141 
 (4.9%, 18.7%) (29 , 110 ) (16.0%, 37.3%) (94 , 219 ) (13.0%, 35.6%) (77 , 209 ) 
Armenia 19.70% 39 33.70% 67 16.80% 33 
 (9.9%, 29.4%) (20 , 58 ) (20.0%, 47.1%) (39 , 93 ) (8.8%, 26.0%) (17 , 51 ) 
Australia 9.90% 88 27.20% 240 24.70% 219 
 (4.9%, 15.5%) (43 , 137 ) (16.0%, 38.2%) (141 , 337 ) (14.1%, 35.5%) (124 , 314 ) 
Austria 12.90% 57 31.80% 140 22.40% 98 
 (6.4%, 19.8%) (28 , 87 ) (19.1%, 44.1%) (84 , 193 ) (12.2%, 33.1%) (54 , 145 ) 
Azerbaijan 15.60% 30 . . 17.00% 33 
 (7.3%, 24.7%) (14 , 48 )   (9.1%, 26.3%) (18 , 51 ) 
Bahrain 7.70% 1 . . 23.30% 3 
 (3.5%, 12.9%) (0 , 1 )   (12.5%, 34.8%) (1 , 4 ) 
Bangladesh 16.40% 209 6.40% 82 3.60% 47 
 (7.9%, 25.6%) (102 , 327 ) (2.3%, 10.5%) (30 , 134 ) (2.3%, 5.0%) (29 , 64 ) 
Barbados 4.60% 0 29.10% 0 16.60% 0 
 (1.8%, 8.7%) (0 , 0 ) (14.9%, 43.7%) (0 , 1 ) (8.9%, 25.5%) (0 , 0 ) 
Belarus 18.60% 16 35.50% 30 20.20% 17 
 (9.3%, 28.2%) (8 , 24 ) (21.6%, 48.4%) (18 , 41 ) (10.5%, 31.1%) (9 , 26 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
Belgium 13.80% 46 29.20% 97 23.90% 79 
 (6.7%, 21.5%) (22 , 71 ) (17.1%, 41.1%) (57 , 136 ) (13.5%, 34.5%) (45 , 114 ) 
Belize 7.70% 0 33.90% 1 14.80% 0 
 (3.3%, 13.5%) (0 , 0 ) (17.0%, 51.9%) (1 , 2 ) (7.9%, 23.1%) (0 , 1 ) 
Benin 5.80% 22 21.90% 84 5.00% 19 
 (2.3%, 11.1%) (9 , 43 ) (10.7%, 33.3%) (41 , 128 ) (2.9%, 7.5%) (11 , 29 ) 
Bhutan 7.00% 1 18.60% 2 5.40% 1 
 (2.9%, 12.5%) (0 , 2 ) (8.1%, 29.5%) (1 , 4 ) (3.3%, 7.9%) (0 , 1 ) 
Bolivia 16.90% 15 22.50% 21 15.70% 14 
 (8.1%, 26.4%) (7 , 24 ) (11.9%, 33.2%) (11 , 30 ) (8.5%, 24.0%) (8 , 22 ) 
Bosnia and Herzegovina 16.20% 16 29.70% 29 15.50% 15 
 (7.8%, 25.3%) (8 , 25 ) (15.3%, 44.8%) (15 , 44 ) (8.4%, 23.8%) (8 , 24 ) 
Botswana 9.20% 4 31.80% 14 8.50% 4 
 (4.0%, 15.9%) (2 , 7 ) (16.5%, 47.7%) (7 , 21 ) (4.6%, 13.5%) (2 , 6 ) 
Brazil 8.40% 386 36.40% 1,674 17.70% 813 
 (3.6%, 14.5%) (165 , 668 ) (19.2%, 54.4%) (882 , 2,500 ) (9.8%, 26.2%) (451 , 1,204 ) 
Brunei 5.60% 1 . . 13.90% 1 
 (2.3%, 10.5%) (0 , 1 )   (7.3%, 22.2%) (1 , 2 ) 
Bulgaria 15.40% 48 31.40% 97 23.30% 72 
 (7.5%, 24.0%) (23 , 74 ) (18.8%, 43.5%) (58 , 134 ) (12.5%, 34.8%) (39 , 108 ) 
Burkina Faso 7.80% 49 22.80% 145 4.40% 28 
 (3.3%, 13.6%) (21 , 86 ) (11.1%, 35.2%) (71 , 224 ) (2.6%, 6.4%) (17 , 41 ) 
Burundi 9.00% 8 . . 2.60% 2 
 (3.9%, 15.4%) (4 , 14 )   (1.9%, 3.3%) (2 , 3 ) 
Cambodia 17.60% 182 . . 2.90% 30 
 (8.7%, 26.8%) (90 , 277 )   (1.9%, 3.8%) (20 , 40 ) 
Cameroon 6.40% 29 23.40% 105 6.60% 30 
 (2.6%, 11.4%) (12 , 51 ) (12.8%, 34.1%) (57 , 153 ) (3.8%, 9.9%) (17 , 45 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
Canada 10.50% 126 31.10% 373 24.70% 296 
 (5.2%, 16.5%) (62 , 198 ) (17.5%, 44.6%) (210 , 535 ) (13.7%, 35.8%) (165 , 429 ) 
Cape Verde 4.90% 1 25.90% 7 6.80% 2 
 (2.0%, 9.1%) (1 , 3 ) (13.7%, 38.2%) (4 , 11 ) (3.8%, 10.4%) (1 , 3 ) 
Central African Republic 6.60% 6 . . 3.90% 4 
 (2.7%, 12.1%) (3 , 11 )   (2.6%, 5.5%) (2 , 5 ) 
Chad 5.80% 14 17.10% 43 4.40% 11 
 (2.4%, 10.5%) (6 , 26 ) (8.1%, 26.6%) (20 , 67 ) (2.6%, 6.3%) (7 , 16 ) 
Chile 14.40% 39 26.50% 72 22.60% 61 
 (6.8%, 23.0%) (18 , 62 ) (14.9%, 38.1%) (40 , 103 ) (12.2%, 33.6%) (33 , 91 ) 
China 18.70% 42,593 27.80% 63,368 7.20% 16,461 
 (9.8%, 27.4%) (22,226,  (14.8%, 41.1%) (33,659,  (4.1%, 10.4%) (9,423, 23,643 ) 
  62,399 )  93,569 )   
Colombia 7.40% 27% 25.70% 93% 17.80% 64% 
 (3.1%, 13.3%) (11 , 48 ) (14.0%, 37.4%) (51 , 135 ) (9.6%, 26.8%) (35 , 97 ) 
Comoros 7.30% 0 3.40% 0 4.90% 0 
 (3.0%, 13.1%) (0 , 1 ) (1.2%, 5.7%) (0 , 0 ) (3.0%, 7.0%) (0 , 0 ) 
Congo 6.60% 7 17.20% 19 6.30% 7 
 (2.7%, 11.9%) (3 , 13 ) (9.1%, 25.6%) (10 , 29 ) (3.7%, 9.5%) (4 , 11 ) 
Costa Rica 5.60% 4 29.60% 24 18.80% 15 
 (2.4%, 9.6%) (2 , 8 ) (14.8%, 45.0%) (12 , 36 ) (10.0%, 28.8%) (8 , 23 ) 
Côte d’Ivoire 5.60% 73 25.50% 331 6.70% 87 
 (2.4%, 10.2%) (31 , 132 ) (12.9%, 38.8%) (167 , 503 ) (3.9%, 10.1%) (50 , 131 ) 
Croatia 12.30% 27 37.90% 83 20.90% 46 
 (5.9%, 19.5%) (13 , 43 ) (21.7%, 54.0%) (48 , 118 ) (11.1%, 31.4%) (24 , 69 ) 
Cuba 9.70% 8 26.90% 23 17.40% 15 
 (4.2%, 16.9%) (4 , 14 ) (14.1%, 40.0%) (12 , 34 ) (9.2%, 26.6%) (8 , 23 ) 
Cyprus 17.30% 3 . . 22.60% 4 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (8.4%, 26.9%) (2 , 5 )   (12.0%, 33.9%) (2 , 6 ) 
Czech Republic 12.10% 42 35.40% 124 25.60% 90 
 (5.7%, 19.1%) (20 , 67 ) (21.4%, 48.7%) (75 , 171 ) (14.1%, 37.4%) (50 , 131 ) 
Democratic Republic of the Congo 6.20% 112 26.60% 481 4.30% 77 
 (2.5%, 11.3%) (46 , 204 ) (12.5%, 41.4%) (226 , 749 ) (2.8%, 6.0%) (51 , 108 ) 
Denmark 13.10% 20 29.60% 44 23.10% 34 
 (6.6%, 19.9%) (10 , 30 ) (18.2%, 40.4%) (27 , 60 ) (12.8%, 33.7%) (19 , 50 ) 
Djibouti 14.60% 1 . . 7.80% 1 
 (6.8%, 23.4%) (0 , 2 )   (4.4%, 12.6%) (0 , 1 ) 
Dominican Republic 8.40% 14 28.20% 46 13.70% 22 
 (3.8%, 13.7%) (6 , 22 ) (14.5%, 42.3%) (24 , 69 ) (7.3%, 21.1%) (12 , 34 ) 
Ecuador 6.50% 15 28.40% 66 16.90% 39 
 (2.9%, 10.9%) (7 , 25 ) (15.0%, 42.3%) (35 , 98 ) (9.1%, 25.8%) (21 , 60 ) 
Egypt 12.80% 1,411 29.20% 3,234 19.40% 2,146 
 (5.9%, 20.7%) (651 , 2,285 ) (11.0%, 49.6%) (1,219 , 5,485 ) (10.4%, 29.6%) (1,147 , 3,268 ) 
El Salvador 7.60% 8 . . 16.70% 18 
 (3.2%, 13.6%) (3 , 15 )   (8.8%, 25.9%) (10 , 28 ) 
Equatorial Guinea 7.60% 1 . . 5.10% 1 
 (3.1%, 13.5%) (0 , 2 )   (3.1%, 7.5%) (0 , 1 ) 
Eritrea 5.60% 1 8.20% 2 3.90% 1 
 (2.3%, 10.4%) (1 , 3 ) (4.9%, 11.5%) (1 , 3 ) (2.4%, 5.5%) (1 , 1 ) 
Estonia 16.00% 3 40.40% 7 20.50% 4 
 (8.0%, 24.2%) (1 , 4 ) (23.7%, 56.7%) (4 , 10 ) (11.2%, 30.5%) (2 , 5 ) 
Ethiopia 3.40% 9 20.70% 53 3.40% 9 
 (1.4%, 6.2%) (4 , 16 ) (9.7%, 32.2%) (25 , 83 ) (2.2%, 4.7%) (6 , 12 ) 
Fiji 10.10% 3 29.60% 9 22.60% 7 
 (4.5%, 17.2%) (1 , 5 ) (13.2%, 47.2%) (4 , 15 ) (11.5%, 35.0%) (4 , 11 ) 
Finland 10.30% 28 30.90% 83 22.80% 61 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (5.1%, 15.9%) (14 , 43 ) (18.5%, 42.8%) (50 , 115 ) (12.8%, 33.1%) (34 , 89 ) 
France 14.00% 698 30.90% 1,538 24.00% 1,194 
 (7.0%, 21.3%) (348 , 1,063 ) (18.9%, 42.3%) (942 , 2,106 ) (13.2%, 35.0%) (658 , 1,744 ) 
Gabon 6.70% 1 . . 10.30% 1 
 (2.8%, 12.2%) (0 , 2 )   (5.5%, 16.6%) (1 , 2 ) 
Georgia 15.50% 30 29.90% 57 17.30% 33 
 (7.4%, 24.3%) (14 , 46 ) (15.7%, 44.4%) (30 , 84 ) (9.1%, 27.1%) (17 , 52 ) 
Germany 12.40% 569 29.50% 1,360 23.50% 1,082 
 (6.2%, 19.0%) (284 , 875 ) (18.2%, 40.4%) (836 , 1,860 ) (13.4%, 33.7%) (616 , 1,554 ) 
Ghana 4.20% 51 20.60% 252 5.80% 71 
 (1.7%, 7.6%) (21 , 93 ) (9.2%, 32.6%) (112 , 399 ) (3.4%, 8.4%) (41 , 103 ) 
Greece 18.80% 97 29.80% 153 23.60% 122 
 (9.8%, 27.6%) (50 , 142 ) (17.2%, 42.2%) (88 , 217 ) (12.8%, 35.0%) (66 , 180 ) 
Guatemala 6.00% 26 20.50% 89 15.50% 67 
 (2.5%, 10.9%) (11 , 47 ) (10.5%, 30.9%) (46 , 134 ) (8.3%, 23.7%) (36 , 103 ) 
Guinea 5.10% 28 . . 5.30% 29 
 (2.1%, 9.4%) (12 , 52 )   (3.2%, 7.6%) (18 , 42 ) 
Guinea-Bissau 5.20% 4 . . 6.10% 4 
 (2.1%, 9.5%) (1 , 7 )   (3.5%, 9.0%) (2 , 6 ) 
Guyana 9.50% 1 . . 12.90% 1 
 (4.1%, 16.4%) (0 , 1 )   (6.9%, 20.2%) (1 , 2 ) 
Haiti 7.00% 7 . . 8.70% 8 
 (3.1%, 12.0%) (3 , 11 )   (4.8%, 13.2%) (5 , 12 ) 
Honduras 9.50% 17 . . 14.60% 26 
 (4.2%, 16.0%) (7 , 28 )   (7.8%, 22.5%) (14 , 39 ) 
Hungary 14.20% 36 37.30% 94 25.00% 63 
 (6.9%, 22.2%) (17 , 56 ) (22.4%, 51.6%) (57 , 131 ) (13.6%, 36.6%) (35 , 93 ) 
Iceland 11.00% 0 24.20% 1 23.20% 1 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (5.5%, 16.8%) (0 , 1 ) (13.4%, 35.0%) (0 , 1 ) (12.6%, 34.4%) (0 , 1 ) 
India 12.10% 1,449 18.80% 2,259 4.10% 495 
 (5.9%, 18.9%) (705 , 2,266 ) (8.4%, 29.9%) (1,005 , 3,590 ) (2.5%, 5.7%) (295 , 684 ) 
Indonesia 19.30% 1,845 20.40% 1,947 4.50% 428 
 (10.0%, 28.3%) (961 , 2,705 ) (7.5%, 34.1%) (715 , 3,264 ) (2.7%, 6.2%) (257 , 597 ) 
Iran 9.20% 77 17.00% 143 17.90% 151 
 (4.0%, 15.6%) (34 , 131 ) (6.0%, 28.6%) (51 , 241 ) (9.9%, 26.7%) (83 , 224 ) 
Iraq 13.60% 38 5.10% 14 18.80% 52 
 (6.3%, 21.9%) (17 , 61 ) (1.9%, 8.6%) (5 , 24 ) (9.9%, 29.0%) (27 , 80 ) 
Ireland 12.20% 11 31.20% 28 23.20% 21 
 (5.9%, 19.3%) (5 , 17 ) (18.7%, 43.4%) (17 , 39 ) (12.6%, 34.5%) (11 , 31 ) 
Israel 12.10% 16 17.00% 23 24.80% 34 
 (5.7%, 19.4%) (8 , 26 ) (9.0%, 25.0%) (12 , 34 ) (13.5%, 36.4%) (18 , 49 ) 
Italy 12.20% 667 27.10% 1,485 23.30% 1,277 
 (6.0%, 18.8%) (329 , 1,030 ) (16.3%, 37.6%) (892 , 2,062 ) (13.2%, 33.3%) (725 , 1,827 ) 
Jamaica 10.60% 8 29.10% 22 14.70% 11 
 (4.7%, 17.8%) (4 , 14 ) (14.1%, 44.7%) (11 , 34 ) (8.0%, 22.2%) (6 , 17 ) 
Japan 18.20% 3,411 25.60% 4,795 9.10% 1,703 
 (9.4%, 27.3%) (1,764 , 5,096 ) (14.8%, 36.3%) (2,767 , 6,793 ) (5.3%, 13.0%) (985 , 2,427 ) 
Jordan 16.70% 15 . . 22.10% 19 
 (8.1%, 25.9%) (7 , 23 )   (11.8%, 33.3%) (10 , 29 ) 
Kazakhstan 9.80% 59 30.10% 181 19.40% 117 
 (4.5%, 16.2%) (27 , 97 ) (16.8%, 43.4%) (101 , 261 ) (10.1%, 30.1%) (61 , 181 ) 
Kenya 9.20% 36 24.00% 93 5.40% 21 
 (4.0%, 15.8%) (16 , 61 ) (11.0%, 37.7%) (43 , 147 ) (3.2%, 7.9%) (12 , 31 ) 
Kuwait 11.60% 4 16.60% 6 26.90% 10 
 (5.2%, 19.3%) (2 , 7 ) (5.7%, 28.0%) (2 , 10 ) (15.1%, 38.8%) (5 , 14 ) 
Kyrgyzstan 14.10% 20 27.40% 39 15.40% 22 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (6.9%, 21.8%) (10 , 31 ) (13.6%, 41.6%) (19 , 59 ) (8.3%, 23.8%) (12 , 34 ) 
Laos 20.60% 219 28.50% 304 3.00% 32 
 (10.3%, 30.8%) (110 , 328 ) (14.9%, 42.6%) (158 , 453 ) (2.0%, 4.0%) (21 , 42 ) 
Latvia 17.00% 14 34.30% 27 21.20% 17 
 (8.5%, 25.8%) (7 , 21 ) (20.4%, 47.6%) (16 , 38 ) (11.0%, 32.5%) (9 , 26 ) 
Lebanon 17.50% 11 16.40% 10 23.00% 14 
 (8.7%, 26.7%) (5 , 16 ) (8.6%, 24.1%) (5 , 14 ) (12.2%, 34.7%) (7 , 21 ) 
Lesotho 17.80% 10 28.90% 17 5.60% 3 
 (8.8%, 27.0%) (5 , 15 ) (14.7%, 43.7%) (8 , 25 ) (3.2%, 8.5%) (2 , 5 ) 
Liberia 6.50% 13 . . 4.90% 10 
 (2.8%, 11.6%) (6 , 23 )   (3.1%, 6.9%) (6 , 14 ) 
Libya 7.70% 7 . . 23.20% 22 
 (3.2%, 13.6%) (3 , 13 )   (12.4%, 34.7%) (12 , 33 ) 
Lithuania 14.70% 10 35.20% 23 21.50% 14 
 (7.4%, 22.3%) (5 , 14 ) (21.5%, 48.0%) (14 , 31 ) (11.6%, 32.4%) (7 , 21 ) 
Luxembourg 12.50% 4 . . 24.20% 8 
 (6.1%, 19.5%) (2 , 7 )   (12.7%, 36.3%) (4 , 12 ) 
Macedonia 17.00% 9 . . 20.90% 10 
 (8.3%, 26.3%) (4 , 13 )   (11.0%, 31.8%) (6 , 16 ) 
Madagascar 14.30% 28 14.40% 28 4.80% 9 
 (6.6%, 23.0%) (13 , 45 ) (6.9%, 22.0%) (13 , 43 ) (3.0%, 7.0%) (6 , 14 ) 
Malawi 10.60% 11 19.90% 21 3.80% 4 
 (4.9%, 17.4%) (5 , 18 ) (8.3%, 32.2%) (9 , 34 ) (2.4%, 5.2%) (3 , 6 ) 
Malaysia 15.10% 116 12.80% 98 9.70% 74 
 (7.1%, 24.0%) (54 , 184 ) (4.7%, 21.4%) (36 , 164 ) (5.4%, 14.7%) (41 , 113 ) 
Maldives 11.90% 1 . . 6.20% 0 
 (5.3%, 19.6%) (0 , 1 )   (3.8%, 8.5%) (0 , 0 ) 
Mali 7.60% 16 4.60% 10 5.30% 11 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (3.2%, 13.5%) (7 , 28 ) (2.0%, 7.6%) (4 , 16 ) (3.1%, 7.7%) (7 , 16 ) 
Malta 12.80% 1 . . 24.90% 2 
 (5.9%, 20.8%) (0 , 1 )   (13.4%, 37.0%) (1 , 2 ) 
Mauritania 7.10% 11 1.80% 3 6.80% 11 
 (3.0%, 12.6%) (5 , 20 ) (0.6%, 3.0%) (1 , 5 ) (3.8%, 10.6%) (6 , 17 ) 
Mauritius 14.00% 2 24.20% 3 10.70% 1 
 (6.8%, 22.0%) (1 , 2 ) (11.9%, 36.8%) (1 , 4 ) (5.8%, 16.5%) (1 , 2 ) 
Mexico 11.20% 206 31.10% 571 21.90% 403 
 (5.3%, 18.0%) (97 , 331 ) (16.3%, 46.3%) (299 , 851 ) (12.1%, 32.3%) (222 , 593 ) 
Micronesia, Federated States of 15.40% 3 24.90% 5 27.80% 6 
 (7.3%, 24.6%) (2 , 5 ) (13.2%, 37.0%) (3 , 8 ) (15.0%, 40.8%) (3 , 9 ) 
Moldova 15.40% 24 39.60% 63 16.60% 26 
 (7.3%, 24.2%) (12 , 38 ) (24.5%, 53.5%) (39 , 85 ) (8.7%, 25.6%) (14 , 41 ) 
Mongolia 15.10% 102 23.50% 159 16.10% 109 
 (7.3%, 23.9%) (49 , 161 ) (12.1%, 35.1%) (82 , 237 ) (8.7%, 24.7%) (59 , 167 ) 
Montenegro 13.60% 2 . . 21.90% 4 
 (6.3%, 21.9%) (1 , 4 )   (11.5%, 33.5%) (2 , 6 ) 
Morocco 10.80% 18 14.50% 25 16.20% 27 
 (4.9%, 17.9%) (8 , 30 ) (5.9%, 23.6%) (10 , 40 ) (8.6%, 24.9%) (15 , 42 ) 
Mozambique 8.90% 23 19.80% 51 3.60% 9 
 (3.9%, 15.3%) (10 , 39 ) (9.6%, 30.1%) (25 , 77 ) (2.3%, 4.8%) (6 , 12 ) 
Myanmar 14.90% 365 16.40% 401 2.90% 71 
 (7.1%, 23.5%) (174 , 575 ) (6.3%, 26.9%) (154 , 659 ) (2.0%, 3.7%) (49 , 89 ) 
Namibia 11.20% 2 26.70% 4 7.40% 1 
 (5.1%, 18.4%) (1 , 3 ) (14.4%, 39.3%) (2 , 7 ) (4.0%, 11.5%) (1 , 2 ) 
Nepal 18.60% 14 21.40% 16 4.20% 3 
 (9.3%, 28.0%) (7 , 21 ) (9.7%, 33.7%) (7 , 26 ) (2.6%, 6.0%) (2 , 5 ) 
Netherlands 11.40% 28 31.60% 76 21.10% 51 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (5.7%, 17.5%) (14 , 42 ) (18.0%, 45.0%) (44 , 109 ) (11.7%, 30.9%) (28 , 75 ) 
New Zealand 10.00% 15 29.20% 44 24.70% 37 
 (5.0%, 15.4%) (7 , 23 ) (16.6%, 41.7%) (25 , 62 ) (13.8%, 35.8%) (21 , 54 ) 
Nicaragua 7.40% 10 39.90% 54 15.10% 20 
 (3.1%, 13.2%) (4 , 18 ) (19.4%, 62.5%) (26 , 84 ) (8.0%, 23.3%) (11 , 31 ) 
Niger 3.40% 10 . . 3.90% 12 
 (1.3%, 6.5%) (4 , 20 )   (2.5%, 5.6%) (8 , 17 ) 
Nigeria 5.10% 328 33.50% 2,152 6.10% 394 
 (2.1%, 9.1%) (137 , 584 ) (18.3%, 48.8%) (1,177 , 3,138 ) (3.5%, 9.0%) (227 , 578 ) 
North Korea 16.80% 443 . . 7.00% 185 
 (8.1%, 26.2%) (213 , 689 )   (4.2%, 10.0%) (109 , 264 ) 
Norway 12.30% 12 24.50% 24 22.90% 22 
 (6.2%, 18.7%) (6 , 18 ) (14.3%, 34.6%) (14 , 33 ) (12.7%, 33.5%) (12 , 32 ) 
Oman 6.10% 2 . . 20.70% 8 
 (2.8%, 10.1%) (1 , 4 )   (11.0%, 31.0%) (4 , 11 ) 
Pakistan 13.30% 262 0.00% 1 6.20% 122 
 (6.2%, 21.5%) (121 , 423 ) (0.0%, 0.1%) (0 , 1 ) (3.6%, 9.5%) (70 , 187 ) 
Palestine 18.70% 8 . . . . 
 (9.5%, 28.0%) (4 , 12 )     
Panama 6.60% 4 . . 18.80% 11 
 (3.0%, 11.2%) (2 , 7 )   (10.0%, 28.5%) (6 , 17 ) 
Papua New Guinea 18.20% 42 18.60% 43 16.90% 39 
 (8.8%, 27.9%) (20 , 64 ) (10.8%, 26.1%) (25 , 60 ) (8.5%, 27.1%) (20 , 63 ) 
Paraguay 9.90% 6 30.60% 18 16.60% 10 
 (4.4%, 16.8%) (3 , 10 ) (16.2%, 45.3%) (9 , 26 ) (8.7%, 25.7%) (5 , 15 ) 
Peru 6.40% 36 29.40% 165 17.20% 96 
 (2.6%, 11.4%) (15 , 64 ) (15.8%, 43.2%) (89 , 242 ) (9.3%, 26.1%) (52 , 146 ) 
Philippines 17.60% 771 28.10% 1,232 6.20% 272 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (8.8%, 26.7%) (387 , 1,168 ) (14.6%, 42.1%) (638 , 1,843 ) (3.6%, 9.0%) (157 , 394 ) 
Poland 16.00% 93 34.70% 201 23.10% 134 
 (8.1%, 24.0%) (47 , 139 ) (20.6%, 48.3%) (119 , 280 ) (12.8%, 33.7%) (74 , 195 ) 
Portugal 12.50% 61 35.80% 175 20.20% 99 
 (6.2%, 19.4%) (30 , 95 ) (20.3%, 51.2%) (99 , 250 ) (11.2%, 29.9%) (55 , 146 ) 
Qatar 7.80% 3 . . 26.10% 12 
 (3.3%, 13.8%) (1 , 6 )   (14.2%, 38.5%) (6 , 17 ) 
Romania 15.50% 135 38.50% 334 21.90% 190 
 (7.7%, 23.7%) (67 , 205 ) (22.6%, 54.0%) (196 , 468 ) (11.7%, 32.7%) (101 , 283 ) 
Russia 19.20% 454 39.40% 932 20.00% 475 
 (9.8%, 28.4%) (233 , 672 ) (22.8%, 55.6%) (540 , 1,316 ) (11.2%, 29.2%) (266 , 690 ) 
Rwanda 9.90% 29 . . 2.90% 8 
 (4.4%, 16.7%) (13 , 48 )   (2.2%, 3.5%) (6 , 10 ) 
Samoa 15.80% 0 26.80% 1 28.60% 1 
 (7.5%, 24.8%) (0 , 1 ) (13.1%, 41.1%) (0 , 1 ) (15.5%, 41.8%) (0 , 1 ) 
Saudi Arabia 7.90% 34 . . 24.00% 105 
 (3.4%, 13.6%) (15 , 59 )   (13.4%, 35.2%) (58 , 153 ) 
Senegal 8.20% 30 5.00% 18 6.10% 23 
 (3.5%, 14.2%) (13 , 52 ) (2.0%, 8.2%) (7 , 30 ) (3.5%, 9.1%) (13 , 33 ) 
Serbia 12.80% 24 . . 21.00% 39 
 (5.9%, 20.9%) (11 , 39 )   (11.4%, 31.2%) (21 , 58 ) 
Sierra Leone 12.00% 33 32.20% 90 5.40% 15 
 (5.3%, 19.7%) (15 , 55 ) (16.6%, 48.5%) (46 , 136 ) (3.1%, 8.0%) (9 , 22 ) 
Singapore 9.80% 49 25.00% 123 11.10% 55 
 (4.5%, 16.3%) (22 , 80 ) (11.9%, 38.5%) (59 , 190 ) (6.3%, 16.4%) (31 , 81 ) 
Slovakia 13.20% 23 36.90% 63 22.70% 39 
 (6.1%, 21.3%) (11 , 37 ) (21.3%, 52.2%) (37 , 90 ) (12.4%, 33.5%) (21 , 58 ) 
Slovenia 11.40% 15 32.90% 43 22.20% 29 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
 (5.0%, 19.2%) (7 , 25 ) (20.2%, 45.0%) (26 , 58 ) (11.7%, 33.4%) (15 , 43 ) 
Solomon Islands 14.80% 3 23.30% 5 15.50% 3 
 (6.8%, 23.9%) (2 , 5 ) (10.7%, 36.4%) (2 , 8 ) (7.9%, 25.0%) (2 , 6 ) 
Somalia 8.40% 5 . . 5.10% 3 
 (3.6%, 14.7%) (2 , 9 )   (3.1%, 7.5%) (2 , 5 ) 
South Africa 14.20% 149 27.20% 285 12.50% 132 
 (6.9%, 22.1%) (73 , 232 ) (14.7%, 40.2%) (154 , 421 ) (6.7%, 19.5%) (71 , 204 ) 
South Korea 20.20% 1,658 35.70% 2,935 9.70% 797 
 (10.5%, 29.4%) (866 , 2,417 ) (21.7%, 48.9%) (1,787 , 4,019 ) (5.7%, 13.6%) (469 , 1,118 ) 
South Sudan . . . . . . 
Spain 15.00% 451 36.60% 1,101 23.80% 716 
 (7.6%, 22.6%) (227 , 680 ) (20.0%, 53.6%) (600 , 1,612 ) (13.5%, 34.1%) (405 , 1,027 ) 
Sri Lanka 9.80% 37 17.80% 67 4.30% 16 
 (4.4%, 16.3%) (17 , 61 ) (7.0%, 29.1%) (26 , 110 ) (2.7%, 5.9%) (10 , 22 ) 
Sudan 3.40% 14 18.40% 73 6.30% 25 
 (1.2%, 7.3%) (5 , 29 ) (8.0%, 29.5%) (32 , 117 ) (3.7%, 9.5%) (15 , 38 ) 
Suriname 4.30% 0 . . 16.70% 1 
 (1.7%, 8.1%) (0 , 1 )   (8.7%, 26.2%) (1 , 2 ) 
Swaziland 5.00% 3 26.40% 14 7.80% 4 
 (2.1%, 9.0%) (1 , 5 ) (13.0%, 40.5%) (7 , 21 ) (4.4%, 12.3%) (2 , 6 ) 
Sweden 7.80% 16 27.80% 56 22.20% 44 
 (3.8%, 12.4%) (7 , 25 ) (16.3%, 39.1%) (33 , 78 ) (12.5%, 32.1%) (25 , 64 ) 
Switzerland 13.20% 62 27.30% 129 23.50% 111 
 (6.6%, 20.0%) (31 , 95 ) (16.4%, 37.9%) (78 , 179 ) (13.0%, 34.4%) (61 , 163 ) 
Syria 11.10% 31 18.80% 52 18.60% 52 
 (4.9%, 18.6%) (14 , 52 ) (7.3%, 31.1%) (20 , 87 ) (9.9%, 28.3%) (28 , 79 ) 
Tajikistan 13.40% 16 . . 14.10% 17 
 (6.2%, 21.8%) (7 , 26 )   (7.7%, 21.6%) (9 , 26 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
Tanzania 9.50% 24 25.80% 64 4.60% 11 
 (4.2%, 16.3%) (10 , 41 ) (12.5%, 40.0%) (31 , 99 ) (2.8%, 6.5%) (7 , 16 ) 
Thailand 16.90% 1,708 27.30% 2,757 6.20% 630 
 (8.5%, 25.4%) (862 , 2,567 ) (14.7%, 40.3%) (1,481 , 4,069 ) (3.6%, 9.2%) (365 , 925 ) 
The Bahamas 7.00% 0 . . 21.70% 0 
 (2.9%, 12.5%) (0 , 0 )   (11.3%, 33.2%) (0 , 1 ) 
The Gambia 10.70% 15 . . 6.20% 9 
 (4.8%, 18.0%) (7 , 26 )   (3.5%, 9.4%) (5 , 13 ) 
Timor-Leste 20.90% 4 . . 2.60% 1 
 (10.7%, 30.8%) (2 , 6 )   (1.8%, 3.4%) (0 , 1 ) 
Togo 17.60% 43 . . 4.90% 12 
 (8.7%, 27.1%) (21 , 67 )   (2.9%, 7.3%) (7 , 18 ) 
Trinidad and Tobago 11.40% 1 . . 15.10% 1 
 (5.0%, 19.1%) (0 , 1 )   (7.9%, 23.8%) (1 , 2 ) 
Tunisia 15.80% 9 17.00% 10 18.20% 10 
 (7.7%, 24.5%) (4 , 14 ) (6.8%, 27.8%) (4 , 16 ) (9.8%, 27.5%) (5 , 15 ) 
Turkey 15.60% 174 22.60% 251 21.50% 240 
 (7.5%, 24.6%) (84 , 274 ) (9.7%, 36.3%) (108 , 404 ) (11.9%, 31.6%) (133 , 352 ) 
Turkmenistan 15.00% 17 . . 17.30% 20 
 (7.0%, 23.9%) (8 , 28 )   (9.1%, 26.7%) (11 , 31 ) 
Uganda 10.10% 48 34.40% 163 3.40% 16 
 (4.5%, 16.7%) (21 , 79 ) (18.6%, 50.5%) (88 , 240 ) (2.3%, 4.1%) (11 , 19 ) 
Ukraine 18.40% 67 39.10% 141 20.10% 73 
 (9.2%, 28.0%) (33 , 101 ) (22.5%, 55.3%) (82 , 200 ) (10.4%, 31.1%) (38 , 112 ) 
United Arab Emirates 8.50% 4 6.90% 3 26.50% 12 
 (3.9%, 14.1%) (2 , 6 ) (2.7%, 11.3%) (1 , 5 ) (14.5%, 38.8%) (6 , 17 ) 
United Kingdom 11.60% 182 29.10% 458 23.70% 373 
 (5.8%, 17.6%) (92 , 277 ) (18.0%, 39.9%) (282 , 627 ) (13.7%, 33.6%) (216 , 528 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 (CI) (CI) (CI) (CI) (CI) (CI) 
United States 9.00% 1,620 32.00% 5,730 26.60% 4,765 
 (4.5%, 14.1%) (799 , 2,534 ) (17.5%, 46.5%) (3,141 , 8,342 ) (15.2%, 37.8%) (2,733 , 6,775 ) 
Uruguay 14.10% 8 29.70% 16 22.10% 12 
 (6.6%, 22.8%) (4 , 12 ) (15.8%, 43.9%) (9 , 24 ) (11.7%, 33.5%) (6 , 18 ) 
Uzbekistan 8.80% 40 . . 16.20% 74 
 (3.8%, 14.9%) (17 , 68 )   (8.7%, 25.1%) (39 , 114 ) 
Vanuatu 14.50% 2 18.30% 3 18.10% 3 
 (6.9%, 22.6%) (1 , 3 ) (7.7%, 29.3%) (1 , 4 ) (9.2%, 28.7%) (1 , 4 ) 
Venezuela 10.00% 33 . . 21.70% 72 
 (4.4%, 17.1%) (15 , 57 )   (11.6%, 32.8%) (38 , 109 ) 
Vietnam 20.00% 2,408 23.90% 2,880 2.80% 341 
 (10.5%, 29.3%) (1,258 , 3,519 ) (11.9%, 36.4%) (1,432 , 4,382 ) (1.8%, 3.5%) (222 , 421 ) 
Western Sahara . . . . . . 
Yemen 12.40% 24 . . 12.60% 24 
 (5.7%, 20.3%) (11 , 39 )   (6.9%, 19.3%) (13 , 37 ) 
Zambia 9.20% 7 22.50% 18 6.10% 5 
 (4.1%, 15.7%) (3 , 12 ) (10.3%, 35.5%) (8 , 28 ) (3.5%, 9.3%) (3 , 7 ) 
Zimbabwe 9.40% 22 25.30% 59 6.70% 16 
 (4.2%, 16.0%) (10 , 37 ) (12.2%, 39.3%) (28 , 92 ) (3.8%, 10.3%) (9 , 24 ) 
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Table 3-9.  Fraction and number of hepatocellular carcinoma cases attributable to lifestyle risk factors in women by country 
Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Afghanistan 1.10% 2 . . 2.80% 6 
 
(0.4%, 2.2%) (1 , 4 ) 
  
(1.0%, 5.9%) (2 , 12 ) 
Albania 1.40% 1 . . 10.30% 4 
 
(0.5%, 2.8%) (0 , 1 ) 
  
(4.0%, 19.3%) (2 , 8 ) 
Algeria 0.40% 1 5.30% 10 14.30% 27 
 
(0.1%, 0.8%) (0 , 2 ) (1.3%, 11.1%) (2 , 21 ) (6.3%, 24.5%) (12 , 45 ) 
Angola 0.60% 1 . . 5.30% 9 
 
(0.2%, 1.3%) (0 , 2 ) 
  
(1.8%, 11.1%) (3 , 18 ) 
Argentina 8.70% 40 34.80% 158 14.40% 66 
 
(3.5%, 15.8%) (16 , 72 ) (11.7%, 52.1%) (53 , 237 ) (6.4%, 24.5%) (29 , 111 ) 
Armenia 1.20% 2 34.70% 54 11.10% 17 
 
(0.5%, 2.6%) (1 , 4 ) (11.5%, 53.1%) (18 , 82 ) (4.4%, 20.5%) (7 , 32 ) 
Australia 8.90% 32 28.30% 101 12.90% 46 
 
(4.2%, 14.1%) (15 , 50 ) (8.4%, 45.8%) (30 , 164 ) (6.1%, 21.2%) (22 , 76 ) 
Austria 9.70% 20 33.40% 71 10.20% 22 
 
(4.7%, 15.4%) (10 , 33 ) (10.0%, 53.4%) (21 , 113 ) (4.3%, 17.9%) (9 , 38 ) 
Azerbaijan 0.30% 1 . . 11.80% 19 
 
(0.1%, 0.8%) (0 , 1 ) 
  
(4.7%, 21.4%) (8 , 34 ) 
Bahrain 3.40% 0 . . 18.50% 1 
 
(1.4%, 6.0%) (0 , 0 ) 
  
(8.8%, 29.7%) (1 , 2 ) 
Bangladesh 0.80% 7 0.10% 1 2.60% 21 
 
(0.3%, 1.7%) (3 , 14 ) (0.0%, 0.1%) (0 , 1 ) (1.0%, 5.1%) (8 , 42 ) 
Barbados 0.90% 0 37.90% 1 14.10% 0 
 
(0.3%, 2.1%) (0 , 0 ) (13.7%, 54.9%) (0 , 1 ) (6.1%, 24.3%) (0 , 1 ) 
Belarus 4.50% 2 34.60% 18 13.30% 7 
 
(1.7%, 8.7%) (1 , 5 ) (10.4%, 55.3%) (5 , 29 ) (5.5%, 23.8%) (3 , 12 ) 
110 
 
Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Belgium 10.90% 16 29.00% 43 12.30% 18 
 
(5.1%, 17.9%) (7 , 26 ) (8.5%, 47.4%) (13 , 70 ) (5.7%, 20.5%) (8 , 30 ) 
Belize 0.90% 0 24.10% 1 13.00% 0 
 
(0.3%, 1.9%) (0 , 0 ) (7.8%, 37.9%) (0 , 1 ) (5.4%, 23.0%) (0 , 1 ) 
Benin 1.60% 3 24.50% 50 5.60% 11 
 
(0.6%, 3.2%) (1 , 6 ) (8.3%, 36.5%) (17 , 74 ) (2.1%, 10.6%) (4 , 22 ) 
Bhutan 1.60% 0 17.60% 1 3.80% 0 
 
(0.5%, 3.4%) (0 , 0 ) (5.6%, 27.2%) (0 , 1 ) (1.3%, 7.9%) (0 , 0 ) 
Bolivia 9.30% 10 28.00% 30 11.80% 12 
 
(3.9%, 16.6%) (4 , 17 ) (9.5%, 41.6%) (10 , 44 ) (4.8%, 21.3%) (5 , 22 ) 
Bosnia and Herzegovina 11.00% 9 13.80% 12 9.40% 8 
 
(4.7%, 18.7%) (4 , 16 ) (3.8%, 25.5%) (3 , 21 ) (3.5%, 18.1%) (3 , 15 ) 
Botswana 2.60% 1 23.90% 5 12.00% 3 
 
(1.0%, 5.3%) (0 , 1 ) (7.4%, 38.9%) (2 , 9 ) (4.7%, 22.2%) (1 , 5 ) 
Brazil 5.80% 182 37.60% 1,173 11.90% 372 
 
(2.3%, 11.0%) (72 , 343 ) (13.5%, 54.6%) (420 , 1,703 ) (5.4%, 20.1%) (169 , 628 ) 
Brunei 3.50% 0 . . 10.10% 0 
 
(1.3%, 7.0%) (0 , 0 ) 
  
(3.7%, 19.6%) (0 , 1 ) 
Bulgaria 9.10% 15 26.80% 44 12.80% 21 
 
(3.9%, 15.8%) (6 , 26 ) (7.5%, 45.6%) (12 , 75 ) (5.3%, 22.8%) (9 , 37 ) 
Burkina Faso 4.20% 16 24.50% 95 3.70% 14 
 
(1.6%, 8.0%) (6 , 31 ) (6.8%, 43.1%) (26 , 167 ) (1.4%, 7.2%) (6 , 28 ) 
Burundi 4.00% 3 . . 3.00% 2 
 
(1.5%, 7.9%) (1 , 6 ) 
  
(1.1%, 6.2%) (1 , 4 ) 
Cambodia 2.40% 14 . . 2.30% 14 
 
(1.0%, 4.7%) (6 , 28 ) 
  
(0.9%, 4.5%) (5 , 26 ) 
Cameroon 1.30% 2 25.60% 37 6.70% 10 
 
(0.5%, 2.7%) (1 , 4 ) (7.3%, 43.1%) (11 , 62 ) (2.7%, 12.5%) (4 , 18 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Canada 9.60% 45 30.40% 145 13.80% 66 
 
(4.6%, 15.1%) (22 , 72 ) (9.6%, 47.3%) (46 , 225 ) (6.4%, 23.0%) (30 , 109 ) 
Cape Verde 1.40% 0 21.50% 4 6.30% 1 
 
(0.5%, 3.0%) (0 , 1 ) (6.7%, 34.5%) (1 , 6 ) (2.3%, 12.2%) (0 , 2 ) 
Central African Republic 0.60% 0 . . 4.20% 2 
 
(0.2%, 1.2%) (0 , 1 ) 
  
(1.5%, 8.7%) (1 , 4 ) 
Chad 1.00% 1 13.10% 15 4.30% 5 
 
(0.4%, 2.2%) (0 , 3 ) (3.0%, 27.3%) (3 , 31 ) (1.6%, 8.5%) (2 , 10 ) 
Chile 12.90% 33 33.00% 84 15.50% 39 
 
(5.8%, 21.3%) (15 , 54 ) (11.0%, 50.0%) (28 , 128 ) (7.0%, 25.8%) (18 , 66 ) 
China 1.70% 1,332 23.20% 18,247 4.20% 3,334 
 
(0.8%, 2.9%) (591 , 2,288 ) (7.4%, 36.2%) (5,837 , 28,529 ) (1.8%, 7.4%) (1,446 , 5,865 ) 
Colombia 3.20% 13 27.80% 111 13.10% 52 
 
(1.2%, 6.6%) (5 , 27 ) (9.1%, 42.1%) (36 , 169 ) (5.7%, 22.3%) (23 , 90 ) 
Comoros 4.40% 0 1.00% 0 5.40% 0 
 
(1.6%, 8.5%) (0 , 0 ) (0.2%, 2.7%) (0 , 0 ) (2.0%, 10.6%) (0 , 0 ) 
Congo 0.60% 0 16.00% 13 7.00% 6 
 
(0.2%, 1.3%) (0 , 1 ) (4.5%, 28.0%) (4 , 22 ) (2.6%, 13.4%) (2 , 11 ) 
Costa Rica 1.90% 1 36.80% 20 13.30% 7 
 
(0.8%, 3.6%) (0 , 2 ) (13.5%, 52.4%) (7 , 28 ) (5.7%, 23.2%) (3 , 12 ) 
Côte d’Ivoire 1.40% 7 20.00% 106 6.70% 35 
 
(0.5%, 2.8%) (3 , 15 ) (5.9%, 34.3%) (31 , 181 ) (2.6%, 12.7%) (14 , 67 ) 
Croatia 9.40% 9 38.40% 35 12.10% 11 
 
(4.3%, 15.7%) (4 , 14 ) (12.2%, 59.4%) (11 , 54 ) (5.0%, 21.8%) (5 , 20 ) 
Cuba 5.60% 5 20.60% 18 14.50% 12 
 
(2.1%, 10.6%) (2 , 9 ) (6.5%, 32.7%) (6 , 28 ) (6.4%, 24.7%) (5 , 21 ) 
Cyprus 9.30% 1 . . 13.10% 1 
 
(3.8%, 16.5%) (0 , 2 ) 
  
(5.5%, 23.1%) (1 , 2 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Czech Republic 8.50% 17 39.90% 82 14.70% 30 
 
(3.9%, 13.9%) (8 , 28 ) (12.7%, 61.0%) (26 , 125 ) (6.6%, 24.8%) (13 , 51 ) 
Democratic Republic of the Congo 0.60% 7 28.30% 334 4.40% 52 
 
(0.2%, 1.3%) (2 , 15 ) (9.9%, 41.6%) (116 , 490 ) (1.6%, 8.9%) (19 , 104 ) 
Denmark 13.00% 7 32.20% 18 10.90% 6 
 
(6.5%, 20.0%) (4 , 11 ) (9.5%, 51.8%) (5 , 29 ) (4.7%, 19.2%) (3 , 11 ) 
Djibouti 3.20% 0 . . 7.10% 0 
 
(1.2%, 6.4%) (0 , 0 ) 
  
(2.5%, 14.2%) (0 , 1 ) 
Dominican Republic 5.60% 9 29.00% 44 12.30% 19 
 
(2.5%, 9.7%) (4 , 15 ) (9.4%, 45.0%) (14 , 68 ) (5.3%, 21.4%) (8 , 32 ) 
Ecuador 1.30% 4 22.50% 61 12.50% 34 
 
(0.5%, 2.5%) (1 , 7 ) (6.0%, 41.1%) (16 , 112 ) (5.0%, 22.5%) (14 , 61 ) 
Egypt 0.40% 18 9.00% 408 17.00% 772 
 
(0.1%, 0.7%) (7 , 34 ) (2.8%, 14.4%) (127 , 655 ) (8.2%, 27.4%) (372 , 1,243 ) 
El Salvador 1.30% 2 . . 13.00% 21 
 
(0.5%, 2.6%) (1 , 4 ) 
  
(5.5%, 22.9%) (9 , 36 ) 
Equatorial Guinea 0.60% 0 . . 5.50% 0 
 
(0.2%, 1.3%) (0 , 0 ) 
  
(1.9%, 11.1%) (0 , 0 ) 
Eritrea 0.40% 0 6.80% 2 3.60% 1 
 
(0.1%, 0.8%) (0 , 0 ) (1.8%, 12.1%) (0 , 3 ) (1.4%, 7.1%) (0 , 2 ) 
Estonia 7.90% 1 37.70% 6 13.50% 2 
 
(3.6%, 13.2%) (1 , 2 ) (12.0%, 58.3%) (2 , 9 ) (6.1%, 22.8%) (1 , 4 ) 
Ethiopia 0.50% 2 16.60% 59 3.30% 12 
 
(0.2%, 1.1%) (1 , 4 ) (4.7%, 28.8%) (17 , 102 ) (1.3%, 6.4%) (4 , 23 ) 
Fiji 2.10% 0 12.80% 2 16.90% 3 
 
(0.8%, 4.0%) (0 , 1 ) (4.0%, 20.4%) (1 , 4 ) (7.1%, 29.2%) (1 , 5 ) 
Finland 7.80% 11 29.80% 42 11.30% 16 
 
(3.8%, 12.4%) (5 , 17 ) (8.3%, 49.7%) (12 , 70 ) (5.1%, 19.0%) (7 , 27 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
France 11.50% 161 32.50% 456 12.00% 168 
 
(5.6%, 18.0%) (78 , 253 ) (9.5%, 52.3%) (134 , 735 ) (5.2%, 20.8%) (73 , 291 ) 
Gabon 1.10% 0 . . 9.90% 1 
 
(0.4%, 2.4%) (0 , 0 ) 
  
(3.7%, 18.9%) (0 , 2 ) 
Georgia 2.40% 3 26.10% 38 11.60% 17 
 
(0.9%, 4.5%) (1 , 6 ) (8.4%, 41.1%) (12 , 59 ) (4.5%, 21.4%) (6 , 31 ) 
Germany 9.10% 183 29.40% 594 11.20% 227 
 
(4.3%, 14.5%) (88 , 293 ) (8.3%, 48.7%) (167 , 984 ) (5.2%, 18.7%) (106 , 377 ) 
Ghana 0.60% 2 15.90% 55 7.00% 24 
 
(0.2%, 1.1%) (1 , 4 ) (4.5%, 27.3%) (16 , 94 ) (2.8%, 13.0%) (10 , 45 ) 
Greece 11.50% 29 34.10% 86 13.50% 34 
 
(5.4%, 18.3%) (14 , 46 ) (10.9%, 53.1%) (27 , 133 ) (5.9%, 23.5%) (15 , 59 ) 
Guatemala 1.10% 6 11.60% 57 12.10% 59 
 
(0.4%, 2.4%) (2 , 12 ) (3.4%, 19.7%) (17 , 96 ) (5.1%, 21.3%) (25 , 104 ) 
Guinea 0.70% 3 . . 5.00% 17 
 
(0.3%, 1.5%) (1 , 5 ) 
  
(1.9%, 9.7%) (7 , 34 ) 
Guinea-Bissau 1.10% 0 . . 5.60% 2 
 
(0.4%, 2.5%) (0 , 1 ) 
  
(2.0%, 10.9%) (1 , 4 ) 
Guyana 1.40% 0 . . 12.80% 1 
 
(0.5%, 2.9%) (0 , 0 ) 
  
(5.2%, 23.0%) (0 , 1 ) 
Haiti 2.30% 2 . . 8.30% 6 
 
(0.9%, 4.5%) (1 , 3 ) 
  
(3.2%, 15.7%) (2 , 12 ) 
Honduras 1.40% 3 . . 11.30% 21 
 
(0.5%, 3.0%) (1 , 5 ) 
  
(4.6%, 20.4%) (8 , 37 ) 
Hungary 9.40% 11 36.80% 42 12.90% 15 
 
(4.2%, 15.8%) (5 , 18 ) (11.3%, 57.6%) (13 , 66 ) (5.6%, 22.5%) (6 , 26 ) 
Iceland 10.90% 0 23.40% 1 11.70% 0 
 
(5.4%, 16.8%) (0 , 0 ) (7.0%, 37.6%) (0 , 1 ) (5.0%, 20.6%) (0 , 0 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
India 1.10% 81 10.00% 713 2.90% 207 
 
(0.5%, 2.1%) (34 , 146 ) (3.0%, 16.9%) (214 , 1,200 ) (1.2%, 5.4%) (85 , 380 ) 
Indonesia 1.10% 36 3.20% 109 3.90% 134 
 
(0.5%, 1.9%) (16 , 64 ) (1.0%, 5.4%) (32 , 183 ) (1.5%, 7.5%) (52 , 254 ) 
Iran 1.40% 9 9.30% 60 14.50% 93 
 
(0.5%, 3.0%) (3 , 19 ) (2.9%, 15.1%) (18 , 97 ) (6.9%, 23.7%) (44 , 152 ) 
Iraq 1.00% 3 0.30% 1 15.20% 48 
 
(0.4%, 2.1%) (1 , 6 ) (0.1%, 0.6%) (0 , 2 ) (6.7%, 25.9%) (21 , 81 ) 
Ireland 11.30% 6 32.00% 16 10.90% 6 
 
(5.3%, 18.2%) (3 , 9 ) (8.8%, 53.7%) (4 , 27 ) (4.6%, 19.3%) (2 , 10 ) 
Israel 9.20% 7 13.90% 10 15.10% 11 
 
(4.1%, 15.6%) (3 , 11 ) (4.0%, 23.3%) (3 , 17 ) (6.8%, 25.5%) (5 , 19 ) 
Italy 8.40% 228 27.40% 740 12.30% 333 
 
(4.0%, 13.6%) (108 , 367 ) (7.8%, 45.6%) (210 , 1,235 ) (5.8%, 20.3%) (157 , 550 ) 
Jamaica 3.00% 2 31.80% 18 14.70% 8 
 
(1.2%, 5.9%) (1 , 3 ) (11.0%, 47.4%) (6 , 26 ) (6.6%, 24.6%) (4 , 14 ) 
Japan 5.20% 512 23.90% 2,369 3.90% 387 
 
(2.4%, 8.7%) (237 , 860 ) (6.9%, 39.6%) (680 , 3,914 ) (1.7%, 6.8%) (166 , 675 ) 
Jordan 3.80% 2 . . 17.90% 9 
 
(1.4%, 7.3%) (1 , 4 ) 
  
(8.7%, 28.7%) (4 , 15 ) 
Kazakhstan 6.10% 25 28.00% 117 12.40% 52 
 
(2.7%, 10.6%) (11 , 44 ) (7.9%, 47.7%) (33 , 198 ) (5.0%, 22.3%) (21 , 93 ) 
Kenya 1.00% 3 10.00% 30 4.90% 15 
 
(0.4%, 2.1%) (1 , 6 ) (2.5%, 19.8%) (8 , 59 ) (1.9%, 9.6%) (6 , 29 ) 
Kuwait 1.40% 0 9.00% 1 20.70% 2 
 
(0.5%, 2.9%) (0 , 0 ) (2.8%, 14.4%) (0 , 1 ) (10.4%, 32.1%) (1 , 2 ) 
Kyrgyzstan 0.70% 1 23.50% 25 9.40% 10 
 
(0.3%, 1.4%) (0 , 1 ) (7.5%, 36.7%) (8 , 39 ) (3.6%, 17.8%) (4 , 19 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Laos 5.30% 24 18.30% 82 2.50% 11 
 
(2.0%, 10.3%) (9 , 46 ) (5.3%, 31.5%) (24 , 142 ) (1.0%, 5.0%) (4 , 23 ) 
Latvia 7.20% 3 34.60% 17 14.50% 7 
 
(3.1%, 12.5%) (1 , 6 ) (11.0%, 53.7%) (5 , 26 ) (6.2%, 25.0%) (3 , 12 ) 
Lebanon 12.60% 5 9.40% 4 16.40% 7 
 
(5.8%, 20.6%) (2 , 8 ) (2.6%, 16.1%) (1 , 7 ) (7.4%, 27.5%) (3 , 11 ) 
Lesotho 0.50% 0 19.10% 3 10.00% 2 
 
(0.2%, 1.1%) (0 , 0 ) (5.7%, 32.4%) (1 , 5 ) (3.8%, 19.0%) (1 , 3 ) 
Liberia 0.60% 1 . . 4.80% 6 
 
(0.2%, 1.2%) (0 , 1 ) 
  
(1.7%, 9.6%) (2 , 11 ) 
Libya 0.40% 0 . . 18.20% 13 
 
(0.1%, 1.3%) (0 , 1 ) 
  
(8.6%, 29.5%) (6 , 22 ) 
Lithuania 4.00% 1 34.30% 13 15.10% 6 
 
(1.8%, 7.0%) (1 , 3 ) (10.3%, 55.0%) (4 , 21 ) (6.8%, 25.4%) (3 , 9 ) 
Luxembourg 10.40% 2 . . 10.70% 2 
 
(4.9%, 16.9%) (1 , 3 ) 
  
(4.2%, 19.7%) (1 , 3 ) 
Macedonia 10.40% 3 . . 12.50% 4 
 
(4.4%, 18.2%) (1 , 5 ) 
  
(5.1%, 22.3%) (1 , 6 ) 
Madagascar 3.20% 3 9.90% 10 4.10% 4 
 
(1.2%, 6.5%) (1 , 6 ) (2.9%, 16.4%) (3 , 16 ) (1.5%, 7.9%) (2 , 8 ) 
Malawi 2.10% 2 6.60% 6 4.00% 4 
 
(0.8%, 4.4%) (1 , 4 ) (1.9%, 11.7%) (2 , 11 ) (1.5%, 7.8%) (1 , 7 ) 
Malaysia 0.90% 3 3.00% 9 6.70% 19 
 
(0.3%, 1.9%) (1 , 5 ) (0.8%, 5.6%) (2 , 16 ) (2.6%, 12.8%) (8 , 37 ) 
Maldives 4.00% 0 . . 4.90% 0 
 
(1.6%, 7.8%) (0 , 0 ) 
  
(1.8%, 10.0%) (0 , 0 ) 
Mali 1.50% 1 1.50% 1 4.80% 4 
 
(0.6%, 3.2%) (1 , 3 ) (0.4%, 2.6%) (0 , 2 ) (1.8%, 9.3%) (2 , 9 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Malta 8.60% 0 . . 14.70% 0 
 
(3.5%, 15.4%) (0 , 0 ) 
  
(6.3%, 25.4%) (0 , 1 ) 
Mauritania 1.40% 1 1.60% 1 6.20% 5 
 
(0.5%, 3.0%) (0 , 2 ) (0.5%, 2.8%) (0 , 2 ) (2.3%, 12.3%) (2 , 9 ) 
Mauritius 1.30% 0 16.20% 2 9.10% 1 
 
(0.5%, 2.5%) (0 , 0 ) (4.8%, 26.5%) (1 , 3 ) (3.6%, 16.9%) (0 , 2 ) 
Mexico 4.00% 80 24.90% 495 15.60% 310 
 
(1.7%, 7.1%) (34 , 142 ) (7.5%, 41.6%) (149 , 827 ) (7.3%, 25.4%) (146 , 505 ) 
Micronesia, Federated States of 4.60% 0 11.40% 0 21.20% 1 
 
(1.8%, 8.9%) (0 , 0 ) (3.3%, 20.1%) (0 , 1 ) (10.3%, 33.5%) (0 , 1 ) 
Moldova 2.10% 2 39.60% 39 11.70% 12 
 
(0.8%, 3.9%) (1 , 4 ) (11.9%, 62.1%) (12 , 61 ) (4.7%, 21.3%) (5 , 21 ) 
Mongolia 2.40% 11 21.40% 103 9.90% 47 
 
(0.9%, 4.5%) (4 , 22 ) (6.9%, 32.6%) (33 , 156 ) (3.8%, 18.5%) (18 , 89 ) 
Montenegro 8.00% 1 . . 12.50% 1 
 
(3.2%, 14.6%) (0 , 2 ) 
  
(5.0%, 22.5%) (1 , 3 ) 
Morocco 0.30% 0 0.10% 0 13.20% 17 
 
(0.1%, 0.6%) (0 , 1 ) (0.0%, 0.2%) (0 , 0 ) (5.6%, 22.9%) (7 , 29 ) 
Mozambique 1.80% 3 16.90% 25 4.00% 6 
 
(0.7%, 3.7%) (1 , 5 ) (5.3%, 26.7%) (8 , 39 ) (1.5%, 7.7%) (2 , 11 ) 
Myanmar 3.00% 32 1.60% 18 2.50% 27 
 
(1.2%, 5.8%) (13 , 62 ) (0.5%, 2.8%) (5 , 30 ) (0.9%, 4.9%) (10 , 53 ) 
Namibia 5.20% 0 24.40% 2 10.30% 1 
 
(2.1%, 9.6%) (0 , 1 ) (6.5%, 44.2%) (0 , 3 ) (4.0%, 19.0%) (0 , 1 ) 
Nepal 10.40% 6 11.70% 6 2.70% 1 
 
(4.6%, 17.4%) (2 , 9 ) (3.6%, 18.8%) (2 , 10 ) (1.0%, 5.4%) (1 , 3 ) 
Netherlands 9.80% 10 34.60% 34 10.40% 10 
 
(4.8%, 15.5%) (5 , 15 ) (11.1%, 53.5%) (11 , 52 ) (4.6%, 18.1%) (5 , 18 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
New Zealand 9.90% 7 28.90% 19 13.30% 9 
 
(4.9%, 15.4%) (3 , 10 ) (8.8%, 46.2%) (6 , 31 ) (6.1%, 22.2%) (4 , 15 ) 
Nicaragua 2.30% 3 32.10% 40 12.20% 15 
 
(0.9%, 4.7%) (1 , 6 ) (11.6%, 46.8%) (14 , 58 ) (5.1%, 21.4%) (6 , 27 ) 
Niger 1.10% 1 . . 3.80% 4 
 
(0.4%, 2.4%) (0 , 3 ) 
  
(1.4%, 7.3%) (2 , 8 ) 
Nigeria 1.40% 48 33.40% 1,135 5.90% 200 
 
(0.5%, 2.8%) (18 , 95 ) (10.4%, 53.4%) (355 , 1,817 ) (2.4%, 10.9%) (81 , 370 ) 
North Korea 1.30% 16 . . 4.80% 59 
 
(0.5%, 2.7%) (6 , 33 ) 
  
(1.7%, 9.6%) (21 , 118 ) 
Norway 11.90% 7 25.60% 15 12.30% 7 
 
(5.9%, 18.4%) (3 , 11 ) (7.7%, 41.0%) (4 , 24 ) (5.6%, 20.8%) (3 , 12 ) 
Oman 0.50% 0 . . 16.00% 2 
 
(0.2%, 1.0%) (0 , 0 ) 
  
(7.3%, 26.5%) (1 , 4 ) 
Pakistan 2.60% 28 0.00% 0 4.40% 46 
 
(1.0%, 5.3%) (10 , 55 ) (0.0%, 0.0%) (0 , 0 ) (1.6%, 8.7%) (17 , 91 ) 
Palestine 1.60% 0 . . . . 
 
(0.6%, 3.2%) (0 , 1 ) 
    
Panama 1.70% 1 . . 13.90% 6 
 
(0.7%, 3.2%) (0 , 1 ) 
  
(6.0%, 24.1%) (3 , 11 ) 
Papua New Guinea 8.40% 12 23.50% 34 11.90% 17 
 
(3.4%, 15.4%) (5 , 22 ) (7.8%, 35.3%) (11 , 51 ) (4.5%, 22.4%) (6 , 32 ) 
Paraguay 3.30% 2 31.80% 22 10.50% 7 
 
(1.3%, 6.5%) (1 , 4 ) (10.4%, 49.1%) (7 , 34 ) (4.1%, 19.7%) (3 , 14 ) 
Peru 2.40% 17 35.00% 245 12.80% 90 
 
(0.9%, 4.9%) (6 , 34 ) (12.7%, 49.8%) (89 , 349 ) (5.5%, 22.2%) (39 , 156 ) 
Philippines 4.70% 86 17.10% 316 4.40% 81 
 
(2.0%, 8.4%) (36 , 154 ) (4.9%, 30.2%) (89 , 556 ) (1.8%, 8.1%) (33 , 149 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Poland 9.20% 46 31.70% 159 13.70% 69 
 
(4.3%, 15.0%) (22 , 75 ) (9.6%, 50.7%) (48 , 254 ) (6.2%, 23.0%) (31 , 115 ) 
Portugal 4.10% 6 38.50% 56 11.00% 16 
 
(1.8%, 7.0%) (3 , 10 ) (12.6%, 58.8%) (18 , 86 ) (4.6%, 19.5%) (7 , 29 ) 
Qatar 0.60% 0 . . 20.60% 1 
 
(0.2%, 1.4%) (0 , 0 ) 
  
(10.1%, 32.4%) (1 , 2 ) 
Romania 7.40% 31 40.50% 172 12.70% 54 
 
(3.4%, 12.3%) (14 , 52 ) (14.1%, 59.7%) (60 , 254 ) (5.3%, 22.4%) (23 , 95 ) 
Russia 6.20% 113 38.00% 692 15.40% 281 
 
(2.7%, 10.8%) (49 , 197 ) (12.1%, 58.7%) (221 , 1,071 ) (7.7%, 24.3%) (140 , 444 ) 
Rwanda 4.20% 7 . . 3.40% 6 
 
(1.7%, 7.9%) (3 , 13 ) 
  
(1.2%, 6.7%) (2 , 11 ) 
Samoa 6.50% 0 15.80% 0 22.60% 0 
 
(2.6%, 12.1%) (0 , 0 ) (4.9%, 25.4%) (0 , 0 ) (11.2%, 35.1%) (0 , 0 ) 
Saudi Arabia 0.40% 1 . . 18.80% 33 
 
(0.2%, 0.9%) (0 , 2 ) 
  
(9.5%, 29.4%) (16 , 51 ) 
Senegal 0.90% 2 1.50% 3 6.10% 14 
 
(0.3%, 1.7%) (1 , 4 ) (0.4%, 3.1%) (1 , 7 ) (2.3%, 11.6%) (5 , 27 ) 
Serbia 9.40% 9 . . 11.70% 12 
 
(4.0%, 16.6%) (4 , 16 ) 
  
(5.0%, 20.5%) (5 , 20 ) 
Sierra Leone 2.60% 4 31.90% 52 5.40% 9 
 
(0.9%, 5.3%) (2 , 9 ) (9.7%, 51.9%) (16 , 84 ) (2.0%, 10.5%) (3 , 17 ) 
Singapore 1.50% 2 28.30% 42 6.10% 9 
 
(0.6%, 3.0%) (1 , 4 ) (9.8%, 41.6%) (14 , 61 ) (2.4%, 11.5%) (4 , 17 ) 
Slovakia 6.20% 6 33.40% 31 12.20% 11 
 
(2.5%, 11.5%) (2 , 11 ) (10.6%, 51.8%) (10 , 48 ) (5.2%, 21.3%) (5 , 20 ) 
Slovenia 8.60% 4 37.50% 18 12.60% 6 
 
(3.4%, 15.7%) (2 , 8 ) (11.5%, 58.7%) (6 , 29 ) (5.1%, 22.5%) (3 , 11 ) 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
Solomon Islands 6.40% 0 13.10% 1 12.50% 1 
 
(2.5%, 12.1%) (0 , 1 ) (4.1%, 20.8%) (0 , 1 ) (4.7%, 23.2%) (0 , 1 ) 
Somalia 1.30% 1 . . 4.00% 2 
 
(0.5%, 2.8%) (0 , 2 ) 
  
(1.4%, 8.2%) (1 , 4 ) 
South Africa 4.00% 29 17.80% 130 16.40% 119 
 
(1.7%, 7.0%) (12 , 51 ) (4.4%, 35.3%) (32 , 256 ) (7.7%, 26.8%) (56 , 195 ) 
South Korea 2.20% 62 30.50% 866 5.00% 143 
 
(0.9%, 3.9%) (27 , 111 ) (9.8%, 47.2%) (279 , 1,340 ) (2.0%, 9.2%) (58 , 261 ) 
South Sudan . . . . . . 
Spain 10.60% 121 39.00% 444 13.00% 148 
 
(5.1%, 16.8%) (58 , 191 ) (13.4%, 58.0%) (153 , 660 ) (6.1%, 21.4%) (70 , 243 ) 
Sri Lanka 0.70% 1 1.20% 2 4.00% 8 
 
(0.3%, 1.5%) (1 , 3 ) (0.3%, 2.0%) (1 , 4 ) (1.5%, 7.9%) (3 , 16 ) 
Sudan 0.40% 1 19.90% 34 5.60% 10 
 
(0.1%, 1.7%) (0 , 3 ) (6.6%, 30.4%) (11 , 52 ) (2.0%, 11.0%) (3 , 19 ) 
Suriname 1.00% 0 . . 15.10% 1 
 
(0.4%, 2.3%) (0 , 0 ) 
  
(6.5%, 26.1%) (0 , 1 ) 
Swaziland 1.30% 0 14.90% 2 11.40% 2 
 
(0.5%, 2.7%) (0 , 0 ) (4.5%, 24.2%) (1 , 3 ) (4.4%, 21.1%) (1 , 3 ) 
Sweden 9.60% 10 30.60% 33 10.90% 12 
 
(4.6%, 15.2%) (5 , 16 ) (9.4%, 48.6%) (10 , 52 ) (4.8%, 18.5%) (5 , 20 ) 
Switzerland 11.30% 16 27.20% 39 11.00% 16 
 
(5.5%, 17.5%) (8 , 25 ) (7.6%, 45.8%) (11 , 65 ) (4.7%, 19.3%) (7 , 28 ) 
Syria 2.70% 6 9.50% 20 14.20% 30 
 
(1.0%, 5.5%) (2 , 12 ) (2.9%, 15.6%) (6 , 33 ) (6.1%, 24.6%) (13 , 52 ) 
Tajikistan 1.40% 1 . . 8.90% 8 
 
(0.5%, 2.9%) (0 , 3 ) 
  
(3.3%, 16.9%) (3 , 15 ) 
Tanzania 1.10% 1 21.40% 25 4.70% 5 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
 
(0.4%, 2.3%) (0 , 3 ) (5.7%, 39.3%) (7 , 46 ) (1.8%, 8.9%) (2 , 10 ) 
Thailand 1.70% 68 9.70% 380 5.10% 199 
 
(0.7%, 3.1%) (29 , 121 ) (2.8%, 17.0%) (108 , 665 ) (2.0%, 9.8%) (78 , 381 ) 
The Bahamas 2.40% 0 . . 17.80% 0 
 
(0.9%, 5.0%) (0 , 0 ) 
  
(8.0%, 29.6%) (0 , 0 ) 
The Gambia 0.40% 0 . . 5.80% 3 
 
(0.1%, 0.9%) (0 , 0 ) 
  
(2.2%, 11.3%) (1 , 6 ) 
Timor-Leste 1.90% 0 . . 2.20% 0 
 
(0.7%, 4.0%) (0 , 0 ) 
  
(0.8%, 4.2%) (0 , 0 ) 
Togo 5.90% 9 . . 5.30% 8 
 
(2.4%, 10.9%) (4 , 17 ) 
  
(2.0%, 10.4%) (3 , 16 ) 
Trinidad and Tobago 3.20% 0 . . 13.30% 1 
 
(1.2%, 6.6%) (0 , 0 ) 
  
(5.4%, 23.9%) (0 , 2 ) 
Tunisia 0.80% 0 0.00% 0 14.90% 5 
 
(0.3%, 1.6%) (0 , 1 ) (0.0%, 0.0%) (0 , 0 ) (6.7%, 25.0%) (2 , 9 ) 
Turkey 5.60% 28 7.40% 37 16.60% 83 
 
(2.4%, 10.0%) (12 , 50 ) (2.0%, 14.0%) (10 , 70 ) (8.1%, 26.4%) (40 , 132 ) 
Turkmenistan 1.60% 1 . . 11.00% 9 
 
(0.5%, 3.3%) (0 , 3 ) 
  
(4.3%, 20.4%) (4 , 17 ) 
Uganda 1.80% 6 36.00% 124 3.60% 12 
 
(0.6%, 3.6%) (2 , 12 ) (11.6%, 55.9%) (40 , 192 ) (1.3%, 7.1%) (5 , 25 ) 
Ukraine 5.60% 15 37.70% 100 14.10% 37 
 
(2.4%, 9.9%) (6 , 26 ) (12.0%, 58.5%) (32 , 155 ) (6.0%, 24.6%) (16 , 65 ) 
United Arab Emirates 0.30% 0 3.30% 0 20.10% 3 
 
(0.1%, 0.7%) (0 , 0 ) (1.0%, 5.6%) (0 , 1 ) (9.8%, 31.7%) (1 , 5 ) 
United Kingdom 11.30% 95 29.80% 253 13.10% 111 
 
(5.6%, 17.3%) (47 , 146 ) (8.2%, 50.2%) (69 , 425 ) (6.4%, 21.1%) (54 , 178 ) 
United States 8.00% 500 30.70% 1,934 15.60% 981 
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Country Smoking PAF Smoking PAC Alcohol PAF Alcohol PAC Adiposity PAF Adiposity PAC 
 
(CI) (CI) (CI) (CI) (CI) (CI) 
 
(3.8%, 12.6%) (241 , 793 ) (9.8%, 48.0%) (614 , 3,022 ) (7.7%, 24.8%) (485 , 1,558 ) 
Uruguay 9.50% 2 29.90% 8 14.70% 4 
 
(4.1%, 16.6%) (1 , 4 ) (9.4%, 47.4%) (2 , 12 ) (6.3%, 25.4%) (2 , 6 ) 
Uzbekistan 0.60% 2 . . 9.80% 36 
 
(0.2%, 1.2%) (1 , 4 ) 
  
(3.8%, 18.4%) (14 , 67 ) 
Vanuatu 2.20% 0 6.00% 0 13.80% 0 
 
(0.9%, 4.1%) (0 , 0 ) (1.8%, 10.1%) (0 , 0 ) (5.5%, 24.8%) (0 , 1 ) 
Venezuela 5.20% 13 . . 15.40% 40 
 
(2.0%, 10.0%) (5 , 26 ) 
  
(6.9%, 25.9%) (18 , 67 ) 
Vietnam 1.90% 69 4.30% 158 2.20% 81 
 
(0.8%, 3.4%) (29 , 124 ) (1.2%, 7.6%) (45 , 282 ) (0.9%, 4.0%) (32 , 149 ) 
Western Sahara . . . . . . 
Yemen 4.60% 5 . . 9.90% 11 
 
(1.8%, 8.8%) (2 , 10 ) 
  
(3.9%, 18.4%) (4 , 20 ) 
Zambia 1.90% 1 12.70% 8 6.30% 4 
 
(0.7%, 3.8%) (0 , 2 ) (3.4%, 24.2%) (2 , 15 ) (2.4%, 11.9%) (2 , 7 ) 
Zimbabwe 1.60% 3 8.00% 17 11.30% 24 
 
(0.6%, 3.2%) (1 , 7 ) (2.1%, 15.6%) (5 , 33 ) (4.7%, 20.3%) (10 , 43 ) 
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Figure 4-1. Flow chart of flavonoid database development 
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Table 4-1. Socio-demographic characteristics of participants in dietary analysis of Jiangsu 
case-control study 
Characteristics Case (%) Control (%) p-value* 
Total N=1,266 N=5,376  
Study area    
   Dafeng 616 (48.7) 2498 (46.5) 0.004 
   Ganyu 370 (29.2) 1824 (33.9)  
   Chuzhou 280 (22.1) 1054 (19.6)  
Gender    
   Female 289 (22.8) 1461 (27.2) 0.002 
   Male 977 (77.2) 3915 (72.8)  
Age group    
   <50 318 (25.1) 557 (10.4) <0.001 
   50-59 357 (28.2) 1202 (22.4)  
   60-69 322 (25.4) 1756 (32.7)  
   70-79 219 (17.3) 1518 (28.2)  
   80- 50 (3.9) 343 (6.4)  
Education level    
   Illiteracy 508 (40.1) 2722 (50.6) <0.001 
   Primary 397 (31.4) 1643 (30.6)  
   Middle 282 (22.3) 775 (14.4)  
   High School and Above 79 (6.2) 236 (4.4)  
Family History of Liver Cancer    
   No 435 (77.7) 4208 (95.5) <0.001 
   Yes 125 (22.3) 199 (4.5)  
*Chisq p-value 
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Table 4-2. Major liver cancer risk factors in dietary analysis of Jiangsu case-control study 
  ca/co pb 
aOR 
(95% CI)a ptrend 
sbOR 
(95% CI)a 
miOR  
(95% CI)a 
HBsAg 
      Negative 223/4,169 <0.001 1.00 (Ref) <0.001 1.00 (Ref) 1.00 (Ref) 
Positive 337/242 
 
20.56 (16.41, 25.76) 
 
19.06 (15.28, 23.77) 4.94 (4.29, 5.69) 
Mildew 
         Unexposed 1,126/4,928 0.006 1.00 (Ref) 0.588 1.00 (Ref) 1.00 (Ref) 
   Exposed 119/383 
 
1.12 (0.74, 1.71) 
 
1.13 (0.75, 1.68) 1.11 (0.94, 1.31) 
Grain storage 
        Unclean 709/2,727 0.001 1.00 (Ref) 0.779 1.00 (Ref) 1.00 (Ref) 
   Clean 557/2,649 
 
0.97 (0.78, 1.21) 
 
0.96 (0.77, 1.19) 0.95 (0.87, 1.03) 
Ever drink alcohol 
        No 551/2,503  0.051 1.00 (Ref) 0.105 1.00 (Ref) 1.00 (Ref) 
   Yes 715/2,873  
 
1.39 (1.04, 1.87) 
 
1.18 (0.93, 1.50) 1.04 (0.95, 1.14) 
Grams ethanol/week in the 1990's 
       Never 551/2,503  <0.001 1.00 (Ref) 0.027 1.00 (Ref) 1.00 (Ref) 
   1-500 273/1,364  
 
1.10 (0.82, 1.47) 
 
1.06 (0.80, 1.41) 0.89 (0.79, 1.02) 
   500+ 442/1,509  
 
1.39 (1.04, 1.87) 
 
1.29 (0.98, 1.70) 1.20 (1.06, 1.37) 
Ever smoke 
         No 539/2,393  0.212 1.00 (Ref) 0.059 1.00 (Ref) 1.00 (Ref) 
   Yes 727/2,983  
 
1.27 (0.93, 1.74) 
 
1.25 (0.98, 1.60) 1.04 (0.95, 1.15) 
Pack-years smoking 
        Never 539/2,393  0.094 1.00 (Ref) 0.084 1.00 (Ref) 1.00 (Ref) 
   0-20 195/707  
 
1.27 (0.91, 1.77) 
 
1.25 (0.91, 1.71) 0.95 (0.81, 1.12) 
   20+ 532/2,276  
 
1.28 (0.84, 1.95) 
 
1.24 (0.96, 1.62) 1.10 (0.96, 1.25) 
BMI 
         <18.5 152/343  <0.001 1.00 (Ref) <0.001 1.00 (Ref) 1.00 (Ref) 
   18.5-23 711/2,617  
 
0.41 (0.29, 0.58) 
 
0.51 (0.37, 0.71) 1.11 (0.96, 1.28) 
   23-27.5 333/2,004  
 
0.18 (0.12, 0.26) 
 
0.23 (0.16, 0.33) 0.58 (0.49, 0.68) 
   >=27.5 62/388    0.23 (0.13, 0.41)   0.33 (0.20, 0.55) 0.65 (0.50, 0.85) 
ca, cases; co, controls; aOR, adjusted odds ratio; sbOR, semi-Bayes adjusted odds ratio; miOR, multiple imputation 
adjusted odds ratio 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level 
(illiteracy, primary school, middle school, high school and college), family history of liver cancer (yes, no), alcohol 
consumption (0, <500g/day, >500g/day, if not outcome of interest), pack-years of smoking (continuous, if not 
outcome of interest), and HBsAg status (positive, negative, if not outcome of interest) 
bp for Chisq 
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Table 4-3. Food categories and constituent foods in the Jiangsu case-control study 
Food categories and constituent foods in the Jiangsu case-control study 
Fruits 
apples and pears, peaches, tangerines, oranges, grapes, pineapple, melon, 
watermelon, persimmon, banana, gingko, jujubes 
Vegetables 
Includes all of the vegetables included in vegetable subclasses (red, green, 
starch, other) 
Red Vegetables red hot chili peppers, carrot, pumpkin and other winter gourds, tomato 
Green Vegetables 
seaweed, kelp, green vegetables (including: bok choi, spinach, broccoli, 
asparagus, cabbage, cauliflower), wosun or asparagus lettuce 
Starch Vegetables potato, taro 
Other Vegetables 
green onions, onion, garlic leaves, garlic bulb, green pepper, mushrooms, 
leeks, eggplant, seitan, bamboo shoots, ginger, beans, radishes, pickled 
cucumber, pickled mustard stem, pickled kohlrabi, salted vegetables, 
wood ear 
Legumes & Seeds 
soybeans, soy milk, tofu, fried tofu, bean sprouts, broad bean paste, dried 
bean curd and other bean curd products (e.g. vegetarian meat), fermented 
beans, stinky tofu, fermented tofu, peanuts, pumpkin seeds 
Meat 
stir-fried pork, braised meat, meatballs, shredded pork, preserved pork, 
beef and mutton, poultry, ham sausage, salted meat, animal liver, viscera, 
smoked fish, smoked meat, shrimp sauce, deep fried meat 
Fish fresh fish, salted fish, shellfish, shrimp, crab, snails, eel, squid, frog 
Dairy & Eggs chicken eggs, other eggs, fresh milk, powdered milk 
Grains 
rice, noodles, barley porridge, maize gruel, glutinous rice, sesame seed 
bread, deep fried dough sticks, oil fried pancakes 
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Table 4-4. Description of dietary consumption in dietary analysis in Jiangsu study 
 Case  Control Case  Control pa 
 Mean (SD) Mean (SD) Median Q1 Q3  Median Q1 Q3  
Daily Total Calories 2,318 (914) 2,259 (901) 2,210 1,656 2,895  2,160 1,630 2,832 0.057 
Percent Calories from Macronutrients (%)          
     Carbohydrates 67 (13) 68 (13) 69 59 77  70 60 78 0.231 
     Protein 12 (3) 12 (3) 12 10 14  12 10 13 0.814 
     Fat 14 (9) 14 (8) 12 8 18  11 7 17 0.688 
     Alcohol 8 (13) 8 (12) 0 0 14  0 0 14 0.178 
Glycemic Index and Load           
     Glycemic Index 96 (12) 95 (12) 101 91 104  100 88 104 0.1011 
     Glycemic Load 363 (159) 356 (160) 381 257 482  379 253 465 0.3221 
Food Categories (g/week)           
     Fruits 305 (411) 278 (386) 178 80 383  163 73 336 0.022 
     Vegetables 1,766 (1,353) 1,666 (1,350) 1,391 857 2,234  1,308 775 2,177 0.003 
     Soy and Legumes 513 (520) 556 (555) 383 171 676  414 208 721 0.001 
     Meat 352 (376) 334 (352) 237 107 467  225 111 432 0.284 
     Fish 198 (339) 173 (275) 115 44 231  100 40 202 0.001 
     Dairy and Eggs 316 (431) 290 (351) 200 83 365  200 92 350 0.980 
     Grains 3,451 (1,401) 3,426 (1,369) 3,247 2,317 4,321  3,279 2,404 4,296 0.862 
Flavonoids (mg/week)           
     Total flavonoids 1,806 (5,282) 1,794 (3,480) 346 169 993  369 184 1,681 0.025 
     Flavonol 113 (193) 112 (139) 60 33 131  63 30 137 0.898 
     Flavones 34 (27) 32 (27) 27 16 43  25 14 41 0.001 
     Flavanones 4 (15) 4 (11) 0 0 4  0 0 3 0.020 
     Catechins & Epicatechins 1,456 (5,033) 1,439 (3,293) 31 13 369  36 14 1,517 0.034 
     Theaflavins 12 (44) 12 (29) 0 0 0  0 0 0 0.087 
     Anthocyanidins 36 (56) 38 (65) 20 9 39  21 10 41 0.134 
     Isoflavonoids 150 (151) 159 (150) 108 52 205  120 60 208 0.006 
aWilcoxon signed-rank test, with p<0.05 considered significant
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Table 4-5. Associations between food categories and liver cancer in dietary analysis of Jiangsu case-control study 
  cOR ptrend aORa ptrend sbORa miORa 
Fruits (g/week) 
           T1 (0-113) 1.00 (Ref) 0.173 1.00 (Ref) 0.331 1.00 (Ref) 1.00 (Ref) 
     T2 (113-270) 1.05 (0.90, 1.22)   0.84 (0.64, 1.09)   0.84 (0.65, 1.10) 0.97 (0.86, 1.09) 
     T3 (270+) 1.11 (0.96, 1.29)   0.88 (0.67, 1.15)   0.88 (0.68, 1.15) 1.01 (0.90, 1.14) 
per 257g increase 1.04 (1.00, 1.08) 0.055 1.00 (0.92, 1.09) 0.984   
 Vegetables (g/week) 
           T1 (0-1,041) 1.00 (Ref) 0.071 1.00 (Ref) 0.176 1.00 (Ref) 1.00 (Ref) 
     T2 (1,041-1,822) 1.10 (0.95, 1.29) 
 
1.13 (0.87, 1.46) 
 
1.12 (0.87, 1.44) 0.95 (0.83, 1.08) 
     T3 (1,822+) 1.15 (0.99, 1.34) 
 
1.21 (0.92, 1.60) 
 
1.20 (0.91, 1.57) 1.13 (0.99, 1.28) 
per 1,261g increase 1.06 (1.00, 1.12) 0.064 1.12 (1.01, 1.24) 0.040 
  Soy & Legumes (g/week) 
           T1 (0-292) 1.00 (Ref) 0.004 1.00 (Ref) 0.237 1.00 (Ref) 1.00 (Ref) 
     T2 (292-598) 0.88 (0.76, 1.02)  0.86 (0.66, 1.11) 
 
0.87 (0.67, 1.12) 1.00 (0.89, 1.13) 
     T3 (598+) 0.80 (0.69, 0.93) 
 
0.86 (0.66, 1.12) 
 
0.86 (0.66, 1.12) 0.91 (0.81, 1.02) 
per 490g increase 0.90 (0.84, 0.96) 0.001 0.91 (0.80, 1.02) 0.107 
  Meat (g/week) 
           T1 (0-176) 1.00 (Ref) 0.497 1.00 (Ref) 0.071 1.00 (Ref) 1.00 (Ref) 
     T2 (176-351) 0.91 (0.78, 1.06) 
 
0.97 (0.74, 1.26) 
 
0.97 (0.75, 1.26) 0.95 (0.84, 1.09) 
     T3 (351+) 1.05 (0.91, 1.22) 0.76 (0.57, 1.02) 
 
0.77 (0.59, 1.02) 0.92 (0.81, 1.05) 
per 285g increase 1.03 (0.98, 1.08) 0.275 0.93 (0.82, 1.06) 0.274 
  Fish (g/week) 
           T1 (0-75) 1.00 (Ref) 0.014 1.00 (Ref) 0.450 1.00 (Ref) 1.00 (Ref) 
     T2 (75-158) 0.98 (0.84, 1.14) 
 
1.07 (0.80, 1.41) 
 
1.06 (0.81, 1.40) 0.96 (0.85, 1.08) 
     T3 (158+) 1.22 (1.05, 1.41) 
 
1.11 (0.85, 1.45) 
 
1.10 (0.85, 1.43) 1.06 (0.95, 1.19) 
per 135g increase 1.03 (1.01, 1.06) 0.008 1.05 (1.00, 1.09) 0.043 
  Dairy & Eggs (g/week) 
           T1 (0-114) 1.00 (Ref) 0.981 1.00 (Ref) 0.235 1.00 (Ref) 1.00 (Ref) 
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  cOR ptrend aORa ptrend sbORa miORa 
     T2 (114-295) 0.94 (0.81, 1.09) 
 
0.87 (0.68, 1.13) 
 
0.88 (0.68, 1.13) 0.93 (0.83, 1.05) 
     T3 (295+) 1.00 (0.86, 1.16) 
 
0.85 (0.63, 1.13) 
 
0.85 (0.64, 1.14) 1.09 (0.97, 1.24) 
per 271g increase 1.05 (1.00, 1.09) 0.037 1.03 (0.93, 1.13) 0.569 
  Grains (g/week) 
           T1 (0-3,171) 1.00 (Ref) 0.024 1.00 (Ref) 0.020 1.00 (Ref) 1.00 (Ref) 
     T2 (3,171-3,762) 0.82 (0.71, 0.96) 
 
0.93 (0.70, 1.24) 
 
0.93 (0.70, 1.22) 0.94 (0.83, 1.06) 
     T3 (3,762+) 0.85 (0.73, 0.98) 
 
1.39 (1.04, 1.85) 
 
1.37 (1.03, 1.81) 1.06 (0.93, 1.20) 
per 937g increase 0.94 (0.88, 1.00) 0.070 1.25 (1.09, 1.42) 0.001     
cOR, crude odds ratio; aOR, adjusted odds ratio; sbOR, semi-Bayes adjusted odds ratio; miOR, multiple imputation adjusted odds ratio 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day), pack-years of smoking (continuous), daily kcal, 
and HBsAg status (positive, negative) 
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Table 4-6. Associations between glycemic index, glycemic load, and macronutrients with liver cancer in dietary analysis of 
Jiangsu case-control study 
  cOR ptrend aORa ptrend sbORa miORa 
Glycemic Index 
           T1 (0-93) 1.00 (Ref) 0.276 1.00 (Ref) 0.507 1.00 (Ref) 1.00 (Ref) 
     T2 (93-103) 1.20 (1.03, 1.39)  0.84 (0.59, 1.20)  0.84 (0.60, 1.19) 0.94 (0.83, 1.05) 
     T3 (103+) 1.09 (0.94, 1.27)  1.03 (0.70, 1.52)  1.04 (0.72, 1.50) 1.05 (0.91, 1.22) 
per 16.47 increase 1.08 (1.00, 1.18) 0.064 1.01 (0.82, 1.25) 0.915  
 Glycemic Load 
           T1 (0-323) 1.00 (Ref) 0.799 1.00 (Ref) 0.055 1.00 (Ref) 1.00 (Ref) 
     T2 (323-402) 1.00 (0.86, 1.17)  1.03 (0.77, 1.39)  1.02 (0.77, 1.36) 1.03 (0.91, 1.16) 
     T3 (402+) 0.98 (0.84, 1.14)  1.36 (0.98, 1.87)  1.33 (0.97, 1.82) 1.06 (0.92, 1.21) 
per 124.88 increase 0.97 (0.90, 1.05) 0.425 1.22 (1.02, 1.46) 0.028  
 Carbohydrates (% kcal) 
           T1( 0-0.64) 1.00 (Ref) 0.302 1.00 (Ref) 0.001 1.00 (Ref) 1.00 (Ref) 
     T2 (0.64-0.75) 1.02 (0.88, 1.18)  1.33 (0.99, 1.79)  1.30 (0.98, 1.72) 1.03 (0.91, 1.16) 
     T3 (0.75+) 0.92 (0.79, 1.07)  1.72 (1.24, 2.39)  1.66 (1.21, 2.28) 1.14 (1.00, 1.30) 
per 18% increase 0.95 (0.88, 1.03) 0.252 1.31 (1.08, 1.59) 0.006  
 Protein (% kcal) 
           T1 (0-0.11) 1.00 (Ref) 0.683 1.00 (Ref) 0.568 1.00 (Ref) 1.00 (Ref) 
     T2( 0.11-0.13) 0.89 (0.77, 1.04)  1.11 (0.84, 1.46)  1.10 (0.84, 1.44) 0.96 (0.85, 1.08) 
     T3 (0.13+) 1.03 (0.89, 1.19)  1.09 (0.81, 1.46)  1.08 (0.81, 1.44) 1.11 (0.98, 1.25) 
per 3% increase 0.96 (0.89, 1.03) 0.241 1.06 (0.92, 1.23) 0.406  
 Fat (% kcal) 
           T1 (0-0.09) 1.00 (Ref) 0.357 1.00 (Ref) 0.129 1.00 (Ref) 1.00 (Ref) 
     T2 (0.09-0.15) 1.01 (0.86, 1.17)  1.07 (0.83, 1.39)  1.08 (0.84, 1.38) 1.02 (0.91, 1.15) 
     T3 (0.15+) 1.07 (0.92, 1.25)  0.79 (0.59, 1.05)  0.80 (0.60, 1.05) 0.96 (0.84, 1.08) 
per 1% increase 1.03 (0.96, 1.11) 0.358 0.93 (0.80, 1.08) 0.327 
  Fiber (g/week) 
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  cOR ptrend aORa ptrend sbORa miORa 
     T1 (0-51) 1.00 (Ref) 0.536 1.00 (Ref) 0.275 1.00 (Ref) 1.00 (Ref) 
     T2 (51-68) 1.01 (0.87, 1.17)  1.08 (0.83, 1.41)  1.08 (0.83, 1.40) 0.95 (0.85, 1.07) 
     T3 (68+) 1.05 (0.90, 1.22)  1.17 (0.88, 1.54)  1.16 (0.88, 1.52) 1.06 (0.93, 1.21) 
per 27.21g increase 1.02 (0.97, 1.09) 0.424 1.08 (0.97, 1.21) 0.14 
  Cholesterol (mg/week) 
           T1 (0-980) 1.00 (Ref) 0.945 1.00 (Ref) 0.212 1.00 (Ref) 1.00 (Ref) 
     T2 (980-1,963) 0.91 (0.78, 1.06)  0.73 (0.56, 0.95)  0.74 (0.57, 0.96) 0.87 (0.77, 0.98) 
     T3 (1,963+) 1.01 (0.87, 1.17)  0.86 (0.65, 1.14)  0.87 (0.66, 1.15) 1.06 (0.94, 1.20) 
per 1,544 mg increase 1.03 (0.98, 1.08) 0.289 1.00 (0.90, 1.12) 0.975     
cOR, crude odds ratio; aOR, adjusted odds ratio; sbOR, semi-Bayes adjusted odds ratio; miOR, multiple imputation adjusted odds ratio 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day), pack-years of smoking (continuous), daily kcal, 
and HBsAg status (positive, negative) 
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Table 4-7. Main sources of dietary flavonoids in Jiangsu case-control study 
 
Foods Richest in Subclass of 
Flavonoid 
Main Dietary Sources of 
Flavonoid Among Controls  
(% of Subclass) 
Flavonols Onion (37.2 mg/100g) 
Grape (20.8 mg/100g) 
Banana (10.2 mg/100g) 
Green tea (43.5%) 
Green vegetables (11.1%) 
Onion (4.6%) 
Flavones Green pepper (5.4 mg/100g) 
Carrot (4.4mg/100g) 
Ginkgo (4.3mg/100g) 
Green vegetables (45.5%) 
Green pepper (10.2%) 
Green tea (9.6%) 
Flavanones Tangerine (18.0 mg/100g) 
Orange (42.6 mg/100g) 
Tangerine (75.7%) 
Orange (24.3%) 
Catechins and Epicatechins Soybeans (37.4 mg/100g) 
Green tea (131.7 mg/1g) 
Oolong tea (49.7 mg/1g) 
Green tea (92.5%) 
Oolong tea (3.0%) 
Black tea (2.4%) 
Theaflavins Green tea (1.2 mg/1g) Green tea (100%) 
Anthocyanidins Radishes (63.1 mg/100g) 
Grapes (49.0 mg/100g) 
Beans (8.0 mg/100g) 
Radishes (46%) 
Salted vegetables (21%) 
Beans (12%) 
Isoflavones Stinky tofu and fermented tofu 
(35.6 mg/100g) 
Soybeans (65.8 mg/100g) 
Dried tofu (45.0 mg/100g) 
Tofu (41.4%) 
Dried bean curd and other 
bean curd products (31.1%) 
Soybeans (19.1%) 
Total Flavonoids Green tea (135.6 mg/1g) 
Soybeans (103.8 mg/100g) 
Salted vegetables (80.2 
mg/100g) 
Green tea (77.7%) 
Tofu (3.9%) 
Dried bean curd and other 
bean curd products (2.7%) 
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Table 4-8. Associations between total flavonoid intake and flavonoid subgroups with liver cancer in dietary analysis of Jiangsu 
case-control study 
  cOR ptrend aORa ptrend sbORa miORa 
Total Flavonoids (mg/week) 
          T1 (0-273.23) 1.00 (Ref) 0.010 1.00 (Ref) 0.074 1.00 (Ref) 1.00 (Ref) 
     T2 (273.23-635.83) 0.99 (0.86, 1.15)  1.01 (0.77, 1.31)  1.01 (0.78, 1.31) 1.07 (0.95, 1.20) 
     T3 (635.83+) 0.82 (0.71, 0.96)  0.77 (0.58, 1.01)  0.78 (0.59, 1.02) 0.85 (0.75, 0.97) 
per 1,425.6 increase 1.00 (0.98, 1.02) 0.986 0.96 (0.90, 1.01) 0.112  
 Flavonol (mg/week) 
 
    
      T1 (0-43.13) 1.00 (Ref) 0.882 1.00 (Ref) 0.906 1.00 (Ref) 1.00 (Ref) 
     T2 (43.13-98.53) 1.14 (0.98, 1.32)  1.24 (0.95, 1.60)  1.23 (0.95, 1.58) 1.09 (0.96, 1.23) 
     T3 (98.53+) 0.99 (0.85, 1.15)  0.96 (0.72, 1.28)  0.96 (0.72, 1.27) 0.94 (0.82, 1.09) 
per 95.27 increase 1.00 (0.96, 1.04) 0.985 0.94 (0.86, 1.04) 0.242  
 Flavones (mg/week) 
 
    
      T1 (0-19.21) 1.00 (Ref) 0.020 1.00 (Ref) 0.194 1.00 (Ref) 1.00 (Ref) 
     T2 (19.21-34.41) 1.16 (1.00, 1.36)  1.15 (0.88, 1.49)  1.14 (0.88, 1.47) 1.03 (0.92, 1.16) 
     T3 (34.41+) 1.20 (1.03, 1.40)  1.20 (0.91, 1.57)  1.18 (0.91, 1.55) 1.10 (0.97, 1.24) 
per 24.52 increase 1.06 (1.00, 1.12) 0.036 1.06 (0.96, 1.17) 0.242  
 Flavanones (mg/week)     
      T1 (0-0.27) 1.00 (Ref) 0.060 1.00 (Ref) 0.364 1.00 (Ref) 1.00 (Ref) 
     T2 (0.27-2.07) 0.96 (0.82, 1.12)  0.92 (0.68, 1.24)  0.92 (0.69, 1.24) 0.99 (0.87, 1.12) 
     T3 (2.07+) 1.15 (0.99, 1.33)  1.12 (0.87, 1.46)  1.12 (0.87, 1.45) 1.11 (0.99, 1.25) 
per 3.07 increase 1.01 (1.00, 1.03) 0.079 0.99 (0.96, 1.03) 0.786  
 Catechins Epicatechins (mg/week)     
      T1 (0-26.56) 1.00 (Ref) <0.001 1.00 (Ref) 0.010 1.00 (Ref) 1.00 (Ref) 
     T2 (26.56-86.46) 0.99 (0.86, 1.15)  0.84 (0.63, 1.11)  0.85 (0.64, 1.12) 1.11 (0.98, 1.26) 
     T3 (86.46+) 0.80 (0.68, 0.93)  0.70 (0.53, 0.92)  0.71 (0.54, 0.93) 0.80 (0.71, 0.91) 
per 1,477.95 increase 1.00 (0.98, 1.03) 0.887 0.95 (0.90, 1.01) 0.119  
 Theaflavins (mg/week)     
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  cOR ptrend aORa ptrend sbORa miORa 
     T1( 0) 1.00 (Ref) 0.02 1.00 (Ref) 0.134 1.00 (Ref) 1.00 (Ref) 
     T2 (0-0.7) 0.97 (0.84, 1.12)  1.03 (0.75, 1.42)  1.04 (0.76, 1.41) 1.13 (0.99, 1.28) 
     T3 (0.7+) 0.84 (0.72, 0.98)  0.81 (0.59, 1.10)  0.81 (0.60, 1.10) 0.88 (0.77, 1.00) 
per 0.7 increase 1.00 (1.00, 1.00) 0.66 1.00 (1.00, 1.00) 0.195  
 Anthocyanidins (mg/week)     
      T1( 0-14.01) 1.00 (Ref) 0.03 1.00 (Ref) 0.343 1.00 (Ref) 1.00 (Ref) 
     T2 (14.01-32.11) 0.93 (0.80, 1.08)  0.94 (0.73, 1.21)  0.94 (0.73, 1.21) 1.02 (0.91, 1.15) 
     T3 (32.11+) 0.85 (0.73, 0.98)  0.87 (0.66, 1.16)  0.88 (0.66, 1.16) 0.95 (0.84, 1.07) 
per 29.96 increase 0.98 (0.95, 1.01) 0.274 1.00 (0.93, 1.08) 0.990  
 Isoflavonoids (mg/week)     
      T1 (0-89.09) 1.00 (Ref) 0.013 1.00 (Ref) 0.069 1.00 (Ref) 1.00 (Ref) 
     T2 (89.09-170.99) 0.78 (0.67, 0.91)  0.83 (0.63, 1.08)  0.83 (0.64, 1.08) 0.96 (0.85, 1.08) 
     T3 (170.99+) 0.83 (0.72, 0.97)  0.79 (0.60, 1.02)  0.79 (0.61, 1.03) 0.91 (0.81, 1.04) 
per 129.08 increase 0.92 (0.87, 0.98) 0.009 0.93 (0.84, 1.03) 0.182     
cOR, crude odds ratio; aOR, adjusted odds ratio; sbOR, semi-Bayes adjusted odds ratio; miOR, multiple imputation adjusted odds ratio 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day), pack-years of smoking (continuous), daily kcal, 
and HBsAg status (positive, negative)
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Table 4-9. Associations between tea consumption and liver cancer in dietary analysis of 
Jiangsu case-control study 
  ca/co pb 
aORa 
(95% CI) 
sbORa 
(95% CI) 
miORa 
(95% CI) 
Total 1266/5376 
    
Ever drink tea regularly 
     
No 928/3711 0.003 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Yes 338/1665 
 
0.73 (0.56, 0.94) 0.74 (0.57, 0.95) 0.85 (0.78, 0.94) 
Regular tea drinking 
     
No 928/3711 <0.001 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Former 164/148 
 
4.30 (2.81, 6.56) 3.82 (2.54, 5.75) 3.59 (2.81, 4.60) 
Current 174/1517 
 
0.42 (0.31, 0.56) 0.43 (0.32, 0.57) 0.34 (0.28, 0.41) 
Age at start of tea drinking 
     
Never drink 928/3711 <0.001 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
<35 225/963 
 
0.86 (0.63, 1.18) 0.87 (0.64, 1.18) 1.07 (0.91, 1.27) 
35- 113/702 
 
0.59 (0.41, 0.84) 0.61 (0.43, 0.86) 0.73 (0.61, 0.88) 
Total years of tea drinking 
    
Never drink 928/3711 0.01 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
<30 187/889 
 
0.53 (0.39, 0.73) 0.55 (0.40, 0.74) 0.70 (0.59, 0.83) 
30- 151/776 
 
1.18 (0.83, 1.67) 1.18 (0.84, 1.65) 1.20 (1.00, 1.43) 
Type of tea 
     
Never drink 928/3711 0.028 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Black tea 33/208 
 
0.63 (0.36, 1.12) 0.68 (0.40, 1.15) 0.96 (0.54, 1.71) 
Green tea 271/1295 
 
0.75 (0.57, 1.00) 0.77 (0.59, 1.01) 1.22 (0.78, 1.91) 
Floral tea 16/55 
 
0.96 (0.35, 2.65) 0.98 (0.43, 2.23) 1.68 (0.77, 3.65) 
Oolong tea 1/14 
 
0.53 (0.04, 6.33) 0.85 (0.26, 2.80) 0.32 (0.05, 2.17) 
Other 13/80 
 
0.59 (0.23, 1.55) 0.70 (0.33, 1.52) 0.95 (0.44, 2.08) 
Cups of new tea every day 
    
Never drink 928/3711 0.016 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
1 98/582 
 
0.48 (0.32, 0.72) 0.51 (0.35, 0.74) 0.70 (0.53, 0.92) 
2 149/671 
 
0.94 (0.67, 1.32) 0.95 (0.68, 1.32) 0.94 (0.75, 1.18) 
3 55/273 
 
0.70 (0.39, 1.25) 0.74 (0.44, 1.25) 0.97 (0.70, 1.35) 
4+ 30/115 
 
1.59 (0.78, 3.25) 1.45 (0.76, 2.78) 1.31 (0.84, 2.03) 
Times re-brewed 
     
Never drink 928/3711 0.028 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
1~2 72/355 
 
0.55 (0.34, 0.89) 0.59 (0.38, 0.92) 0.87 (0.68, 1.12) 
3+ 260/1286 
 
0.80 (0.61, 1.05) 0.81 (0.62, 1.06) 0.93 (0.78, 1.11) 
Type of water used 
     
Never drink 928/3711 0.001 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Tap water 154/729 
 
0.80 (0.57, 1.12) 0.82 (0.59, 1.13) 1.13 (0.87, 1.46) 
Deep well water 65/437 
 
0.50 (0.32, 0.77) 0.54 (0.36, 0.81) 0.64 (0.46, 0.90) 
Shallow well water 108/412 
 
1.14 (0.72, 1.83) 1.14 (0.74, 1.78) 1.52 (1.11, 2.09) 
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  ca/co pb 
aORa 
(95% CI) 
sbORa 
(95% CI) 
miORa 
(95% CI) 
Pool/ditch/river/rain 10/70 
 
0.44 (0.15, 1.29) 0.60 (0.27, 1.34) 0.65 (0.33, 1.25) 
Monthly g of tea leaves 
     
Never drink 928/3711 0.016 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
0-50 212/1130 
 
0.72 (0.54, 0.95) 0.73 (0.56, 0.97) 0.81 (0.66, 0.99) 
50-250 84/361 
 
0.88 (0.54, 1.42) 0.90 (0.57, 1.42) 1.12 (0.84, 1.51) 
500+ 31/134 
 
0.47 (0.20, 1.10) 0.58 (0.29, 1.16) 0.91 (0.59, 1.41) 
ca/co, cases/controls; aOR, adjusted odds ratio; sbOR, semi-Bayes adjusted odds ratio; miOR, multiple imputation 
adjusted odds ratio 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level 
(illiteracy, primary school, middle school, high school and college), family history of liver cancer (yes, no), alcohol 
consumption (0, <500g/day, >500g/day), pack-years of smoking (continuous), daily kcal, and HBsAg status 
(positive, negative) 
bp for Chisq or Fisher’s Exact Test
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Table 4-10. Joint associations between flavonoid intake, glycemic index, glycemic load, carbohydrate intake, and major liver 
cancer risk factors in Jiangsu case-control study 
  aORa sbORa RERIa RORa 
Total Flavonoid Intake 
       High Flavonoid and Low GI 1.00 (Ref) 1.00 (Ref) RERI: -0.15 (-0.72, 0.42) ROR: 0.88 (0.55, 1.39) 
   Low Flavonoid and Low GI 1.37 (0.97, 1.93) 1.31 (0.93, 1.84) sbRERI: -0.11 (-0.67, 0.45) sbROR: 0.9 (0.58, 1.4) 
   High Flavonoid and High GI 1.10 (0.76, 1.59) 1.13 (0.79, 1.63) 
     Low Flavonoid and High GI 1.32 (0.96, 1.81) 1.33 (0.98, 1.81) 
  
        High Flavonoids and Low GL 1.00 (Ref) 1.00 (Ref) RERI: -0.11 (-0.71, 0.48) ROR: 0.88 (0.55, 1.39) 
   Low Flavonoid and Low GL 1.33 (0.94, 1.86) 1.28 (0.92, 1.80) sbRERI: -0.10 (-0.67, 0.48) sbROR: 0.9 (0.58, 1.39) 
   High Flavonoid and High GL 1.30 (0.90, 1.87) 1.25 (0.87, 1.79) 
     Low Flavonoid and High GL 1.51 (1.10, 2.07) 1.43 (1.06, 1.94) 
  
        High Flavonoid and Low Carbs 1.00 (Ref) 1.00 (Ref) RERI: 0.25 (-0.27, 0.78) ROR: 1.17 (0.75, 1.84) 
   Low Flavonoid and Low Carbs 1.13 (0.82, 1.56) 1.10 (0.80, 1.51) sbRERI: 0.25 (-0.26, 0.77) sbROR: 1.17 (0.76, 1.79) 
   High Flavonoid and High Carbs 1.17 (0.82, 1.66) 1.16 (0.81, 1.64) 
     Low Flavonoid and High Carbs 1.55 (1.14, 2.12) 1.50 (1.11, 2.03) 
  
     Unclean Grain Storage 
       Clean Storage and Low GI 1.00 (Ref) 1.00 (Ref) RERI: -0.44 (-1.04, 0.17) ROR: 0.69 (0.44, 1.08) 
   Unclean Storage and Low GI 1.29 (0.91, 1.83) 1.31 (0.93, 1.85) sbRERI: -0.46 (-1.08, 0.15) sbROR: 0.7 (0.46, 1.08) 
   Clean Storage and High GI 1.36 (0.94, 1.95) 1.40 (0.99, 1.99) 
     Unclean Storage and High GI 1.21 (0.83, 1.76) 1.25 (0.87, 1.78) 
  
        Clean Storage and Low GL 1.00 (Ref) 1.00 (Ref) RERI: -0.4 (-1.02, 0.21) ROR: 0.72 (0.46, 1.12) 
   Unclean Storage and Low GL 1.26 (0.90, 1.77) 1.26 (0.90, 1.76) sbRERI: -0.40 (-1.00, 0.21) sbROR: 0.74 (0.49, 1.13) 
   Clean Storage and High GL 1.53 (1.07, 2.18) 1.48 (1.04, 2.09) 
     Unclean Storage and High GL 1.38 (0.97, 1.98) 1.34 (0.95, 1.90) 
  
        Clean Storage and Low Carbs 1.00 (Ref) 1.00 (Ref) RERI: -0.28 (-0.87, 0.3) ROR: 0.79 (0.51, 1.22) 
   Unclean Storage and Low Carbs 1.18 (0.86, 1.62) 1.18 (0.86, 1.62) sbRERI: -0.29 (-0.87, 0.29) sbROR: 0.8 (0.53, 1.21) 
   Clean Storage and High Carbs 1.51 (1.07, 2.12) 1.50 (1.07, 2.11) 
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  aORa sbORa RERIa RORa 
   Unclean Storage and High Carbs 1.40 (0.99, 1.98) 1.39 (1.00, 1.95) 
  
        Clean Storage and High Flavonoid 1.00 (Ref) 1.00 (Ref) RERI: -0.70 (-1.39, 0.00) ROR: 0.59 (0.38, 0.92) 
   Unclean Storage and High Flavonoid 1.41 (1.01, 1.98) 1.41 (1.01, 1.97) sbRERI: -0.69 (-1.37, -0.00) sbROR: 0.62 (0.41, 0.94) 
   Clean Storage and Low Flavonoid 1.70 (1.22, 2.35) 1.65 (1.20, 2.28) 
     Unclean Storage and Low Flavonoid 1.41 (1.01, 1.99) 1.38 (0.99, 1.92) 
  
     Hepatitis B 
       HBsAg- and Low GI 1.00 (Ref) 1.00 (Ref) RERI: 0.89 (-7.66, 9.44) ROR: 0.9 (0.57, 1.41) 
   HBsAg+  and Low GI 22.00 (15.52, 31.18) 20.34 (14.43, 28.67) sbRERI: -0.79 (-8.24, 6.67) sbROR: 0.9 (0.59, 1.39) 
   HBsAg- and High GI 1.17 (0.84, 1.63) 1.08 (0.79, 1.48) 
     HBsAg+ and High GI 23.06 (16.02, 33.19) 19.63 (13.94, 27.64) 
  
        HBsAg- and Low GL 1.00 (Ref) 1.00 (Ref) RERI: 1.53 (-8.02, 11.08) ROR: 0.76 (0.49, 1.19) 
   HBsAg+  and Low GL 24.29 (17.17, 34.36) 22.34 (15.88, 31.41) sbRERI: -1.51 (-9.63, 6.60) sbROR: 0.78 (0.51, 1.2) 
   HBsAg- and High GL 1.42 (1.04, 1.94) 1.25 (0.92, 1.69) 
     HBsAg+ and High GL 26.24 (18.37, 37.47) 21.07 (15.03, 29.54) 
  
        HBsAg- and Low Carbs 1.00 (Ref) 1.00 (Ref) RERI: 0.58 (-9.1, 10.26) ROR: 0.68 (0.44, 1.06) 
   HBsAg+  and Low Carbs 25.34 (18.20, 35.27) 23.59 (17.04, 32.66) sbRERI: -2.09 (-10.46, 6.29) sbROR: 0.7 (0.46, 1.07) 
   HBsAg- and High Carbs 1.54 (1.13, 2.09) 1.41 (1.04, 1.90) 
     HBsAg+ and High Carbs 26.46 (18.62, 37.59) 21.91 (15.69, 30.58) 
  
        HBsAg- and High Flavonoid 1.00 (Ref) 1.00 (Ref) RERI: -1.73 (-11.13, 7.66) ROR: 0.62 (0.4, 0.97) 
   HBsAg+  and High Flavonoid 27.01 (19.12, 38.16) 24.85 (17.70, 34.88) sbRERI: -3.75 (-12.05, 4.56) sbROR: 0.65 (0.43, 1.00) 
   HBsAg- and Low Flavonoid 1.54 (1.16, 2.05) 1.40 (1.06, 1.84) 
     HBsAg+ and Low Flavonoid 25.82 (18.62, 35.80) 21.50 (15.73, 29.38) 
  
     Ever Drink Alcohol 
       Never Drinker and Low GI 1.00 (Ref) 1.00 (Ref) RERI: 0.19 (-0.27, 0.66) ROR: 1.17 (0.75, 1.82) 
   Drinker and Low GI 1.12 (0.78, 1.62) 0.96 (0.65, 1.42) sbRERI: 0.18 (-0.25, 0.61) sbROR: 1.16 (0.76, 1.77) 
   Never Drinker and High GI 1.02 (0.70, 1.48) 1.05 (0.73, 1.51) 
     Drinker and High GI 1.33 (0.91, 1.96) 1.19 (0.80, 1.76) 
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  aORa sbORa RERIa RORa 
        Never Drinker and Low GL 1.00 (Ref) 1.00 (Ref) RERI: 0.07 (-0.47, 0.62) ROR: 1.01 (0.64, 1.61) 
   Drinker and Low GL 1.28 (0.86, 1.90) 1.01 (0.66, 1.54) sbRERI: 0.12 (-0.36, 0.61) sbROR: 1.08 (0.7, 1.68) 
   Never Drinker and High GL 1.20 (0.81, 1.77) 1.17 (0.80, 1.71) 
     Drinker and High GL 1.55 (1.02, 2.37) 1.30 (0.87, 1.96) 
  
        Never Drinker and Low Carbs 1.00 (Ref) 1.00 (Ref) RERI: 0.29 (-0.22, 0.81) ROR: 1.22 (0.75, 1.99) 
   Drinker and Low Carbs 1.16 (0.78, 1.75) 0.84 (0.54, 1.32) sbRERI: 0.42 (-0.03, 0.88) sbROR: 1.4 (0.87, 2.25) 
   Never Drinker and High Carbs 1.08 (0.73, 1.58) 1.07 (0.73, 1.55) 
     Drinker and High Carbs 1.53 (1.00, 2.35) 1.34 (0.88, 2.02) 
  
        Never Drinker and High Flavonoid 1.00 (Ref) 1.00 (Ref) RERI: 0.21 (-0.31, 0.72) ROR: 1.12 (0.72, 1.75) 
   Drinker and High Flavonoid 1.18 (0.82, 1.68) 1.01 (0.69, 1.46) sbRERI: 0.15 (-0.33, 0.62) sbROR: 1.11 (0.73, 1.69) 
   Never Drinker and Low Flavonoid 1.19 (0.85, 1.68) 1.17 (0.84, 1.64) 
     Drinker and Low Flavonoid 1.58 (1.11, 2.25) 1.32 (0.92, 1.91) 
  
     Ever Smoke Tobacco 
       Never Smoker and Low GI 1.00 (Ref) 1.00 (Ref) RERI: 0.03 (-0.49, 0.55) ROR: 1 (0.64, 1.57) 
   Smoker  and Low GI 1.27 (0.87, 1.84) 0.98 (0.66, 1.45) sbRERI: 0.17 (-0.27, 0.61) sbROR: 1.14 (0.75, 1.74) 
   Never Smoker and High GI 1.11 (0.76, 1.62) 1.05 (0.73, 1.52) 
     Smoker and High GI 1.41 (0.96, 2.06) 1.20 (0.81, 1.78) 
  
        Never Smoker and Low GL 1.00 (Ref) 1.00 (Ref) RERI: 0.21 (-0.31, 0.72) ROR: 1.12 (0.72, 1.76) 
   Smoker  and Low GL 1.17 (0.81, 1.70) 1.03 (0.67, 1.57) sbRERI: 0.11 (-0.38, 0.60) sbROR: 1.07 (0.69, 1.66) 
   Never Smoker and High GL 1.18 (0.82, 1.72) 1.18 (0.81, 1.73) 
     Smoker and High GL 1.56 (1.09, 2.26) 1.32 (0.88, 1.99) 
  
        Never Smoker and Low Carbs 1.00 (Ref) 1.00 (Ref) RERI: 0.06 (-0.52, 0.64) ROR: 0.98 (0.62, 1.54) 
   Smoker and Low Carbs 1.29 (0.89, 1.85) 0.86 (0.55, 1.35) sbRERI: 0.86 (0.55, 1.35) sbROR: 1.39 (0.86, 2.22) 
   Never Smoker and High Carbs 1.34 (0.93, 1.93) 1.07 (0.74, 1.56) 
     Smoker and High Carbs 1.68 (1.17, 2.43) 1.35 (0.89, 2.04) 
  
        Never Smoker and High Flavonoid 1.00 (Ref) 1.00 (Ref) RERI: -0.02 (-0.61, 0.57) ROR: 0.92 (0.59, 1.45) 
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  aORa sbORa RERIa RORa 
   Smoker and High Flavonoid 1.36 (0.94, 1.97) 1.02 (0.70, 1.48) sbRERI: 0.15 (-0.33, 0.63) sbROR: 1.11 (0.73, 1.69) 
   Never Smoker and Low Flavonoid 1.36 (0.95, 1.94) 1.16 (0.83, 1.63) 
     Smoker and Low Flavonoid 1.70 (1.18, 2.44) 1.33 (0.92, 1.92)     
aOR, adjusted odds ratio; sb, semi-Bayes; OR, odds ratio; RERI, relative excess risk due to interaction; ROR, ratio of odds ratios 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day, when not included in interaction term), pack-year of 
smoking (continuous, when not included in interaction term), daily kcal, and HBsAg status (positive, negative, when not included in interaction term) 
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Table 5-1. Gene names and dbsnp numbers of 43 candidate SNPs in Jiangsu case-control 
study 
Gene SNP Gene SNP Gene SNP 
NFKB Pathway Stem Cell Pathway GWAS 
NFKB-IKBKAP rs2230793 Oct4 rs13409 CCR4-GLB1 rs4678680 
NFKB-IKBKAP rs3204145 Oct4 rs3130932 ZBTB12 -C2 rs9267673 
miR-300 rs12894467 Ctbp2 rs3740535 HLA-DQB1- rs9275572 
Micro RNA pathway WNT2 rs3729629 HLA-DQA2  
CXCL12 rs1804429 WNT2 rs4730775 CHEK2 rs738722 
IL15 rs10519613 DVL2 rs222851 TGM5 rs748404 
WWOX rs12828 AXIN1 rs1981492 RUNX1 rs2014300 
pre-miR-146a rs2910164 Notch4 rs915894 PLCE1 rs2274223 
miR-26a1 rs7372209 HEY1 rs1046472 GPC5 rs2352028 
Gemin3 rs197412 HEY2 rs3734637 TERT-CLPTM1L rs4975616 
KRAS rs9266 Notch4 rs520692 IL1RAP rs7626795 
CDK6 rs42031 JAG1 rs8708 SEMA5B rs9868873 
DOCK4 rs3801790 Dec1 rs2269700 HIF1alpha rs2057482 
Rbl2 rs3929   BCM01 rs12934922 
THBS1 rs2292305     
CTNNB1 rs2953     
IL6R rs4072391     
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Table 5-2. Associations between selected SNPs and liver cancer by flavonoid intake in Jiangsu case-control study 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Total 458/2,398 
  
258/1,196 
  
208/1,158 
 
rs1046472 
           
   C:C 266/1423 1.00 (Ref) 1.00 (Ref) 
 
146/712 1.00 (Ref) 1.00 (Ref) 
 
106/686 1.00 (Ref) 1.00 (Ref) 
   A:C 123/728 0.96 (0.69, 1.34) 0.97 (0.70, 1.34) 
 
71/371 1.10 (0.70, 1.74) 1.13 (0.73, 1.75) 
 
50/342 0.77 (0.46, 1.31) 0.80 (0.49, 1.30) 
   A:A 19/108 1.29 (0.62, 2.71) 1.22 (0.63, 2.36) 
 
5/52 0.68 (0.17, 2.72) 0.82 (0.32, 2.14) 
 
12/56 1.31 (0.47, 3.66) 1.19 (0.51, 2.77) 
Log-Add 
 
1.03 (0.79, 1.35) 1.03 (0.79, 1.35) 
  
1.01 (0.68, 1.48) 1.03 (0.71, 1.49) 
  
0.93 (0.62, 1.40) 0.94 (0.63, 1.39) 
Dominant 
 
1.00 (0.73, 1.37) 1.00 (0.73, 1.37) 
  
1.06 (0.68, 1.65) 1.08 (0.71, 1.66) 
  
0.84 (0.51, 1.37) 0.86 (0.54, 1.36) 
Recessive 
 
1.31 (0.63, 2.72) 1.23 (0.64, 2.37) 
  
0.66 (0.17, 2.61) 0.80 (0.31, 2.08) 
  
1.41 (0.51, 3.91) 1.25 (0.54, 2.89) 
rs10519613 
           
   C:C 150/803 1.00 (Ref) 1.00 (Ref) 
 
89/413 1.00 (Ref) 1.00 (Ref) 
 
57/376 1.00 (Ref) 1.00 (Ref) 
   C:A 172/1022 1.07 (0.75, 1.51) 1.06 (0.76, 1.48) 
 
91/498 0.98 (0.61, 1.58) 0.99 (0.64, 1.55) 
 
71/503 1.24 (0.71, 2.15) 1.18 (0.72, 1.96) 
   A:A 85/422 1.31 (0.86, 2.00) 1.29 (0.86, 1.93) 
 
41/216 1.04 (0.57, 1.88) 1.05 (0.61, 1.81) 
 
41/202 1.66 (0.87, 3.13) 1.51 (0.85, 2.68) 
Log-Add 
 
1.13 (0.92, 1.40) 1.14 (0.92, 1.40) 
  
1.01 (0.76, 1.36) 1.02 (0.77, 1.36) 
  
1.28 (0.93, 1.77) 1.28 (0.94, 1.75) 
Dominant 
 
1.14 (0.82, 1.57) 1.14 (0.83, 1.56) 
  
1.00 (0.64, 1.55) 1.01 (0.66, 1.54) 
  
1.37 (0.82, 2.28) 1.34 (0.83, 2.17) 
Recessive 
 
1.26 (0.87, 1.84) 1.25 (0.87, 1.80) 
  
1.05 (0.61, 1.80) 1.05 (0.63, 1.75) 
  
1.46 (0.85, 2.53) 1.39 (0.83, 2.32) 
rs12828 
           
   G:G 165/922 1.00 (Ref) 1.00 (Ref) 
 
92/474 1.00 (Ref) 1.00 (Ref) 
 
65/433 1.00 (Ref) 1.00 (Ref) 
   A:G 163/960 0.91 (0.66, 1.27) 0.91 (0.66, 1.25) 
 
90/476 0.92 (0.59, 1.45) 0.91 (0.59, 1.39) 
 
69/462 1.00 (0.60, 1.67) 1.02 (0.64, 1.63) 
   A:A 71/320 0.90 (0.57, 1.42) 0.90 (0.58, 1.39) 
 
34/150 1.16 (0.61, 2.21) 1.13 (0.63, 2.03) 
 
34/166 0.78 (0.39, 1.55) 0.82 (0.45, 1.51) 
Log-Add 
 
0.94 (0.76, 1.17) 0.94 (0.75, 1.16) 
  
1.03 (0.76, 1.40) 1.02 (0.76, 1.38) 
  
0.91 (0.66, 1.25) 0.91 (0.67, 1.25) 
Dominant 
 
0.91 (0.67, 1.24) 0.90 (0.67, 1.22) 
  
0.98 (0.64, 1.49) 0.96 (0.64, 1.44) 
  
0.93 (0.58, 1.50) 0.95 (0.60, 1.48) 
Recessive 
 
0.94 (0.61, 1.44) 0.94 (0.63, 1.42) 
  
1.20 (0.66, 2.21) 1.18 (0.67, 2.06) 
  
0.78 (0.42, 1.47) 0.81 (0.46, 1.45) 
rs12894467 
           
   T:T 250/1360 1.00 (Ref) 1.00 (Ref) 
 
140/667 1.00 (Ref) 1.00 (Ref) 
 
98/669 1.00 (Ref) 1.00 (Ref) 
   C:T 122/714 1.01 (0.72, 1.42) 1.01 (0.73, 1.41) 
 
65/370 0.88 (0.55, 1.41) 0.91 (0.59, 1.42) 
 
52/329 1.49 (0.88, 2.52) 1.42 (0.87, 2.32) 
   C:C 25/126 0.96 (0.49, 1.89) 0.97 (0.53, 1.78) 
 
10/64 0.62 (0.21, 1.81) 0.73 (0.32, 1.68) 
 
13/61 1.55 (0.63, 3.85) 1.37 (0.63, 2.97) 
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  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
1.00 (0.77, 1.29) 1.00 (0.77, 1.29) 
  
0.84 (0.58, 1.22) 0.85 (0.59, 1.22) 
  
1.34 (0.92, 1.94) 1.33 (0.93, 1.92) 
Dominant 
 
1.00 (0.73, 1.38) 1.01 (0.74, 1.37) 
  
0.84 (0.54, 1.32) 0.86 (0.56, 1.33) 
  
1.50 (0.92, 2.46) 1.47 (0.92, 2.34) 
Recessive 
 
0.96 (0.49, 1.86) 0.97 (0.53, 1.76) 
  
0.65 (0.22, 1.87) 0.75 (0.33, 1.71) 
  
1.35 (0.55, 3.26) 1.25 (0.59, 2.68) 
rs12934922 
           
   A:A 286/1671 1.00 (Ref) 1.00 (Ref) 
 
153/847 1.00 (Ref) 1.00 (Ref) 
 
120/798 1.00 (Ref) 1.00 (Ref) 
   A:T 104/525 1.23 (0.87, 1.75) 1.22 (0.87, 1.71) 
 
57/257 1.69 (1.04, 2.76) 1.52 (0.96, 2.41) 
 
42/253 0.86 (0.50, 1.49) 0.88 (0.53, 1.46) 
   T:T 8/50 1.55 (0.59, 4.06) 1.35 (0.60, 3.05) 
 
5/19 4.84 (1.50, 15.58) 2.37 (0.89, 6.29) 
 
3/31 0.44 (0.07, 2.59) 0.72 (0.25, 2.07) 
Log-Add 
 
1.24 (0.92, 1.66) 1.23 (0.92, 1.65) 
  
1.87 (1.24, 2.80) 1.76 (1.18, 2.61) 
  
0.80 (0.50, 1.29) 0.81 (0.52, 1.27) 
Dominant 
 
1.26 (0.89, 1.76) 1.25 (0.90, 1.74) 
  
1.86 (1.16, 2.97) 1.71 (1.10, 2.68) 
  
0.82 (0.48, 1.39) 0.83 (0.50, 1.36) 
Recessive 
 
1.47 (0.56, 3.83) 1.31 (0.58, 2.93) 
  
4.12 (1.30, 13.08) 2.23 (0.85, 5.86) 
  
0.46 (0.08, 2.67) 0.73 (0.26, 2.10) 
rs13409 
           
   C:C 137/818 1.00 (Ref) 1.00 (Ref) 
 
65/413 1.00 (Ref) 1.00 (Ref) 
 
69/388 1.00 (Ref) 1.00 (Ref) 
   C:T 183/1013 0.93 (0.66, 1.31) 0.93 (0.67, 1.29) 
 
111/498 1.21 (0.75, 1.93) 1.14 (0.73, 1.77) 
 
64/498 0.65 (0.39, 1.10) 0.71 (0.44, 1.16) 
   T:T 85/421 1.06 (0.69, 1.62) 1.07 (0.71, 1.61) 
 
44/218 1.18 (0.64, 2.16) 1.09 (0.62, 1.89) 
 
34/196 0.78 (0.40, 1.51) 0.85 (0.47, 1.53) 
Log-Add 
 
1.01 (0.82, 1.25) 1.02 (0.83, 1.26) 
  
1.10 (0.82, 1.48) 1.07 (0.80, 1.43) 
  
0.84 (0.60, 1.17) 0.86 (0.62, 1.18) 
Dominant 
 
0.97 (0.70, 1.33) 0.97 (0.71, 1.32) 
  
1.20 (0.77, 1.87) 1.14 (0.74, 1.74) 
  
0.69 (0.43, 1.12) 0.73 (0.46, 1.16) 
Recessive 
 
1.10 (0.75, 1.62) 1.11 (0.76, 1.61) 
  
1.06 (0.62, 1.82) 1.02 (0.61, 1.69) 
  
0.98 (0.54, 1.79) 0.99 (0.57, 1.72) 
rs1804429 
           
   T:T 359/1969 1.00 (Ref) 1.00 (Ref) 
 
193/983 1.00 (Ref) 1.00 (Ref) 
 
151/951 1.00 (Ref) 1.00 (Ref) 
   G:T 49/275 1.02 (0.64, 1.64) 1.03 (0.66, 1.61) 
 
30/141 1.45 (0.79, 2.65) 1.36 (0.78, 2.38) 
 
16/129 0.88 (0.40, 1.92) 0.92 (0.47, 1.81) 
   G:G 1/12 0.93 (0.07, 12.57) 0.98 (0.29, 3.34) 
 
/6 0.00 (0.00, .0) 0.91 (0.24, 3.44) 
 
1/6 2.25 (0.12, 42.93) 1.13 (0.31, 4.04) 
Log-Add 
 
1.02 (0.65, 1.58) 1.03 (0.67, 1.56) 
  
1.36 (0.76, 2.44) 1.29 (0.75, 2.22) 
  
0.97 (0.48, 1.96) 0.99 (0.53, 1.84) 
Dominant 
 
1.02 (0.64, 1.62) 1.03 (0.66, 1.60) 
  
1.42 (0.78, 2.59) 1.33 (0.76, 2.33) 
  
0.92 (0.43, 1.97) 0.95 (0.49, 1.85) 
Recessive 
 
0.93 (0.07, 12.53) 0.98 (0.29, 3.34) 
  
0.00 (0.00, .0) 0.91 (0.24, 3.41) 
  
2.28 (0.12, 43.60) 1.13 (0.31, 4.05) 
rs197412 
           
   T:T 182/1011 1.00 (Ref) 1.00 (Ref) 
 
98/511 1.00 (Ref) 1.00 (Ref) 
 
75/477 1.00 (Ref) 1.00 (Ref) 
   T:C 171/972 0.94 (0.68, 1.31) 0.94 (0.68, 1.29) 
 
92/482 1.09 (0.69, 1.73) 1.06 (0.69, 1.63) 
 
71/476 0.83 (0.50, 1.38) 0.81 (0.51, 1.31) 
   C:C 51/247 1.41 (0.87, 2.30) 1.35 (0.85, 2.15) 
 
28/127 1.29 (0.66, 2.51) 1.23 (0.67, 2.24) 
 
21/115 1.81 (0.84, 3.90) 1.60 (0.81, 3.14) 
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  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
1.11 (0.88, 1.40) 1.10 (0.88, 1.38) 
  
1.12 (0.83, 1.53) 1.11 (0.82, 1.51) 
  
1.14 (0.79, 1.65) 1.13 (0.79, 1.62) 
Dominant 
 
1.03 (0.76, 1.40) 1.02 (0.76, 1.39) 
  
1.14 (0.74, 1.74) 1.11 (0.74, 1.68) 
  
0.96 (0.59, 1.55) 0.96 (0.61, 1.51) 
Recessive 
 
1.45 (0.92, 2.30) 1.39 (0.90, 2.16) 
  
1.23 (0.66, 2.31) 1.20 (0.67, 2.13) 
  
1.99 (0.96, 4.11) 1.73 (0.90, 3.33) 
rs1981492 
           
   G:G 203/1148 1.00 (Ref) 1.00 (Ref) 
 
112/588 1.00 (Ref) 1.00 (Ref) 
 
80/537 1.00 (Ref) 1.00 (Ref) 
   A:G 170/864 1.13 (0.81, 1.56) 1.12 (0.82, 1.53) 
 
93/432 1.26 (0.81, 1.96) 1.27 (0.83, 1.92) 
 
71/418 1.00 (0.60, 1.66) 0.99 (0.62, 1.59) 
   A:A 33/217 0.84 (0.49, 1.43) 0.86 (0.52, 1.41) 
 
15/94 0.58 (0.26, 1.32) 0.69 (0.35, 1.37) 
 
17/119 1.23 (0.59, 2.57) 1.21 (0.63, 2.33) 
Log-Add 
 
0.99 (0.79, 1.24) 0.99 (0.79, 1.23) 
  
0.94 (0.68, 1.30) 0.96 (0.70, 1.31) 
  
1.08 (0.77, 1.51) 1.09 (0.78, 1.51) 
Dominant 
 
1.06 (0.78, 1.44) 1.05 (0.78, 1.42) 
  
1.10 (0.73, 1.68) 1.11 (0.74, 1.66) 
  
1.05 (0.66, 1.69) 1.05 (0.67, 1.65) 
Recessive 
 
0.80 (0.48, 1.33) 0.82 (0.51, 1.33) 
  
0.53 (0.24, 1.16) 0.64 (0.32, 1.25) 
  
1.23 (0.61, 2.49) 1.22 (0.65, 2.29) 
rs2014300 
           
   G:G 312/1740 1.00 (Ref) 1.00 (Ref) 
 
170/874 1.00 (Ref) 1.00 (Ref) 
 
128/837 1.00 (Ref) 1.00 (Ref) 
   A:G 83/478 0.93 (0.64, 1.35) 0.93 (0.65, 1.34) 
 
45/241 0.95 (0.56, 1.59) 0.91 (0.56, 1.48) 
 
35/228 0.86 (0.48, 1.55) 0.88 (0.52, 1.51) 
   A:A 7/51 0.94 (0.33, 2.72) 0.96 (0.41, 2.21) 
 
3/21 1.04 (0.22, 4.82) 0.97 (0.34, 2.71) 
 
4/29 0.96 (0.20, 4.58) 0.99 (0.35, 2.77) 
Log-Add 
 
0.94 (0.68, 1.29) 0.94 (0.69, 1.29) 
  
0.97 (0.62, 1.52) 0.92 (0.60, 1.42) 
  
0.90 (0.55, 1.47) 0.91 (0.58, 1.44) 
Dominant 
 
0.93 (0.65, 1.33) 0.93 (0.66, 1.33) 
  
0.95 (0.58, 1.58) 0.91 (0.56, 1.46) 
  
0.87 (0.50, 1.52) 0.89 (0.53, 1.49) 
Recessive 
 
0.96 (0.33, 2.75) 0.97 (0.42, 2.23) 
  
1.05 (0.23, 4.85) 0.98 (0.35, 2.74) 
  
0.99 (0.21, 4.69) 1.00 (0.36, 2.80) 
rs2057482 
           
   C:C 269/1453 1.00 (Ref) 1.00 (Ref) 
 
139/703 1.00 (Ref) 1.00 (Ref) 
 
119/721 1.00 (Ref) 1.00 (Ref) 
   T:C 128/676 1.03 (0.74, 1.44) 1.03 (0.75, 1.42) 
 
74/362 0.83 (0.52, 1.32) 0.84 (0.54, 1.30) 
 
48/303 1.08 (0.65, 1.81) 1.08 (0.67, 1.74) 
   T:T 14/100 0.95 (0.45, 2.04) 0.96 (0.49, 1.86) 
 
7/55 0.83 (0.30, 2.36) 0.91 (0.40, 2.07) 
 
6/45 1.03 (0.33, 3.25) 1.00 (0.41, 2.43) 
Log-Add 
 
1.01 (0.77, 1.31) 1.01 (0.77, 1.31) 
  
0.87 (0.60, 1.26) 0.87 (0.61, 1.25) 
  
1.05 (0.70, 1.58) 1.05 (0.71, 1.54) 
Dominant 
 
1.02 (0.74, 1.41) 1.02 (0.75, 1.39) 
  
0.83 (0.53, 1.30) 0.84 (0.55, 1.28) 
  
1.07 (0.66, 1.75) 1.07 (0.67, 1.70) 
Recessive 
 
0.94 (0.44, 2.00) 0.95 (0.49, 1.84) 
  
0.89 (0.32, 2.48) 0.94 (0.41, 2.14) 
  
1.01 (0.32, 3.14) 0.99 (0.41, 2.38) 
rs222851 
           
   A:A 148/886 1.00 (Ref) 1.00 (Ref) 
 
79/438 1.00 (Ref) 1.00 (Ref) 
 
60/430 1.00 (Ref) 1.00 (Ref) 
   A:G 190/1001 1.29 (0.92, 1.82) 1.26 (0.91, 1.75) 
 
104/504 1.16 (0.72, 1.86) 1.12 (0.72, 1.74) 
 
78/476 1.37 (0.82, 2.30) 1.30 (0.81, 2.11) 
   G:G 63/327 1.39 (0.86, 2.24) 1.33 (0.84, 2.08) 
 
38/163 1.75 (0.93, 3.28) 1.58 (0.89, 2.82) 
 
25/162 0.98 (0.44, 2.18) 0.97 (0.49, 1.92) 
144 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
1.20 (0.96, 1.51) 1.20 (0.96, 1.49) 
  
1.29 (0.95, 1.76) 1.28 (0.94, 1.73) 
  
1.08 (0.76, 1.54) 1.07 (0.76, 1.51) 
Dominant 
 
1.31 (0.95, 1.81) 1.29 (0.94, 1.77) 
  
1.28 (0.82, 2.00) 1.26 (0.82, 1.93) 
  
1.28 (0.78, 2.10) 1.23 (0.77, 1.96) 
Recessive 
 
1.20 (0.78, 1.86) 1.18 (0.78, 1.79) 
  
1.61 (0.91, 2.84) 1.50 (0.88, 2.56) 
  
0.83 (0.39, 1.73) 0.86 (0.45, 1.65) 
rs2230793 
           
   A:A 204/1076 1.00 (Ref) 1.00 (Ref) 
 
108/539 1.00 (Ref) 1.00 (Ref) 
 
87/520 1.00 (Ref) 1.00 (Ref) 
   A:C 170/934 1.07 (0.77, 1.47) 1.07 (0.78, 1.46) 
 
96/477 1.27 (0.81, 1.97) 1.24 (0.81, 1.88) 
 
66/442 0.87 (0.53, 1.42) 0.88 (0.55, 1.40) 
   C:C 35/233 0.93 (0.54, 1.59) 0.94 (0.57, 1.55) 
 
15/109 0.68 (0.30, 1.52) 0.76 (0.38, 1.51) 
 
19/116 1.38 (0.65, 2.93) 1.29 (0.67, 2.50) 
Log-Add 
 
1.00 (0.79, 1.26) 1.00 (0.80, 1.26) 
  
0.98 (0.71, 1.36) 0.98 (0.72, 1.35) 
  
1.06 (0.75, 1.51) 1.07 (0.76, 1.49) 
Dominant 
 
1.04 (0.77, 1.41) 1.04 (0.77, 1.40) 
  
1.14 (0.75, 1.75) 1.12 (0.75, 1.68) 
  
0.96 (0.60, 1.52) 0.97 (0.62, 1.51) 
Recessive 
 
0.90 (0.54, 1.51) 0.91 (0.56, 1.47) 
  
0.60 (0.28, 1.32) 0.70 (0.36, 1.37) 
  
1.48 (0.72, 3.02) 1.35 (0.72, 2.57) 
rs2269700 
           
   T:T 220/1519 1.00 (Ref) 1.00 (Ref) 
 
116/761 1.00 (Ref) 1.00 (Ref) 
 
98/728 1.00 (Ref) 1.00 (Ref) 
   C:T 183/652 1.00 (0.72, 1.39) 1.00 (0.72, 1.38) 
 
104/322 0.94 (0.60, 1.48) 0.94 (0.61, 1.45) 
 
68/320 1.07 (0.64, 1.79) 1.06 (0.66, 1.73) 
   C:C 14/90 0.58 (0.24, 1.38) 0.69 (0.34, 1.41) 
 
6/49 0.17 (0.04, 0.79) 0.41 (0.16, 1.05) 
 
6/39 1.10 (0.33, 3.67) 1.06 (0.43, 2.64) 
Log-Add 
 
0.90 (0.69, 1.19) 0.91 (0.69, 1.18) 
  
0.74 (0.50, 1.09) 0.73 (0.50, 1.07) 
  
1.06 (0.70, 1.61) 1.06 (0.71, 1.58) 
Dominant 
 
0.94 (0.69, 1.30) 0.94 (0.69, 1.29) 
  
0.82 (0.52, 1.27) 0.81 (0.53, 1.23) 
  
1.07 (0.65, 1.75) 1.07 (0.67, 1.71) 
Recessive 
 
0.58 (0.25, 1.37) 0.69 (0.34, 1.40) 
  
0.18 (0.04, 0.80) 0.42 (0.16, 1.06) 
  
1.08 (0.33, 3.57) 1.05 (0.43, 2.60) 
rs2274223 
           
   A:A 263/1402 1.00 (Ref) 1.00 (Ref) 
 
145/704 1.00 (Ref) 1.00 (Ref) 
 
108/671 1.00 (Ref) 1.00 (Ref) 
   A:G 116/705 0.89 (0.63, 1.26) 0.90 (0.64, 1.25) 
 
61/348 0.90 (0.55, 1.45) 0.88 (0.56, 1.39) 
 
48/349 0.83 (0.48, 1.41) 0.85 (0.52, 1.39) 
   G:G 21/97 1.19 (0.60, 2.34) 1.17 (0.63, 2.16) 
 
13/48 1.21 (0.49, 2.98) 1.14 (0.53, 2.46) 
 
7/44 1.10 (0.32, 3.84) 1.08 (0.43, 2.74) 
Log-Add 
 
0.98 (0.76, 1.28) 0.99 (0.76, 1.28) 
  
1.00 (0.70, 1.42) 0.98 (0.69, 1.39) 
  
0.91 (0.59, 1.41) 0.92 (0.61, 1.40) 
Dominant 
 
0.93 (0.67, 1.29) 0.94 (0.68, 1.29) 
  
0.94 (0.60, 1.48) 0.93 (0.60, 1.42) 
  
0.85 (0.51, 1.42) 0.88 (0.54, 1.41) 
Recessive 
 
1.23 (0.63, 2.41) 1.20 (0.65, 2.20) 
  
1.25 (0.51, 3.05) 1.17 (0.55, 2.51) 
  
1.17 (0.34, 4.03) 1.11 (0.44, 2.82) 
rs2292305 
           
   T:T 181/1014 1.00 (Ref) 1.00 (Ref) 
 
101/499 1.00 (Ref) 1.00 (Ref) 
 
71/498 1.00 (Ref) 1.00 (Ref) 
   C:T 180/935 1.15 (0.83, 1.59) 1.14 (0.83, 1.57) 
 
95/472 1.47 (0.92, 2.35) 1.43 (0.92, 2.21) 
 
77/446 1.01 (0.62, 1.66) 1.03 (0.65, 1.64) 
   C:C 35/268 0.83 (0.48, 1.44) 0.85 (0.51, 1.41) 
 
17/143 1.03 (0.48, 2.22) 1.03 (0.53, 2.02) 
 
17/120 0.65 (0.28, 1.49) 0.72 (0.36, 1.46) 
145 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
0.99 (0.78, 1.25) 0.99 (0.79, 1.25) 
  
1.15 (0.83, 1.59) 1.15 (0.84, 1.59) 
  
0.88 (0.62, 1.25) 0.88 (0.63, 1.24) 
Dominant 
 
1.08 (0.79, 1.48) 1.08 (0.79, 1.46) 
  
1.38 (0.88, 2.16) 1.36 (0.88, 2.08) 
  
0.93 (0.58, 1.49) 0.94 (0.60, 1.47) 
Recessive 
 
0.77 (0.46, 1.31) 0.80 (0.49, 1.30) 
  
0.85 (0.41, 1.73) 0.89 (0.47, 1.68) 
  
0.65 (0.29, 1.42) 0.71 (0.36, 1.41) 
rs2352028 
           
   C:C 277/1430 1.00 (Ref) 1.00 (Ref) 
 
159/712 1.00 (Ref) 1.00 (Ref) 
 
110/692 1.00 (Ref) 1.00 (Ref) 
   C:T 127/717 1.00 (0.72, 1.39) 1.02 (0.74, 1.40) 
 
58/361 0.78 (0.49, 1.25) 0.81 (0.52, 1.26) 
 
59/341 1.24 (0.76, 2.02) 1.22 (0.77, 1.93) 
   T:T 15/124 0.71 (0.32, 1.57) 0.77 (0.39, 1.51) 
 
11/66 0.80 (0.30, 2.16) 0.87 (0.39, 1.92) 
 
4/58 0.45 (0.10, 1.95) 0.64 (0.25, 1.67) 
Log-Add 
 
0.93 (0.72, 1.21) 0.94 (0.73, 1.22) 
  
0.83 (0.58, 1.20) 0.85 (0.59, 1.20) 
  
1.00 (0.67, 1.50) 0.98 (0.66, 1.45) 
Dominant 
 
0.96 (0.70, 1.31) 0.97 (0.71, 1.32) 
  
0.78 (0.50, 1.22) 0.81 (0.53, 1.23) 
  
1.13 (0.70, 1.82) 1.10 (0.70, 1.72) 
Recessive 
 
0.71 (0.33, 1.56) 0.77 (0.39, 1.50) 
  
0.86 (0.32, 2.31) 0.90 (0.41, 2.00) 
  
0.42 (0.10, 1.79) 0.62 (0.24, 1.60) 
rs2910164 
           
   C:C 131/826 1.00 (Ref) 1.00 (Ref) 
 
69/420 1.00 (Ref) 1.00 (Ref) 
 
52/393 1.00 (Ref) 1.00 (Ref) 
   G:C 202/1040 1.04 (0.74, 1.46) 1.05 (0.76, 1.45) 
 
111/497 1.00 (0.63, 1.60) 1.05 (0.68, 1.63) 
 
84/523 1.24 (0.74, 2.11) 1.21 (0.75, 1.96) 
   G:G 63/394 0.69 (0.43, 1.11) 0.71 (0.45, 1.11) 
 
32/218 0.58 (0.30, 1.14) 0.66 (0.36, 1.20) 
 
29/168 0.93 (0.46, 1.91) 0.92 (0.49, 1.73) 
Log-Add 
 
0.87 (0.70, 1.09) 0.87 (0.70, 1.08) 
  
0.81 (0.59, 1.10) 0.83 (0.62, 1.13) 
  
1.01 (0.72, 1.42) 1.00 (0.72, 1.39) 
Dominant 
 
0.94 (0.68, 1.29) 0.94 (0.69, 1.29) 
  
0.88 (0.56, 1.37) 0.91 (0.60, 1.40) 
  
1.16 (0.70, 1.90) 1.13 (0.71, 1.80) 
Recessive 
 
0.67 (0.43, 1.04) 0.69 (0.46, 1.05) 
  
0.58 (0.31, 1.07) 0.64 (0.37, 1.12) 
  
0.82 (0.43, 1.57) 0.84 (0.47, 1.51) 
rs2953 
           
   T:T 222/1267 1.00 (Ref) 1.00 (Ref) 
 
118/636 1.00 (Ref) 1.00 (Ref) 
 
92/609 1.00 (Ref) 1.00 (Ref) 
   G:T 157/836 0.88 (0.64, 1.22) 0.88 (0.64, 1.20) 
 
87/415 1.01 (0.64, 1.58) 1.00 (0.66, 1.54) 
 
63/408 0.80 (0.48, 1.34) 0.80 (0.50, 1.29) 
   G:G 27/164 1.02 (0.55, 1.88) 1.02 (0.58, 1.79) 
 
16/86 1.14 (0.49, 2.63) 1.07 (0.52, 2.20) 
 
11/73 0.97 (0.38, 2.48) 1.01 (0.46, 2.21) 
Log-Add 
 
0.95 (0.74, 1.21) 0.94 (0.74, 1.20) 
  
1.04 (0.74, 1.46) 1.03 (0.74, 1.43) 
  
0.90 (0.61, 1.32) 0.90 (0.62, 1.30) 
Dominant 
 
0.90 (0.66, 1.23) 0.90 (0.66, 1.21) 
  
1.03 (0.67, 1.57) 1.02 (0.68, 1.53) 
  
0.83 (0.51, 1.34) 0.83 (0.53, 1.31) 
Recessive 
 
1.07 (0.58, 1.95) 1.06 (0.61, 1.85) 
  
1.13 (0.50, 2.57) 1.07 (0.52, 2.17) 
  
1.05 (0.42, 2.65) 1.07 (0.50, 2.33) 
rs3130932 
           
   T:T 200/1043 1.00 (Ref) 1.00 (Ref) 
 
109/531 1.00 (Ref) 1.00 (Ref) 
 
80/500 1.00 (Ref) 1.00 (Ref) 
   G:T 161/957 0.84 (0.61, 1.16) 0.85 (0.62, 1.16) 
 
97/471 0.83 (0.53, 1.29) 0.87 (0.57, 1.32) 
 
60/462 0.94 (0.56, 1.57) 0.92 (0.57, 1.48) 
   G:G 48/256 0.92 (0.57, 1.50) 0.94 (0.59, 1.48) 
 
19/125 0.48 (0.23, 1.02) 0.59 (0.31, 1.12) 
 
27/126 2.05 (1.04, 4.05) 1.77 (0.96, 3.27) 
146 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
0.92 (0.74, 1.15) 0.92 (0.74, 1.15) 
  
0.74 (0.54, 1.02) 0.76 (0.56, 1.04) 
  
1.30 (0.93, 1.82) 1.27 (0.92, 1.76) 
Dominant 
 
0.86 (0.64, 1.16) 0.86 (0.64, 1.16) 
  
0.74 (0.49, 1.12) 0.77 (0.52, 1.15) 
  
1.16 (0.72, 1.85) 1.14 (0.73, 1.77) 
Recessive 
 
1.00 (0.63, 1.59) 1.00 (0.64, 1.56) 
  
0.53 (0.26, 1.08) 0.62 (0.33, 1.16) 
  
2.11 (1.12, 4.00) 1.82 (1.01, 3.29) 
rs3204145 
           
   T:T 181/1054 1.00 (Ref) 1.00 (Ref) 
 
93/507 1.00 (Ref) 1.00 (Ref) 
 
76/526 1.00 (Ref) 1.00 (Ref) 
   A:T 182/959 1.28 (0.93, 1.77) 1.26 (0.92, 1.72) 
 
105/505 1.48 (0.94, 2.31) 1.45 (0.95, 2.22) 
 
72/437 1.06 (0.65, 1.74) 1.04 (0.66, 1.66) 
   A:A 38/250 0.92 (0.55, 1.54) 0.91 (0.56, 1.48) 
 
20/133 0.89 (0.44, 1.80) 0.87 (0.46, 1.63) 
 
18/114 1.09 (0.49, 2.39) 1.04 (0.52, 2.07) 
Log-Add 
 
1.05 (0.84, 1.32) 1.04 (0.84, 1.30) 
  
1.08 (0.79, 1.47) 1.07 (0.79, 1.44) 
  
1.05 (0.74, 1.49) 1.03 (0.73, 1.46) 
Dominant 
 
1.20 (0.88, 1.63) 1.18 (0.87, 1.59) 
  
1.33 (0.87, 2.05) 1.31 (0.87, 1.97) 
  
1.07 (0.67, 1.71) 1.05 (0.67, 1.64) 
Recessive 
 
0.81 (0.50, 1.32) 0.82 (0.52, 1.30) 
  
0.72 (0.37, 1.40) 0.74 (0.40, 1.35) 
  
1.05 (0.50, 2.23) 1.02 (0.53, 1.98) 
rs3729629 
           
   G:G 210/1019 1.00 (Ref) 1.00 (Ref) 
 
120/478 1.00 (Ref) 1.00 (Ref) 
 
82/522 1.00 (Ref) 1.00 (Ref) 
   C:G 172/987 0.93 (0.68, 1.28) 0.95 (0.70, 1.28) 
 
92/517 0.62 (0.40, 0.97) 0.67 (0.44, 1.02) 
 
73/455 1.29 (0.80, 2.10) 1.28 (0.81, 2.01) 
   C:C 39/248 0.69 (0.39, 1.21) 0.74 (0.44, 1.23) 
 
15/132 0.43 (0.19, 1.01) 0.55 (0.28, 1.10) 
 
20/111 1.06 (0.47, 2.40) 1.03 (0.51, 2.08) 
Log-Add 
 
0.87 (0.69, 1.10) 0.88 (0.70, 1.11) 
  
0.64 (0.46, 0.90) 0.66 (0.48, 0.92) 
  
1.12 (0.79, 1.58) 1.12 (0.80, 1.56) 
Dominant 
 
0.89 (0.66, 1.20) 0.90 (0.67, 1.20) 
  
0.59 (0.39, 0.90) 0.62 (0.41, 0.93) 
  
1.25 (0.79, 1.98) 1.24 (0.80, 1.91) 
Recessive 
 
0.71 (0.42, 1.23) 0.75 (0.46, 1.24) 
  
0.54 (0.24, 1.23) 0.64 (0.32, 1.26) 
  
0.94 (0.43, 2.04) 0.94 (0.48, 1.86) 
rs3734637 
           
   A:A 271/1339 1.00 (Ref) 1.00 (Ref) 
 
157/669 1.00 (Ref) 1.00 (Ref) 
 
103/652 1.00 (Ref) 1.00 (Ref) 
   A:C 118/756 0.71 (0.50, 1.00) 0.73 (0.53, 1.02) 
 
57/381 0.65 (0.40, 1.05) 0.69 (0.44, 1.08) 
 
55/356 0.94 (0.56, 1.57) 0.98 (0.61, 1.59) 
   C:C 21/156 0.51 (0.25, 1.01) 0.58 (0.32, 1.05) 
 
11/76 0.57 (0.22, 1.45) 0.67 (0.32, 1.43) 
 
9/78 0.47 (0.17, 1.29) 0.60 (0.27, 1.31) 
Log-Add 
 
0.71 (0.55, 0.92) 0.72 (0.56, 0.93) 
  
0.70 (0.49, 1.01) 0.71 (0.50, 1.01) 
  
0.80 (0.55, 1.16) 0.81 (0.56, 1.16) 
Dominant 
 
0.67 (0.48, 0.92) 0.69 (0.50, 0.94) 
  
0.64 (0.41, 1.00) 0.66 (0.43, 1.01) 
  
0.83 (0.51, 1.34) 0.85 (0.54, 1.34) 
Recessive 
 
0.56 (0.29, 1.11) 0.62 (0.34, 1.13) 
  
0.65 (0.25, 1.64) 0.73 (0.34, 1.55) 
  
0.48 (0.18, 1.30) 0.60 (0.27, 1.31) 
rs3740535 
           
   G:G 226/1233 1.00 (Ref) 1.00 (Ref) 
 
118/636 1.00 (Ref) 1.00 (Ref) 
 
96/574 1.00 (Ref) 1.00 (Ref) 
   A:G 153/844 0.90 (0.65, 1.24) 0.90 (0.66, 1.24) 
 
85/418 1.14 (0.73, 1.78) 1.11 (0.73, 1.69) 
 
62/411 0.69 (0.42, 1.14) 0.74 (0.46, 1.18) 
   A:A 34/175 0.92 (0.52, 1.61) 0.92 (0.55, 1.55) 
 
20/77 1.74 (0.83, 3.66) 1.51 (0.77, 2.95) 
 
14/97 0.45 (0.18, 1.12) 0.59 (0.28, 1.22) 
147 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
0.93 (0.74, 1.18) 0.93 (0.74, 1.18) 
  
1.25 (0.91, 1.72) 1.23 (0.89, 1.68) 
  
0.68 (0.47, 0.99) 0.70 (0.49, 1.01) 
Dominant 
 
0.90 (0.66, 1.22) 0.90 (0.67, 1.22) 
  
1.24 (0.81, 1.88) 1.21 (0.81, 1.80) 
  
0.64 (0.40, 1.03) 0.67 (0.43, 1.05) 
Recessive 
 
0.96 (0.55, 1.65) 0.96 (0.58, 1.59) 
  
1.65 (0.81, 3.38) 1.46 (0.76, 2.81) 
  
0.53 (0.22, 1.28) 0.65 (0.31, 1.33) 
rs3801790 
           
   A:A 153/856 1.00 (Ref) 1.00 (Ref) 
 
83/445 1.00 (Ref) 1.00 (Ref) 
 
66/393 1.00 (Ref) 1.00 (Ref) 
   A:G 192/994 1.15 (0.82, 1.61) 1.16 (0.84, 1.60) 
 
105/487 1.40 (0.88, 2.22) 1.38 (0.89, 2.14) 
 
76/495 0.81 (0.48, 1.36) 0.82 (0.51, 1.33) 
   G:G 61/368 0.80 (0.49, 1.28) 0.81 (0.52, 1.27) 
 
32/186 0.74 (0.38, 1.45) 0.80 (0.44, 1.44) 
 
26/170 0.81 (0.39, 1.66) 0.85 (0.45, 1.59) 
Log-Add 
 
0.94 (0.76, 1.18) 0.95 (0.76, 1.18) 
  
0.96 (0.71, 1.29) 0.97 (0.73, 1.31) 
  
0.88 (0.62, 1.24) 0.88 (0.63, 1.23) 
Dominant 
 
1.05 (0.77, 1.45) 1.05 (0.77, 1.44) 
  
1.20 (0.77, 1.86) 1.20 (0.78, 1.82) 
  
0.81 (0.50, 1.32) 0.81 (0.51, 1.29) 
Recessive 
 
0.73 (0.47, 1.14) 0.75 (0.50, 1.14) 
  
0.62 (0.33, 1.14) 0.68 (0.39, 1.19) 
  
0.91 (0.47, 1.76) 0.93 (0.51, 1.68) 
rs3929 
           
   G:G 263/1531 1.00 (Ref) 1.00 (Ref) 
 
135/749 1.00 (Ref) 1.00 (Ref) 
 
115/749 1.00 (Ref) 1.00 (Ref) 
   C:G 128/673 1.00 (0.72, 1.40) 1.00 (0.73, 1.38) 
 
77/362 0.87 (0.55, 1.37) 0.89 (0.58, 1.37) 
 
47/304 1.16 (0.70, 1.93) 1.13 (0.70, 1.82) 
   C:C 16/92 1.06 (0.47, 2.38) 1.05 (0.52, 2.11) 
 
10/37 1.14 (0.36, 3.62) 1.10 (0.45, 2.69) 
 
5/54 1.00 (0.29, 3.41) 1.00 (0.40, 2.49) 
Log-Add 
 
1.01 (0.77, 1.33) 1.01 (0.78, 1.33) 
  
0.93 (0.64, 1.37) 0.95 (0.66, 1.38) 
  
1.09 (0.73, 1.64) 1.08 (0.73, 1.60) 
Dominant 
 
1.01 (0.74, 1.39) 1.01 (0.74, 1.38) 
  
0.89 (0.57, 1.38) 0.92 (0.60, 1.39) 
  
1.14 (0.70, 1.86) 1.11 (0.70, 1.77) 
Recessive 
 
1.06 (0.48, 2.36) 1.05 (0.52, 2.10) 
  
1.19 (0.38, 3.75) 1.12 (0.46, 2.74) 
  
0.96 (0.28, 3.22) 0.98 (0.39, 2.43) 
rs4072391 
           
   C:C 332/1870 1.00 (Ref) 1.00 (Ref) 
 
179/935 1.00 (Ref) 1.00 (Ref) 
 
136/902 1.00 (Ref) 1.00 (Ref) 
   C:T 66/364 1.06 (0.70, 1.60) 1.04 (0.70, 1.55) 
 
34/186 1.00 (0.56, 1.77) 0.97 (0.57, 1.65) 
 
30/170 1.15 (0.61, 2.15) 1.11 (0.62, 1.98) 
   T:T 7/32 0.57 (0.17, 1.88) 0.74 (0.30, 1.79) 
 
3/13 0.34 (0.05, 2.28) 0.72 (0.24, 2.13) 
 
4/19 0.75 (0.15, 3.66) 0.91 (0.32, 2.57) 
Log-Add 
 
0.95 (0.67, 1.34) 0.95 (0.67, 1.32) 
  
0.86 (0.52, 1.42) 0.87 (0.54, 1.39) 
  
1.03 (0.62, 1.71) 1.03 (0.64, 1.66) 
Dominant 
 
1.00 (0.67, 1.48) 0.99 (0.67, 1.45) 
  
0.92 (0.52, 1.60) 0.90 (0.54, 1.52) 
  
1.09 (0.60, 1.98) 1.07 (0.61, 1.86) 
Recessive 
 
0.57 (0.17, 1.86) 0.73 (0.30, 1.78) 
  
0.34 (0.05, 2.27) 0.72 (0.24, 2.13) 
  
0.73 (0.15, 3.58) 0.90 (0.32, 2.55) 
rs42031 
           
   A:A 365/2061 1.00 (Ref) 1.00 (Ref) 
 
196/1027 1.00 (Ref) 1.00 (Ref) 
 
152/1000 1.00 (Ref) 1.00 (Ref) 
   A:T 51/200 1.78 (1.11, 2.86) 1.70 (1.08, 2.66) 
 
28/102 2.01 (1.05, 3.85) 1.72 (0.94, 3.14) 
 
21/93 1.78 (0.87, 3.64) 1.58 (0.83, 3.01) 
   T:T 2/13 2.05 (0.37, 11.37) 1.30 (0.42, 4.06) 
 
2/7 3.70 (0.59, 23.02) 1.57 (0.47, 5.21) 
 
/6 0.00 (0.00, .0) 0.91 (0.24, 3.40) 
148 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
1.69 (1.12, 2.55) 1.64 (1.10, 2.45) 
  
1.98 (1.15, 3.40) 1.83 (1.09, 3.09) 
  
1.57 (0.81, 3.04) 1.44 (0.78, 2.65) 
Dominant 
 
1.80 (1.14, 2.85) 1.72 (1.11, 2.67) 
  
2.12 (1.14, 3.95) 1.86 (1.04, 3.32) 
  
1.71 (0.84, 3.47) 1.53 (0.80, 2.90) 
Recessive 
 
1.92 (0.35, 10.63) 1.28 (0.41, 3.96) 
  
3.43 (0.56, 21.11) 1.55 (0.47, 5.12) 
  
0.00 (0.00, .0) 0.90 (0.24, 3.38) 
rs4678680 
           
   T:T 360/2046 1.00 (Ref) 1.00 (Ref) 
 
194/1031 1.00 (Ref) 1.00 (Ref) 
 
150/976 1.00 (Ref) 1.00 (Ref) 
   G:T 46/249 1.00 (0.60, 1.64) 0.99 (0.62, 1.59) 
 
25/118 1.35 (0.70, 2.62) 1.21 (0.66, 2.23) 
 
19/129 0.68 (0.31, 1.50) 0.74 (0.38, 1.47) 
   G:G 4/11 0.84 (0.15, 4.63) 0.93 (0.32, 2.72) 
 
4/4 1.61 (0.20, 12.80) 1.19 (0.37, 3.86) 
 
/7 0.00 (0.00, .0) 0.79 (0.22, 2.85) 
Log-Add 
 
0.98 (0.63, 1.51) 0.97 (0.64, 1.48) 
  
1.33 (0.75, 2.34) 1.25 (0.73, 2.13) 
  
0.63 (0.30, 1.34) 0.69 (0.36, 1.32) 
Dominant 
 
0.98 (0.61, 1.60) 0.98 (0.62, 1.55) 
  
1.37 (0.73, 2.59) 1.25 (0.70, 2.25) 
  
0.65 (0.30, 1.41) 0.71 (0.36, 1.38) 
Recessive 
 
0.84 (0.15, 4.63) 0.93 (0.32, 2.73) 
  
1.57 (0.20, 12.40) 1.19 (0.37, 3.85) 
  
0.00 (0.00, .0) 0.80 (0.22, 2.87) 
rs4730775 
           
   C:C 258/1282 1.00 (Ref) 1.00 (Ref) 
 
145/641 1.00 (Ref) 1.00 (Ref) 
 
105/618 1.00 (Ref) 1.00 (Ref) 
   C:T 124/794 0.77 (0.55, 1.08) 0.79 (0.57, 1.09) 
 
63/396 0.71 (0.45, 1.14) 0.75 (0.48, 1.17) 
 
53/383 0.73 (0.43, 1.22) 0.77 (0.47, 1.25) 
   T:T 23/152 0.67 (0.36, 1.25) 0.72 (0.41, 1.27) 
 
12/80 0.68 (0.28, 1.62) 0.80 (0.39, 1.67) 
 
10/70 0.73 (0.28, 1.88) 0.81 (0.38, 1.76) 
Log-Add 
 
0.79 (0.62, 1.02) 0.80 (0.63, 1.03) 
  
0.77 (0.54, 1.09) 0.80 (0.57, 1.12) 
  
0.79 (0.54, 1.17) 0.81 (0.56, 1.17) 
Dominant 
 
0.75 (0.55, 1.03) 0.76 (0.56, 1.04) 
  
0.71 (0.46, 1.09) 0.75 (0.49, 1.13) 
  
0.73 (0.45, 1.18) 0.76 (0.48, 1.20) 
Recessive 
 
0.73 (0.39, 1.36) 0.77 (0.44, 1.35) 
  
0.75 (0.32, 1.78) 0.86 (0.42, 1.77) 
  
0.82 (0.32, 2.07) 0.87 (0.40, 1.86) 
rs4975616 
           
   A:A 285/1606 1.00 (Ref) 1.00 (Ref) 
 
156/789 1.00 (Ref) 1.00 (Ref) 
 
118/792 1.00 (Ref) 1.00 (Ref) 
   A:G 104/570 1.12 (0.79, 1.59) 1.11 (0.79, 1.56) 
 
53/292 1.22 (0.75, 1.98) 1.14 (0.72, 1.80) 
 
44/263 1.13 (0.65, 1.95) 1.10 (0.66, 1.83) 
   G:G 13/67 1.16 (0.48, 2.83) 1.10 (0.52, 2.34) 
 
10/37 1.36 (0.45, 4.10) 1.17 (0.49, 2.82) 
 
3/30 1.17 (0.26, 5.19) 1.07 (0.38, 2.98) 
Log-Add 
 
1.10 (0.83, 1.47) 1.10 (0.83, 1.46) 
  
1.19 (0.81, 1.76) 1.14 (0.78, 1.66) 
  
1.11 (0.70, 1.76) 1.10 (0.71, 1.70) 
Dominant 
 
1.12 (0.80, 1.57) 1.12 (0.80, 1.55) 
  
1.23 (0.77, 1.96) 1.16 (0.74, 1.81) 
  
1.13 (0.67, 1.92) 1.11 (0.68, 1.82) 
Recessive 
 
1.13 (0.46, 2.73) 1.08 (0.51, 2.29) 
  
1.29 (0.43, 3.84) 1.14 (0.48, 2.74) 
  
1.14 (0.26, 5.01) 1.06 (0.38, 2.95) 
rs520692 
           
   A:A 314/1724 1.00 (Ref) 1.00 (Ref) 
 
169/877 1.00 (Ref) 1.00 (Ref) 
 
130/822 1.00 (Ref) 1.00 (Ref) 
   A:G 97/504 1.13 (0.78, 1.62) 1.12 (0.79, 1.59) 
 
51/244 1.31 (0.79, 2.18) 1.29 (0.80, 2.09) 
 
42/247 1.07 (0.62, 1.83) 1.07 (0.65, 1.78) 
   G:G 3/42 0.59 (0.12, 2.82) 0.79 (0.29, 2.13) 
 
1/14 0.65 (0.07, 6.12) 0.93 (0.29, 2.93) 
 
2/25 0.60 (0.06, 6.32) 0.85 (0.27, 2.70) 
149 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
1.04 (0.75, 1.45) 1.04 (0.76, 1.43) 
  
1.19 (0.75, 1.88) 1.20 (0.78, 1.86) 
  
1.00 (0.61, 1.64) 1.01 (0.63, 1.60) 
Dominant 
 
1.09 (0.76, 1.56) 1.08 (0.77, 1.53) 
  
1.27 (0.77, 2.09) 1.26 (0.78, 2.02) 
  
1.04 (0.61, 1.77) 1.04 (0.63, 1.71) 
Recessive 
 
0.58 (0.12, 2.74) 0.78 (0.29, 2.10) 
  
0.62 (0.07, 5.78) 0.91 (0.29, 2.87) 
  
0.59 (0.06, 6.21) 0.85 (0.27, 2.68) 
rs7372209 
           
   C:C 213/1131 1.00 (Ref) 1.00 (Ref) 
 
123/565 1.00 (Ref) 1.00 (Ref) 
 
81/545 1.00 (Ref) 1.00 (Ref) 
   C:T 145/908 0.85 (0.61, 1.18) 0.86 (0.63, 1.18) 
 
76/457 0.69 (0.44, 1.08) 0.73 (0.47, 1.11) 
 
63/435 0.99 (0.60, 1.65) 0.97 (0.60, 1.56) 
   T:T 41/215 0.82 (0.48, 1.40) 0.84 (0.51, 1.38) 
 
18/117 0.58 (0.26, 1.26) 0.66 (0.34, 1.30) 
 
21/93 1.11 (0.51, 2.40) 1.09 (0.55, 2.14) 
Log-Add 
 
0.88 (0.70, 1.12) 0.89 (0.70, 1.11) 
  
0.73 (0.52, 1.01) 0.74 (0.54, 1.02) 
  
1.03 (0.73, 1.46) 1.02 (0.73, 1.44) 
Dominant 
 
0.85 (0.62, 1.15) 0.85 (0.63, 1.15) 
  
0.66 (0.43, 1.02) 0.69 (0.46, 1.04) 
  
1.02 (0.63, 1.63) 1.00 (0.64, 1.57) 
Recessive 
 
0.87 (0.52, 1.47) 0.89 (0.55, 1.44) 
  
0.67 (0.31, 1.44) 0.74 (0.38, 1.43) 
  
1.11 (0.53, 2.34) 1.10 (0.57, 2.12) 
rs738722 
           
   C:C 226/1220 1.00 (Ref) 1.00 (Ref) 
 
128/613 1.00 (Ref) 1.00 (Ref) 
 
91/586 1.00 (Ref) 1.00 (Ref) 
   C:T 146/806 0.90 (0.65, 1.26) 0.92 (0.67, 1.26) 
 
73/407 0.62 (0.38, 0.99) 0.64 (0.41, 0.99) 
 
63/383 1.34 (0.81, 2.23) 1.31 (0.81, 2.10) 
   T:T 28/179 0.98 (0.52, 1.85) 0.99 (0.55, 1.75) 
 
15/87 0.83 (0.34, 2.02) 0.88 (0.42, 1.86) 
 
13/90 1.47 (0.59, 3.69) 1.29 (0.59, 2.82) 
Log-Add 
 
0.95 (0.74, 1.22) 0.95 (0.74, 1.22) 
  
0.75 (0.52, 1.08) 0.75 (0.53, 1.07) 
  
1.27 (0.87, 1.84) 1.26 (0.88, 1.81) 
Dominant 
 
0.92 (0.67, 1.25) 0.93 (0.68, 1.26) 
  
0.65 (0.41, 1.01) 0.66 (0.43, 1.01) 
  
1.36 (0.84, 2.21) 1.34 (0.85, 2.12) 
Recessive 
 
1.02 (0.55, 1.90) 1.01 (0.57, 1.79) 
  
1.00 (0.42, 2.37) 1.00 (0.48, 2.09) 
  
1.31 (0.54, 3.20) 1.20 (0.56, 2.57) 
rs748404 
           
   T:T 362/2027 1.00 (Ref) 1.00 (Ref) 
 
194/1023 1.00 (Ref) 1.00 (Ref) 
 
151/968 1.00 (Ref) 1.00 (Ref) 
   C:T 45/215 1.16 (0.69, 1.94) 1.15 (0.71, 1.86) 
 
24/99 1.73 (0.87, 3.41) 1.51 (0.80, 2.83) 
 
19/110 0.79 (0.35, 1.76) 0.85 (0.43, 1.70) 
   C:C /12 0.00 (0.00, .0) 0.67 (0.19, 2.30) 
 
/5 0.00 (0.00, .0) 0.94 (0.24, 3.63) 
 
/7 0.00 (0.00, .0) 0.76 (0.21, 2.72) 
Log-Add 
 
1.01 (0.62, 1.64) 1.01 (0.63, 1.60) 
  
1.59 (0.83, 3.04) 1.43 (0.78, 2.63) 
  
0.69 (0.32, 1.46) 0.76 (0.39, 1.46) 
Dominant 
 
1.08 (0.65, 1.81) 1.07 (0.66, 1.74) 
  
1.68 (0.85, 3.31) 1.48 (0.79, 2.77) 
  
0.72 (0.32, 1.60) 0.79 (0.40, 1.57) 
Recessive 
 
0.00 (0.00, .0) 0.67 (0.19, 2.29) 
  
0.00 (0.00, .0) 0.94 (0.24, 3.62) 
  
0.00 (0.00, .0) 0.76 (0.21, 2.72) 
rs7626795 
           
   A:A 267/1481 1.00 (Ref) 1.00 (Ref) 
 
147/747 1.00 (Ref) 1.00 (Ref) 
 
113/710 1.00 (Ref) 1.00 (Ref) 
   A:G 125/666 1.07 (0.76, 1.49) 1.07 (0.78, 1.48) 
 
65/325 1.30 (0.82, 2.07) 1.21 (0.78, 1.89) 
 
50/326 0.84 (0.50, 1.40) 0.86 (0.53, 1.39) 
   G:G 19/101 1.19 (0.54, 2.63) 1.17 (0.58, 2.35) 
 
11/52 1.05 (0.33, 3.41) 1.10 (0.44, 2.71) 
 
7/47 1.30 (0.38, 4.42) 1.14 (0.45, 2.92) 
150 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
1.08 (0.82, 1.41) 1.09 (0.83, 1.43) 
  
1.18 (0.81, 1.73) 1.17 (0.81, 1.69) 
  
0.94 (0.61, 1.44) 0.95 (0.63, 1.43) 
Dominant 
 
1.08 (0.78, 1.49) 1.09 (0.80, 1.49) 
  
1.27 (0.81, 1.99) 1.21 (0.79, 1.86) 
  
0.88 (0.54, 1.44) 0.90 (0.56, 1.43) 
Recessive 
 
1.16 (0.53, 2.56) 1.15 (0.58, 2.30) 
  
0.97 (0.30, 3.10) 1.06 (0.43, 2.60) 
  
1.37 (0.41, 4.62) 1.17 (0.46, 2.99) 
rs8708 
           
   A:A 276/1515 1.00 (Ref) 1.00 (Ref) 
 
150/741 1.00 (Ref) 1.00 (Ref) 
 
115/743 1.00 (Ref) 1.00 (Ref) 
   A:G 101/625 1.06 (0.75, 1.51) 1.05 (0.75, 1.47) 
 
56/333 1.09 (0.68, 1.76) 1.04 (0.66, 1.64) 
 
40/284 1.01 (0.59, 1.73) 1.02 (0.62, 1.68) 
   G:G 20/92 1.22 (0.58, 2.57) 1.16 (0.60, 2.25) 
 
9/44 1.37 (0.48, 3.96) 1.24 (0.53, 2.91) 
 
10/45 1.16 (0.36, 3.77) 1.06 (0.43, 2.63) 
Log-Add 
 
1.08 (0.82, 1.42) 1.07 (0.82, 1.40) 
  
1.12 (0.77, 1.64) 1.10 (0.76, 1.59) 
  
1.04 (0.68, 1.59) 1.03 (0.69, 1.55) 
Dominant 
 
1.08 (0.78, 1.51) 1.07 (0.78, 1.48) 
  
1.12 (0.71, 1.77) 1.08 (0.70, 1.67) 
  
1.03 (0.62, 1.71) 1.03 (0.64, 1.67) 
Recessive 
 
1.20 (0.57, 2.51) 1.14 (0.59, 2.21) 
  
1.34 (0.47, 3.82) 1.23 (0.52, 2.88) 
  
1.16 (0.36, 3.72) 1.06 (0.43, 2.62) 
rs915894 
           
   C:C 125/661 1.00 (Ref) 1.00 (Ref) 
 
61/317 1.00 (Ref) 1.00 (Ref) 
 
59/330 1.00 (Ref) 1.00 (Ref) 
   A:C 195/1055 0.98 (0.69, 1.40) 0.99 (0.70, 1.39) 
 
109/529 1.12 (0.68, 1.86) 1.17 (0.73, 1.88) 
 
75/512 0.84 (0.49, 1.43) 0.85 (0.52, 1.38) 
   A:A 84/506 1.03 (0.67, 1.60) 1.03 (0.68, 1.56) 
 
47/263 0.94 (0.51, 1.75) 1.01 (0.57, 1.76) 
 
35/231 1.16 (0.60, 2.25) 1.13 (0.63, 2.04) 
Log-Add 
 
1.01 (0.82, 1.26) 1.02 (0.82, 1.26) 
  
0.98 (0.72, 1.33) 1.02 (0.76, 1.37) 
  
1.05 (0.75, 1.46) 1.04 (0.75, 1.44) 
Dominant 
 
1.00 (0.71, 1.39) 1.00 (0.72, 1.39) 
  
1.06 (0.66, 1.72) 1.13 (0.71, 1.78) 
  
0.92 (0.56, 1.52) 0.93 (0.58, 1.48) 
Recessive 
 
1.05 (0.72, 1.53) 1.04 (0.72, 1.50) 
  
0.88 (0.52, 1.48) 0.92 (0.56, 1.50) 
  
1.29 (0.72, 2.31) 1.23 (0.72, 2.11) 
rs9266 
           
   C:C 254/1428 1.00 (Ref) 1.00 (Ref) 
 
140/728 1.00 (Ref) 1.00 (Ref) 
 
103/674 1.00 (Ref) 1.00 (Ref) 
   C:T 139/710 1.27 (0.91, 1.76) 1.25 (0.91, 1.72) 
 
77/359 1.12 (0.71, 1.76) 1.11 (0.72, 1.72) 
 
58/338 1.40 (0.85, 2.31) 1.34 (0.84, 2.14) 
   T:T 17/116 0.92 (0.45, 1.90) 0.93 (0.49, 1.77) 
 
6/49 0.69 (0.23, 2.09) 0.85 (0.36, 2.01) 
 
9/65 1.56 (0.61, 4.04) 1.33 (0.60, 2.94) 
Log-Add 
 
1.12 (0.86, 1.44) 1.11 (0.86, 1.43) 
  
0.99 (0.68, 1.43) 1.01 (0.71, 1.45) 
  
1.32 (0.91, 1.91) 1.29 (0.90, 1.85) 
Dominant 
 
1.22 (0.89, 1.66) 1.20 (0.88, 1.63) 
  
1.06 (0.68, 1.64) 1.07 (0.70, 1.63) 
  
1.42 (0.88, 2.29) 1.38 (0.88, 2.16) 
Recessive 
 
0.85 (0.42, 1.74) 0.88 (0.47, 1.65) 
  
0.66 (0.22, 1.99) 0.83 (0.35, 1.95) 
  
1.39 (0.55, 3.52) 1.24 (0.57, 2.71) 
rs9267673 
           
   C:C 278/1610 1.00 (Ref) 1.00 (Ref) 
 
152/807 1.00 (Ref) 1.00 (Ref) 
 
114/774 1.00 (Ref) 1.00 (Ref) 
   C:T 108/568 1.16 (0.82, 1.66) 1.15 (0.81, 1.61) 
 
57/294 1.29 (0.78, 2.14) 1.20 (0.74, 1.92) 
 
46/266 1.02 (0.59, 1.74) 1.02 (0.61, 1.68) 
   T:T 15/70 1.84 (0.78, 4.34) 1.55 (0.73, 3.28) 
 
9/24 4.53 (1.57, 13.03) 2.44 (0.97, 6.15) 
 
6/43 0.93 (0.24, 3.60) 0.95 (0.36, 2.51) 
151 
 
  All   Low Flavonoid Intake   High Flavonoid Intake 
dbSNP no. ca/co aORa sbORa   ca/co aORa sbORa   ca/co aORa sbORa 
Log-Add 
 
1.23 (0.92, 1.65) 1.22 (0.92, 1.63) 
  
1.59 (1.05, 2.40) 1.51 (1.02, 2.26) 
  
1.00 (0.64, 1.55) 0.99 (0.65, 1.52) 
Dominant 
 
1.22 (0.87, 1.71) 1.21 (0.87, 1.68) 
  
1.47 (0.91, 2.38) 1.39 (0.88, 2.20) 
  
1.01 (0.60, 1.69) 1.00 (0.61, 1.64) 
Recessive 
 
1.77 (0.75, 4.13) 1.51 (0.71, 3.18) 
  
4.21 (1.48, 11.99) 2.37 (0.95, 5.94) 
  
0.92 (0.24, 3.55) 0.95 (0.36, 2.50) 
rs9275572 
           
   G:G 240/1186 1.00 (Ref) 1.00 (Ref) 
 
134/580 1.00 (Ref) 1.00 (Ref) 
 
96/579 1.00 (Ref) 1.00 (Ref) 
   A:G 140/851 0.96 (0.69, 1.34) 0.96 (0.70, 1.32) 
 
74/438 0.67 (0.42, 1.06) 0.69 (0.44, 1.07) 
 
58/403 1.34 (0.81, 2.22) 1.29 (0.80, 2.07) 
   A:A 23/210 1.02 (0.57, 1.81) 1.01 (0.59, 1.72) 
 
11/107 0.98 (0.44, 2.15) 0.99 (0.50, 1.97) 
 
12/99 1.15 (0.50, 2.68) 1.07 (0.52, 2.21) 
Log-Add 
 
0.99 (0.78, 1.26) 0.99 (0.78, 1.25) 
  
0.83 (0.59, 1.18) 0.83 (0.59, 1.17) 
  
1.17 (0.82, 1.66) 1.14 (0.81, 1.61) 
Dominant 
 
0.97 (0.71, 1.33) 0.97 (0.72, 1.31) 
  
0.72 (0.46, 1.10) 0.73 (0.48, 1.10) 
  
1.30 (0.81, 2.08) 1.25 (0.80, 1.96) 
Recessive 
 
1.04 (0.59, 1.81) 1.02 (0.61, 1.72) 
  
1.14 (0.53, 2.47) 1.10 (0.56, 2.19) 
  
1.04 (0.46, 2.35) 1.00 (0.49, 2.03) 
rs9868873 
           
   G:G 282/1509 1.00 (Ref) 1.00 (Ref) 
 
148/747 1.00 (Ref) 1.00 (Ref) 
 
121/733 1.00 (Ref) 1.00 (Ref) 
   A:G 114/661 1.14 (0.81, 1.60) 1.13 (0.81, 1.56) 
 
64/347 1.20 (0.76, 1.92) 1.18 (0.76, 1.83) 
 
45/304 1.13 (0.67, 1.90) 1.11 (0.68, 1.80) 
   A:A 16/92 1.25 (0.60, 2.58) 1.23 (0.64, 2.35) 
 
11/37 2.19 (0.87, 5.51) 1.79 (0.81, 3.98) 
 
4/54 0.59 (0.16, 2.21) 0.75 (0.29, 1.90) 
Log-Add 
 
1.13 (0.87, 1.47) 1.13 (0.88, 1.47) 
  
1.33 (0.93, 1.91) 1.34 (0.94, 1.91) 
  
0.97 (0.64, 1.47) 0.96 (0.64, 1.43) 
Dominant 
 
1.15 (0.84, 1.59) 1.15 (0.84, 1.57) 
  
1.31 (0.84, 2.03) 1.31 (0.86, 1.99) 
  
1.05 (0.63, 1.73) 1.03 (0.64, 1.64) 
Recessive   1.20 (0.58, 2.47) 1.20 (0.63, 2.28)     2.06 (0.83, 5.12) 1.73 (0.78, 3.81)     0.57 (0.15, 2.12) 0.73 (0.29, 1.86) 
ca/co, cases/controls; aOR, adjusted odds ratios; sbOR, semi-Bayes adjusted odds ratio; Log-Add, log-additive model 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day), pack-year of smoking (continuous), and HBsAg 
status (positive, negative) 
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Table 5-3. Joint associations between selected SNPs and flavonoid intake on liver cancer in Jiangsu case-control study 
    High Flavonoid Intake   Low Flavonoid Intake 
dbsnp no.   aORa sbORa   aORa sbORa 
rs1046472 
         AC+AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.48 (0.86, 2.56) 1.45 (0.85, 2.47) 
   CC 
 
1.13 (0.70, 1.82) 1.11 (0.69, 1.77) 
 
1.34 (0.82, 2.18) 1.30 (0.82, 2.06) 
   Interaction 
 
RERI: -0.28 (-1.15, 0.6) sbRERI: -0.26 (-1.11, 0.59) 
 
ROR: 0.8 (0.41, 1.54) sbROR: 0.83 (0.46, 1.51) 
rs10519613 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.64 (0.94, 2.85) 1.56 (0.91, 2.67) 
   CA+AA 
 
1.47 (0.89, 2.42) 1.41 (0.87, 2.28) 
 
1.61 (0.97, 2.67) 1.51 (0.94, 2.43) 
   Interaction 
 
RERI: -0.48 (-1.51, 0.54) sbRERI: -0.45 (-1.44, 0.53) 
 
ROR: 0.67 (0.35, 1.31) sbROR: 0.73 (0.4, 1.32) 
rs12828 
         AG+AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.27 (0.83, 1.95) 1.25 (0.82, 1.91) 
   GG 
 
1.03 (0.64, 1.64) 1.01 (0.64, 1.61) 
 
1.32 (0.84, 2.08) 1.29 (0.84, 1.98) 
   Interaction 
 
RERI: 0.03 (-0.69, 0.76) sbRERI: 0.03 (-0.69, 0.74) 
 
ROR: 1.02 (0.54, 1.92) sbROR: 1.02 (0.57, 1.8) 
rs12894467 
         TT 
 
1.00 (Ref) 1.00 (Ref) 
 
1.61 (1.04, 2.47) 1.59 (1.04, 2.42) 
   CT+CC 
 
1.35 (0.84, 2.18) 1.33 (0.83, 2.14) 
 
1.31 (0.80, 2.16) 1.27 (0.80, 2.03) 
   Interaction 
 
RERI: -0.65 (-1.61, 0.31) sbRERI: -0.65 (-1.60, 0.30) 
 
ROR: 0.6 (0.31, 1.17) sbROR: 0.66 (0.37, 1.2) 
rs12934922 
         AT+TT 
 
1.00 (Ref) 1.00 (Ref) 
 
2.27 (1.24, 4.19) 2.23 (1.24, 4.04) 
   AA 
 
1.19 (0.71, 2.00) 1.17 (0.71, 1.93) 
 
1.25 (0.73, 2.13) 1.21 (0.74, 1.99) 
   Interaction 
 
RERI: -1.23 (-2.65, 0.2) sbRERI: -1.19 (-2.56, 0.18) 
 
ROR: 0.46 (0.23, 0.93) sbROR: 0.54 (0.29, 1.00) 
rs13409 
         CT+TT 
 
1.00 (Ref) 1.00 (Ref) 
 
1.58 (1.03, 2.41) 1.55 (1.02, 2.36) 
   CC 
 
1.38 (0.86, 2.21) 1.36 (0.86, 2.17) 
 
1.40 (0.86, 2.27) 1.35 (0.85, 2.13) 
   Interaction 
 
RERI: -0.56 (-1.51, 0.39) sbRERI: -0.57 (-1.50, 0.37) 
 
ROR: 0.64 (0.33, 1.23) sbROR: 0.69 (0.39, 1.25) 
rs1538660 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.15 (0.69, 1.90) 1.12 (0.68, 1.83) 
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    High Flavonoid Intake   Low Flavonoid Intake 
dbsnp no.   aORa sbORa   aORa sbORa 
   CT+TT 
 
1.14 (0.72, 1.80) 1.11 (0.71, 1.75) 
 
1.47 (0.93, 2.32) 1.42 (0.92, 2.19) 
   Interaction 
 
RERI: 0.19 (-0.53, 0.9) sbRERI: 0.19 (-0.51, 0.88) 
 
ROR: 1.13 (0.6, 2.13) sbROR: 1.11 (0.62, 1.97) 
rs1804429 
         GT+GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.76 (0.72, 4.34) 1.65 (0.71, 3.81) 
   TT 
 
1.10 (0.53, 2.28) 1.03 (0.53, 1.99) 
 
1.39 (0.67, 2.92) 1.29 (0.68, 2.47) 
   Interaction 
 
RERI: -0.47 (-1.94, 1.01) sbRERI: -0.38 (-1.71, 0.94) 
 
ROR: 0.72 (0.28, 1.86) sbROR: 0.8 (0.37, 1.75) 
rs197412 
         TC+CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.38 (0.89, 2.14) 1.36 (0.88, 2.10) 
   TT 
 
1.06 (0.67, 1.69) 1.05 (0.66, 1.67) 
 
1.23 (0.77, 1.95) 1.20 (0.77, 1.87) 
   Interaction 
 
RERI: -0.21 (-0.98, 0.55) sbRERI: -0.21 (-0.97, 0.54) 
 
ROR: 0.84 (0.45, 1.58) sbROR: 0.86 (0.49, 1.54) 
rs1981492 
         GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.26 (0.80, 2.00) 1.24 (0.79, 1.95) 
   AA+AG 
 
1.09 (0.69, 1.71) 1.07 (0.68, 1.67) 
 
1.39 (0.87, 2.21) 1.34 (0.87, 2.08) 
   Interaction 
 
RERI: 0.04 (-0.69, 0.77) sbRERI: 0.04 (-0.68, 0.75) 
 
ROR: 1.01 (0.54, 1.89) sbROR: 1.01 (0.57, 1.78) 
rs2014300 
         AG+AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.26 (0.65, 2.45) 1.21 (0.64, 2.30) 
   GG 
 
1.07 (0.63, 1.83) 1.04 (0.62, 1.74) 
 
1.44 (0.83, 2.49) 1.37 (0.83, 2.28) 
   Interaction 
 
RERI: 0.11 (-0.72, 0.94) sbRERI: 0.13 (-0.67, 0.93) 
 
ROR: 1.07 (0.51, 2.23) sbROR: 1.05 (0.55, 2.02) 
rs2057482 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.37 (0.91, 2.07) 1.37 (0.91, 2.04) 
   TC+TT 
 
1.13 (0.70, 1.83) 1.12 (0.70, 1.81) 
 
1.16 (0.73, 1.85) 1.14 (0.73, 1.78) 
   Interaction 
 
RERI: -0.35 (-1.15, 0.45) sbRERI: -0.35 (-1.14, 0.45) 
 
ROR: 0.75 (0.39, 1.43) sbROR: 0.79 (0.44, 1.42) 
rs222851 
         AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.35 (0.78, 2.31) 1.29 (0.76, 2.19) 
   AG+GG 
 
1.31 (0.81, 2.11) 1.26 (0.79, 2.02) 
 
1.74 (1.07, 2.82) 1.64 (1.04, 2.58) 
   Interaction 
 
RERI: 0.08 (-0.77, 0.93) sbRERI: 0.08 (-0.73, 0.90) 
 
ROR: 0.99 (0.51, 1.9) sbROR: 0.99 (0.55, 1.79) 
rs2230793 
         AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.15 (0.71, 1.84) 1.13 (0.71, 1.80) 
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    High Flavonoid Intake   Low Flavonoid Intake 
dbsnp no.   aORa sbORa   aORa sbORa 
   AC+CC 
 
1.00 (0.64, 1.58) 0.99 (0.63, 1.55) 
 
1.30 (0.82, 2.07) 1.27 (0.82, 1.96) 
   Interaction 
 
RERI: 0.15 (-0.52, 0.82) sbRERI: 0.15 (-0.51, 0.81) 
 
ROR: 1.13 (0.61, 2.11) sbROR: 1.11 (0.63, 1.95) 
rs2269700 
         TT 
 
1.00 (Ref) 1.00 (Ref) 
 
1.45 (0.98, 2.15) 1.44 (0.98, 2.13) 
   CT+CC 
 
1.05 (0.65, 1.70) 1.05 (0.65, 1.69) 
 
1.16 (0.72, 1.86) 1.14 (0.72, 1.79) 
   Interaction 
 
RERI: -0.35 (-1.14, 0.45) sbRERI: -0.35 (-1.14, 0.44) 
 
ROR: 0.76 (0.39, 1.46) sbROR: 0.8 (0.44, 1.45) 
rs2274223 
         AG+GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.40 (0.80, 2.46) 1.36 (0.79, 2.34) 
   AA 
 
1.10 (0.67, 1.79) 1.07 (0.66, 1.72) 
 
1.46 (0.88, 2.41) 1.40 (0.87, 2.24) 
   Interaction 
 
RERI: -0.04 (-0.86, 0.78) sbRERI: -0.03 (-0.82, 0.77) 
 
ROR: 0.95 (0.49, 1.84) sbROR: 0.96 (0.53, 1.74) 
rs2292305 
         CT+CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.42 (0.91, 2.22) 1.41 (0.91, 2.20) 
   TT 
 
1.07 (0.68, 1.70) 1.07 (0.68, 1.70) 
 
1.09 (0.68, 1.75) 1.08 (0.69, 1.68) 
   Interaction 
 
RERI: -0.41 (-1.21, 0.38) sbRERI: -0.41 (-1.20, 0.38) 
 
ROR: 0.71 (0.37, 1.35) sbROR: 0.75 (0.42, 1.35) 
rs2352028 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.48 (0.99, 2.22) 1.47 (0.99, 2.18) 
   CT+TT 
 
1.13 (0.71, 1.79) 1.12 (0.71, 1.77) 
 
1.17 (0.72, 1.92) 1.15 (0.73, 1.83) 
   Interaction 
 
RERI: -0.43 (-1.25, 0.39) sbRERI: -0.43 (-1.24, 0.38) 
 
ROR: 0.71 (0.37, 1.34) sbROR: 0.75 (0.42, 1.35) 
rs2910164 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.56 (0.90, 2.70) 1.52 (0.89, 2.60) 
   GC+GG 
 
1.17 (0.72, 1.91) 1.15 (0.71, 1.84) 
 
1.35 (0.82, 2.22) 1.31 (0.82, 2.08) 
   Interaction 
 
RERI: -0.38 (-1.3, 0.54) sbRERI: -0.36 (-1.25, 0.53) 
 
ROR: 0.74 (0.38, 1.43) sbROR: 0.78 (0.43, 1.42) 
rs2953 
         GT+GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.46 (0.88, 2.40) 1.42 (0.87, 2.32) 
   TT 
 
1.20 (0.75, 1.91) 1.17 (0.74, 1.85) 
 
1.41 (0.88, 2.27) 1.36 (0.87, 2.13) 
   Interaction 
 
RERI: -0.24 (-1.08, 0.6) sbRERI: -0.23 (-1.05, 0.59) 
 
ROR: 0.81 (0.43, 1.53) sbROR: 0.84 (0.47, 1.5) 
rs3130932 
         TT 
 
1.00 (Ref) 1.00 (Ref) 
 
1.63 (1.03, 2.58) 1.61 (1.02, 2.53) 
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    High Flavonoid Intake   Low Flavonoid Intake 
dbsnp no.   aORa sbORa   aORa sbORa 
   GT+GG 
 
1.06 (0.67, 1.67) 1.05 (0.67, 1.65) 
 
1.21 (0.76, 1.92) 1.18 (0.76, 1.84) 
   Interaction 
 
RERI: -0.48 (-1.32, 0.37) sbRERI: -0.47 (-1.31, 0.36) 
 
ROR: 0.7 (0.38, 1.3) sbROR: 0.74 (0.42, 1.31) 
rs3204145 
         TT 
 
1.00 (Ref) 1.00 (Ref) 
 
1.11 (0.67, 1.82) 1.08 (0.66, 1.76) 
   AT+AA 
 
1.08 (0.68, 1.71) 1.06 (0.68, 1.67) 
 
1.46 (0.93, 2.31) 1.41 (0.91, 2.17) 
   Interaction 
 
RERI: 0.27 (-0.41, 0.96) sbRERI: 0.27 (-0.40, 0.94) 
 
ROR: 1.22 (0.65, 2.3) sbROR: 1.18 (0.66, 2.1) 
rs3729629 
         GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.98 (1.25, 3.12) 1.96 (1.25, 3.08) 
   CG+CC 
 
1.35 (0.86, 2.12) 1.34 (0.86, 2.09) 
 
1.14 (0.72, 1.81) 1.13 (0.73, 1.74) 
   Interaction 
 
RERI: -1.19 (-2.26, -0.11) sbRERI: -1.18 (-2.24, -0.11) 
 
ROR: 0.43 (0.23, 0.79) sbROR: 0.49 (0.28, 0.86) 
rs3734637 
         AC+CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.12 (0.65, 1.92) 1.07 (0.63, 1.82) 
   AA 
 
1.20 (0.75, 1.93) 1.16 (0.73, 1.84) 
 
1.76 (1.10, 2.83) 1.66 (1.07, 2.59) 
   Interaction 
 
RERI: 0.44 (-0.3, 1.18) sbRERI: 0.43 (-0.28, 1.14) 
 
ROR: 1.31 (0.68, 2.51) sbROR: 1.25 (0.69, 2.25) 
rs3740535 
         AG+AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.81 (1.12, 2.93) 1.76 (1.10, 2.83) 
   GG 
 
1.52 (0.96, 2.41) 1.49 (0.95, 2.34) 
 
1.45 (0.91, 2.33) 1.40 (0.89, 2.18) 
   Interaction 
 
RERI: -0.87 (-1.93, 0.19) sbRERI: -0.85 (-1.89, 0.18) 
 
ROR: 0.53 (0.28, 0.99) sbROR: 0.59 (0.33, 1.04) 
rs3801790 
         AG+GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.58 (1.04, 2.40) 1.56 (1.04, 2.35) 
   AA 
 
1.33 (0.83, 2.13) 1.31 (0.82, 2.10) 
 
1.24 (0.77, 2.01) 1.21 (0.77, 1.91) 
   Interaction 
 
RERI: -0.66 (-1.59, 0.26) sbRERI: -0.66 (-1.58, 0.25) 
 
ROR: 0.59 (0.31, 1.14) sbROR: 0.65 (0.36, 1.17) 
rs3929 
         GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.40 (0.93, 2.10) 1.38 (0.93, 2.06) 
   CG+CC 
 
1.10 (0.68, 1.78) 1.09 (0.68, 1.76) 
 
1.29 (0.81, 2.07) 1.26 (0.81, 1.97) 
   Interaction 
 
RERI: -0.21 (-1.01, 0.59) sbRERI: -0.22 (-1.01, 0.57) 
 
ROR: 0.84 (0.44, 1.6) sbROR: 0.86 (0.48, 1.56) 
rs4072391 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.31 (0.90, 1.89) 1.29 (0.90, 1.86) 
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    High Flavonoid Intake   Low Flavonoid Intake 
dbsnp no.   aORa sbORa   aORa sbORa 
   CT+TT 
 
1.08 (0.60, 1.94) 1.07 (0.60, 1.92) 
 
1.20 (0.67, 2.16) 1.17 (0.68, 2.01) 
   Interaction 
 
RERI: -0.17 (-1.11, 0.77) sbRERI: -0.19 (-1.11, 0.72) 
 
ROR: 0.86 (0.38, 1.94) sbROR: 0.89 (0.44, 1.8) 
rs42031 
         AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.25 (0.88, 1.79) 1.21 (0.86, 1.72) 
   AT+TT 
 
1.66 (0.83, 3.33) 1.62 (0.81, 3.24) 
 
2.58 (1.34, 4.95) 2.16 (1.18, 3.95) 
   Interaction 
 
RERI: 0.66 (-1.23, 2.56) sbRERI: 0.33 (-1.32, 1.97) 
 
ROR: 1.24 (0.48, 3.16) sbROR: 1.16 (0.53, 2.52) 
rs4678680 
         GT+GG 
 
1.00 (Ref) 1.00 (Ref) 
 
2.44 (0.93, 6.40) 2.13 (0.88, 5.17) 
   TT 
 
1.63 (0.75, 3.51) 1.42 (0.72, 2.79) 
 
1.90 (0.87, 4.12) 1.63 (0.84, 3.16) 
   Interaction 
 
RERI: -1.17 (-3.42, 1.08) sbRERI: -0.92 (-2.78, 0.94) 
 
ROR: 0.48 (0.17, 1.31) sbROR: 0.62 (0.27, 1.38) 
rs4730775 
         CT+TT 
 
1.00 (Ref) 1.00 (Ref) 
 
1.22 (0.72, 2.07) 1.17 (0.70, 1.96) 
   CC 
 
1.34 (0.83, 2.16) 1.30 (0.81, 2.06) 
 
1.74 (1.07, 2.83) 1.64 (1.03, 2.59) 
   Interaction 
 
RERI: 0.18 (-0.63, 0.98) sbRERI: 0.17 (-0.60, 0.95) 
 
ROR: 1.06 (0.56, 2.03) sbROR: 1.05 (0.58, 1.89) 
rs4975616 
         AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.32 (0.88, 1.96) 1.29 (0.87, 1.91) 
   AG+GG 
 
1.06 (0.63, 1.78) 1.04 (0.62, 1.74) 
 
1.58 (0.96, 2.60) 1.50 (0.94, 2.40) 
   Interaction 
 
RERI: 0.21 (-0.66, 1.08) sbRERI: 0.17 (-0.67, 1.01) 
 
ROR: 1.13 (0.56, 2.28) sbROR: 1.11 (0.59, 2.06) 
rs520692 
         AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.21 (0.83, 1.76) 1.18 (0.81, 1.72) 
   AG+GG 
 
1.04 (0.62, 1.75) 1.03 (0.62, 1.72) 
 
1.54 (0.91, 2.62) 1.46 (0.89, 2.39) 
   Interaction 
 
RERI: 0.3 (-0.6, 1.19) sbRERI: 0.25 (-0.61, 1.10) 
 
ROR: 1.23 (0.6, 2.53) sbROR: 1.18 (0.62, 2.23) 
rs7372209 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.54 (0.97, 2.44) 1.54 (0.98, 2.41) 
   CT+TT 
 
1.00 (0.63, 1.58) 1.00 (0.63, 1.57) 
 
1.05 (0.65, 1.70) 1.04 (0.67, 1.64) 
   Interaction 
 
RERI: -0.49 (-1.3, 0.32) sbRERI: -0.49 (-1.30, 0.32) 
 
ROR: 0.68 (0.36, 1.28) sbROR: 0.73 (0.41, 1.29) 
rs738722 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.93 (1.24, 3.01) 1.91 (1.24, 2.96) 
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    High Flavonoid Intake   Low Flavonoid Intake 
dbsnp no.   aORa sbORa   aORa sbORa 
   CT+TT 
 
1.43 (0.89, 2.29) 1.42 (0.89, 2.26) 
 
1.17 (0.72, 1.90) 1.15 (0.73, 1.82) 
   Interaction 
 
RERI: -1.19 (-2.28, -0.09) sbRERI: -1.18 (-2.27, -0.09) 
 
ROR: 0.43 (0.22, 0.82) sbROR: 0.5 (0.28, 0.89) 
rs748404 
         CT+CC 
 
1.00 (Ref) 1.00 (Ref) 
 
2.57 (0.94, 7.03) 2.30 (0.91, 5.81) 
   TT 
 
1.32 (0.60, 2.90) 1.19 (0.59, 2.37) 
 
1.59 (0.72, 3.54) 1.41 (0.71, 2.79) 
   Interaction 
 
RERI: -1.28 (-3.71, 1.16) sbRERI: -1.07 (-3.14, 1.00) 
 
ROR: 0.47 (0.17, 1.35) sbROR: 0.62 (0.27, 1.43) 
rs7626795 
         AG+GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.61 (0.92, 2.81) 1.57 (0.91, 2.71) 
   AA 
 
1.15 (0.71, 1.86) 1.13 (0.71, 1.81) 
 
1.32 (0.81, 2.16) 1.28 (0.81, 2.03) 
   Interaction 
 
RERI: -0.44 (-1.39, 0.51) sbRERI: -0.42 (-1.34, 0.50) 
 
ROR: 0.71 (0.37, 1.38) sbROR: 0.76 (0.42, 1.38) 
rs8708 
         AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.30 (0.87, 1.95) 1.28 (0.86, 1.90) 
   AG+GG 
 
1.08 (0.65, 1.78) 1.07 (0.65, 1.75) 
 
1.46 (0.89, 2.37) 1.40 (0.88, 2.21) 
   Interaction 
 
RERI: 0.07 (-0.75, 0.9) sbRERI: 0.05 (-0.75, 0.85) 
 
ROR: 1.04 (0.53, 2.03) sbROR: 1.03 (0.56, 1.89) 
rs915894 
         AC+AA 
 
1.00 (Ref) 1.00 (Ref) 
 
1.30 (0.87, 1.93) 1.29 (0.87, 1.90) 
   CC 
 
1.06 (0.65, 1.73) 1.06 (0.65, 1.72) 
 
1.20 (0.71, 2.01) 1.17 (0.72, 1.91) 
   Interaction 
 
RERI: -0.16 (-0.96, 0.64) sbRERI: -0.17 (-0.96, 0.61) 
 
ROR: 0.87 (0.44, 1.73) sbROR: 0.89 (0.48, 1.65) 
rs9266 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.48 (0.97, 2.25) 1.45 (0.96, 2.19) 
   CT+TT 
 
1.47 (0.93, 2.35) 1.45 (0.91, 2.30) 
 
1.55 (0.96, 2.49) 1.48 (0.94, 2.32) 
   Interaction 
 
RERI: -0.41 (-1.35, 0.54) sbRERI: -0.42 (-1.35, 0.51) 
 
ROR: 0.71 (0.37, 1.34) sbROR: 0.75 (0.42, 1.35) 
rs9267673 
         CC 
 
1.00 (Ref) 1.00 (Ref) 
 
1.16 (0.78, 1.73) 1.14 (0.77, 1.68) 
   CT+TT 
 
1.00 (0.60, 1.66) 0.98 (0.59, 1.62) 
 
1.72 (1.03, 2.85) 1.61 (1.00, 2.59) 
   Interaction 
 
RERI: 0.55 (-0.32, 1.43) sbRERI: 0.49 (-0.34, 1.32) 
 
ROR: 1.48 (0.73, 2.96) sbROR: 1.36 (0.73, 2.54) 
rs9275572 
         GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.54 (1.00, 2.38) 1.53 (1.00, 2.34) 
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    High Flavonoid Intake   Low Flavonoid Intake 
dbsnp no.   aORa sbORa   aORa sbORa 
   AG+AA 
 
1.24 (0.78, 1.96) 1.23 (0.78, 1.94) 
 
1.17 (0.73, 1.87) 1.15 (0.73, 1.79) 
   Interaction 
 
RERI: -0.61 (-1.49, 0.26) sbRERI: -0.61 (-1.48, 0.25) 
 
ROR: 0.61 (0.32, 1.15) sbROR: 0.66 (0.37, 1.18) 
rs9868873 
         GG 
 
1.00 (Ref) 1.00 (Ref) 
 
1.19 (0.80, 1.78) 1.17 (0.78, 1.73) 
   AG+AA 
 
1.02 (0.63, 1.66) 1.00 (0.62, 1.62) 
 
1.55 (0.97, 2.48) 1.48 (0.95, 2.31) 
   Interaction   RERI: 0.35 (-0.43, 1.12) sbRERI: 0.32 (-0.43, 1.06)   ROR: 1.28 (0.67, 2.48) sbROR: 1.23 (0.68, 2.22) 
aOR, adjusted odds ratios; sb, Semi-Bayes; OR, odds ratio; RERI, relative excess risk due to interaction; ROR, ratio of odds ratios 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day, when not included in interaction term), pack-year of 
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Table 5-4. Associations between genetic scores and liver cancer in Jiangsu case-control study by flavonoid intake 
   All  Low Flavonoid Intake  High Flavonoid Intake 
Variable Tertile ca/co aORa pb  ca/co aORa pb  ca/co aORa pb 
PRS T1 0-0.80 132/879 1.00 (Ref) <0.001  65/443 1.00 (Ref) 0.001  61/417 1.00 (Ref) 0.071 
 T2 0.80-1.15 217/1,117 1.60 (1.14, 2.25)   124/555 1.56 (0.97, 2.50)   83/547 1.29 (0.77, 2.16)  
 T3 1.15+ 47/165 2.89 (1.68, 4.95)   29/86 3.50 (1.70, 7.24)   17/76 2.27 (0.98, 5.27)  
              
PRS T1 0-0.80 137/917 1.00 (Ref) <0.001  67/463 1.00 (Ref) 0.001  64/434 1.00 (Ref) 0.009 
(imputed) T2 0.80-1.15 300/1,306 1.96 (1.42, 2.69)   162/642 1.89 (1.22, 2.94)   126/643 1.76 (1.09, 2.83)  
 T3 1.15+ 48/175 2.67 (1.58, 4.52)   29/91 2.84 (1.40, 5.78)   18/81 2.34 (1.04, 5.30)  
              
MGI T1 0-0.56 141/977 1.00 (Ref) <0.001  71/482 1.00 (Ref) 0.001  63/474 1.00 (Ref) 0.092 
 T2 0.56-0.69 97/562 1.06 (0.70, 1.60)   56/289 0.88 (0.50, 1.56)   38/267 1.20 (0.64, 2.24)  
 T3 0.69+ 148/582 2.09 (1.45, 3.02)   88/291 2.33 (1.40, 3.87)   54/281 1.65 (0.93, 2.94)  
              
MGI T1 0-0.56 149/1,023 1.00 (Ref) <0.001  75/508 1.00 (Ref) <0.001  67/493 1.00 (Ref) 0.001 
(imputed) T2 0.56-0.69 107/603 1.16 (0.79, 1.71)   58/305 0.94 (0.55, 1.61)   45/289 1.39 (0.77, 2.50)  
 T3 0.69+ 229/772 2.41 (1.75, 3.34)   125/383 2.36 (1.51, 3.69)   96/376 2.39 (1.46, 3.92)  
ca/co, case/control; aOR, adjusted odds ratio; PRS, polygenic risk score; MGI, multigenetic index 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day), pack-year of smoking (continuous), and HBsAg 
status (positive, negative)  
bp for trend 
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Table 5-5. Joint associations between genetic risk scores and novel dietary factors as well as established risk factors on liver 
cancer in Jiangsu case-control study 
  aORa sbORa RERIa RORa 
Flavonoid Intake 
   High Flavonoid and Low PRS 1.00 (Ref) 1.00 (Ref) RERI: 0.59 (-0.52, 1.7) ROR: 1.11 (0.59, 2.1) 
   Low Flavonoid and Low PRS 1.50 (0.96, 2.35) 1.38 (0.89, 2.14) sbRERI: 0.49 (-0.54, 1.52) sbROR:1.09 (0.61, 1.94) 
   High Flavonoid and High PRS 1.72 (1.08, 2.74) 1.60 (1.01, 2.54) 
     Low Flavonoid and High PRS 2.77 (1.76, 4.36) 2.47 (1.60, 3.81) 
  
        High Flavonoid and Low MGI 1.00 (Ref) 1.00 (Ref) RERI: 0.26 (-0.78, 1.3) ROR: 0.97 (0.5, 1.87) 
   Low Flavonoid and Low MGI 1.67 (1.00, 2.81) 1.52 (0.92, 2.53) sbRERI: 0.23 (-0.75, 1.20) sbROR:0.97 (0.54, 1.77) 
   High Flavonoid and High MGI 1.62 (1.00, 2.63) 1.47 (0.91, 2.36) 
     Low Flavonoid and High MGI 2.57 (1.60, 4.12) 2.22 (1.42, 3.46) 
       
Glycemic Index 
       Low GI and Low PRS 1.00 (Ref) 1.00 (Ref) RERI: 0.92 (-0.39, 2.23) ROR: 1.15 (0.54, 2.48) 
   High GI and Low PRS 1.58 (0.88, 2.86) 1.51 (0.86, 2.66) sbRERI: 0.77 (-0.33, 1.87) sbROR:1.12 (0.57, 2.18) 
   Low GI and High PRS 1.54 (0.81, 2.95) 1.44 (0.75, 2.74) 
     High GI and High PRS 2.99 (1.65, 5.44) 2.72 (1.56, 4.74) 
  
        Low GI and Low MGI 1.00 (Ref) 1.00 (Ref) RERI: 0.97 (-0.13, 2.07) ROR: 1.35 (0.6, 3.03) 
   High GI and Low MGI 1.68 (0.85, 3.33) 1.48 (0.78, 2.78) sbRERI: 0.86 (-0.04, 1.77) sbROR:1.25 (0.62, 2.52) 
   Low GI and High MGI 1.35 (0.68, 2.71) 1.08 (0.55, 2.12) 
     High GI and High MGI 2.89 (1.49, 5.61) 2.42 (1.34, 4.40) 
       
Chronic HBV Infection 
       HBsAg- and Low PRS 1.00 (Ref) 1.00 (Ref) RERI: 12.13 (-6.04, 30.3) ROR: 0.71 (0.38, 1.32) 
   HBsAg+ and Low PRS 29.35 (18.68, 46.13) 24.90 (16.13, 38.43) sbRERI: 3.46 (-9.26, 16.18) sbROR:0.75 (0.42, 1.33) 
   HBsAg- and High PRS 2.06 (1.37, 3.10) 1.77 (1.20, 2.61) 
     HBsAg+ and High PRS 42.52 (26.41, 68.43) 29.13 (18.86, 44.98) 
  
        HBsAg- and Low MGI 1.00 (Ref) 1.00 (Ref) RERI: 18.27 (1.65, 34.88) ROR: 1.3 (0.67, 2.49) 
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  aORa sbORa RERIa RORa 
   HBsAg+ and Low MGI 21.83 (13.12, 36.33) 18.11 (11.12, 29.50) sbRERI: 9.84 (-1.47, 21.15) sbROR:1.24 (0.68, 2.23) 
   HBsAg- and High MGI 1.43 (0.94, 2.19) 1.20 (0.80, 1.79) 
     HBsAg+ and High MGI 40.53 (25.27, 65.02) 28.15 (18.34, 43.20) 
       
Mildew/Aflatoxin Exposure 
       No Mildew and Low PRS 1.00 (Ref) 1.00 (Ref) RERI: 0.72 (-1.73, 3.16) ROR: 1.42 (0.31, 6.46) 
   Mildew and Low PRS 1.00 (0.29, 3.42) 0.98 (0.29, 3.36) sbRERI: 0.19 (-1.72, 2.10) sbROR:1.17 (0.43, 3.24) 
   No Mildew and High PRS 1.72 (1.24, 2.37) 1.69 (1.23, 2.33) 
     Mildew and Higher PRS 2.44 (1.00, 5.92) 1.86 (0.86, 4.04) 
  
        No Mildew and Low MGI 1.00 (Ref) 1.00 (Ref) RERI: 0.51 (-2.1, 3.12) ROR: 1.16 (0.25, 5.42) 
   Mildew and Low MGI 1.33 (0.36, 4.85) 1.29 (0.35, 4.71) sbRERI: 0.04 (-2.15, 2.22) sbROR:1.07 (0.38, 2.98) 
   No Mildew and High MGI 1.57 (1.12, 2.19) 1.53 (1.10, 2.13) 
     Mildew and Higher MGI 2.40 (1.01, 5.71) 1.86 (0.87, 3.98) 
       
Alcohol Drinking 
       Never Drinker and Low PRS 1.00 (Ref) 1.00 (Ref) RERI: -0.97 (-2.4, 0.47) ROR: 0.52 (0.27, 0.99) 
   Drinker and Low PRS 1.79 (1.11, 2.91) 1.68 (1.05, 2.68) sbRERI: -0.95 (-2.31, 0.40) sbROR:0.58 (0.33, 1.04) 
   Never Drinker and High PRS 2.62 (1.60, 4.30) 2.48 (1.53, 4.02) 
     Drinker and High PRS 2.45 (1.49, 4.02) 2.21 (1.39, 3.52) 
  
        Never Drinker and Low MGI 1.00 (Ref) 1.00 (Ref) RERI: -0.64 (-1.91, 0.64) ROR: 0.6 (0.31, 1.17) 
   Drinker and Low MGI 1.78 (1.02, 3.11) 1.65 (0.97, 2.81) sbRERI: -0.60 (-1.78, 0.59) sbROR:0.66 (0.36, 1.2) 
   Never Drinker and High MGI 2.17 (1.29, 3.64) 2.03 (1.23, 3.34) 
     Drinker and High MGI 2.31 (1.36, 3.91) 2.08 (1.28, 3.38) 
       
Smoking 
       Never Smoker and Low PRS 1.00 (Ref) 1.00 (Ref) RERI: -0.45 (-1.74, 0.84) ROR: 0.66 (0.35, 1.27) 
   Smoker and Low PRS 1.62 (1.00, 2.62) 1.51 (0.95, 2.41) sbRERI: -0.45 (-1.66, 0.76) sbROR:0.71 (0.4, 1.28) 
   Never Smoker and High PRS 2.31 (1.38, 3.86) 2.18 (1.32, 3.60) 
     Smoker and High PRS 2.48 (1.51, 4.06) 2.24 (1.41, 3.55) 
  
     
162 
 
  aORa sbORa RERIa RORa 
   Never Smoker and Low MGI 1.00 (Ref) 1.00 (Ref) RERI: -0.37 (-1.59, 0.85) ROR: 0.68 (0.34, 1.35) 
   Smoker and Low MGI 1.69 (0.96, 2.99) 1.55 (0.90, 2.66) sbRERI: -0.33 (-1.46, 0.79) sbROR:0.74 (0.4, 1.36) 
   Never Smoker and High MGI 2.06 (1.19, 3.57) 1.90 (1.12, 3.23) 
     Smoker and High MGI 2.38 (1.39, 4.10) 2.12 (1.29, 3.50)     
aOR, adjusted odds ratios; sb, semi-Bayes; OR, odds ratio; RERI, relative excess risk due to interaction; ROR, ratio of odds ratios 
aAdjusted for study area (Dafeng, Ganyu, Chuzhou), age (continuous), gender (male, female), education level (illiteracy, primary school, middle school, high 
school and college), family history of liver cancer (yes, no), alcohol consumption (0, <500g/day, >500g/day, when not included in interaction term), pack-year of 
smoking (continuous, when not included in interaction term), daily kcal, and HBsAg status (positive, negative, when not included in interaction term) 
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